Development of bioactive implant platforms to assist cardiac tissue repair after myocardial infarction by Castells Sala, Cristina
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TESIS DOCTORAL 
 
 
Título   DEVELOPMENT OF BIOACTIVE IMPLANT PLATFORMS 
TO ASSIST CARDIAC TISSUE REPAIR AFTER 
MYOCARDIAL INFARCTION 
 
 
 
 Realizada por   Cristina Castells i Sala 
 
 
 en el Centro  IQS School of Engineering 
 
 
 
 y en el Departamento  de Bioingeniería 
 
 
 
 Dirigida por  Dr. Carlos E. Semino 
 
 
  
C.
I.F
. G
: 5
90
69
74
0 
 U
ni
ve
rs
ita
t R
am
on
 L
ul
l F
un
da
ci
ó 
Pr
iv
ad
a.
 R
gt
re
. F
un
d.
 G
en
er
al
ita
t d
e C
at
al
un
ya
 n
úm
. 4
72
 (2
8-
02
-9
0)
 
 
   C. Claravall, 1-3 
   08022 Barcelona 
   Tel. 936 022 200 
   Fax 936 022 249 
   E-mail: urlsc@sec.url.es 
   www.url.es 
 
 
 

  
 
 
 
 
 
 
 
 
 
       A tot aquell que ha estat al meu costat 
durant aquesta etapa de la meva vida, 
 en algún moment o altre, 
 d’una manera o una altra. 
 
 
 
 

  
 
 
 
 
 
“It is a miracle that curiosity survives formal education” 
Albert Einstein (1879-1955) 
 
“Prediction is very difficult, especially about the future” 
 Niels Bohr (1885-1962) 
 
“If you want to change the world in some big way, 
 that’s where you should start, biological molecules.” 
Bill Gates (1955) 
 
 
 
 
 
   
 
 
 
  ACKNOWLEGMENTS 
Semblava que el dia no arribaria, però si, ha arribat, i aquí estem al final d’un viatge llarg i dur 
però alhora dolç i emocionant. Els últims quatre anys (aviat es diu) han tingut moments de tot 
tipus, alegres, tristos, eufòrics, depriments, motivants, desesperants i això només per a mi; no 
vull saber el que han representat per aquells que han estat més a prop meu en un moment o altre, 
ja que els meus canvis d’humor poden haver-los acostat a la bogeria. En aquest punt del viatge, i 
després de donar-hi tantes voltes i marejar tant al personal, no voldria acabar sense agrair a tots 
aquells que heu estat al meu costat, el recolzament que m’heu aportat. Poder no trobeu el vostre 
nom entre aquestes línies doncs estic contenta de dir que hi ha massa gent a la qual he d’agrair 
alguna cosa, però espero us sentiu identificats en algun dels següents paràgrafs. 
Primer de tot, vull donar les gràcies al Dr. Semino. “Carlos, mucha gracias por ofrecerme 
trabajar en tu laboratorio y darme la oportunidad de hacer un doctorado y trabajar contigo en 
un proyecto de estas características. A tu lado me he sumergido en el mundo de la biología 
molecular a niveles que desde mi punto de vista químico nunca pensé que llegaría. Gracias por 
transmitirme la pasión por la ciencia y el afán de superación en momentos en los que no creía 
que pudiera salir nada de esos volúmenes tan pequeños. Muchísimas gracias por todo.” 
També vull agrair al a tots els integrants del projecte Europeu RECATABI l’ajuda que m’han 
donat en tot moment i els diversos punts de vista dels que he pogut gaudir. Per mi ha sigut una 
experiència molt rica poder treballar amb especialistes de transfons tant variats, des de  biòlegs i 
veterinaris, passant per químics especialistes en ciència dels materials fins a cirurgians cardíacs. 
Moltes gràcies per obrir-me la porta al món de la cardiologia, el qual he trobat realment 
apassionant . Concretament vull donar les gràcies a el Dr. Manuel Monelon Pradas, la Dra. Ana 
Vallés-Lluch, la Dra. Cristina Martínez-Ramos i la Maria Arnal-Pastor del Centre de 
Biomaterials i Enginyeria de Teixits de la Universitat Politècnica de València; a el Dr. Toni 
Bayes-Genis i la Dra. Carolina Soler-Botija del programa de recerca Heart Failure and Cardiac 
Regeneration (ICREC) de l’Institut Germans Trias i Pujol (IGTP); a el Dr. Juan Carlos 
Chachques del Departament de Cirurgia Cardiovascular de l’hospital Pompidou de Paris; i a el 
Dr. Alexander Deten del Fraunhofer IZI de Leipzig. Treballant amb tots vosaltres realment puc 
dir que he crescut com a científica i he aprés el que significa col·laborar amb grups 
interdisciplinars. Moltíssimes gràcies a tots, ha sigut una gran experiència. Vull fer un incís 
especial per la Cris. “Ha sido un placer conocerte, con tu energía y tu constante y permanente 
felicidad. Curiosamente este proyecto te ha convertido en una gran amiga a la que me alegra 
haber encontrado. Eres un sol.” 
 
VII 
 
 Per una altra banda, vull donar les gràcies a aquells que tot i no estar al llarg de tota la tesi, en 
algun moment o altre han tingut quelcom a veure en el seu desenvolupament, ja sigui directe o 
indirectament. “Vielen Dank Frau Dr. Bianca M. Bussmann und Herrn Dr. Sven Reiche vom 
Translationszentrum für Regenerative Medizin in Leipzig. Ihr habt mir eine unterschiedliche 
Arbeitsweise gezeigt und mir gelernt, an das Warum der Dinge zu denken. Außerdem habt ihr 
mir die beste Art und Weise gezeigt, jeden Schritt zu realisieren. Vielen Dank auch an John für 
die Zusammenarbeit mit mir im Labor und dafür, dass ihr mir Techniken gelenrt habt, die ich 
bis dato nie durchgeführt hatte”.Mil gràcies a la Dra. Maria Pilar Armengol responsable del 
servei de genòmica del IGTP de l’Hospital Germans Tries i Pujol de Badalona. No només 
m’has ajudat amb la part tècnica sinó que m’has ensenyat mil “intríngulis” de la PCR a temps 
real. Ha estat un plaer conèixer-te i espero trobar més gent com tu en el camí que la recerca em 
depari. “Quiero agradecer también al Dr. Jesús Otero del Hospital Universitario de Asturias 
por facilitarnos los fibroblastos humanos los cuales nos han sido tan útiles para testar nuestros 
sistemas.” També al Dr. Juli Bagó per marcar les cèl·lules que hem fet servir per als 
experiments in vivo. Al Dr. Salvador Borrós, director del laboratori de Materials de l’IQS, no 
puc deixar d’agrair-li les facilitats brindades per a l’ús dels equips d’humectabilitat, reometria i 
plasma, però també per els ànims i les interesants converses en els passadissos. Mil milions de 
gràcies a en Benja i la infinita paciència que ha tingut amb mi i amb els meus cops de cap contra 
els conceptes “elèctrics”. I per últim però no menys important gràcies Francesc i Allan per 
ajudar-me a millorar la redacció d’aquesta tesis.  
A títol més personal, vull començar per aquelles persones amb les que he compartit el dia a dia. 
Primer de tot, i amb menció especial a les quatre persones amb qui vaig començar aquest viatge: 
Núria, Tere, Mire i Vero. Nenes ha estat un plaer compartir aquesta etapa de la meva vida amb 
vosaltres. Núria els nostres vinets després d’hores i hores intentant posar el RAD en les 
membranes són inoblidables i no diré irrepetibles perquè espero repetir-ho sempre que sigui 
possible tot i que estiguem cada una a una ciutat diferent. Mire, Tere, Vero amb vosaltres el 
camí s’ha fet infinitament més interessant i fàcil. Us trobaré molt a faltar (bé ja us hi trobo 
doncs soc la última que encara ronda per aquí). Per una altra banda també vull agrair a la 
Lourdes i en Javi les hores de feina i anades d’olla compartides. Amb vosaltres la ciència s’ha 
fet més intensa i també més fàcil d’atacar. Heu convertit l’electro-estimulació i l’epigenètica en 
reptes abordables. No puc oblidar-me però de la resta de gent del laboratori amb la que no he 
treballat directament però que m’heu fet gaudir de l’experiència: Cate, Àlex, Desi, Melva, 
Raphaella, Anna, Juli, Oscar, Sílvia, Ana i Astrid. Anna, et dec un incís especial. Has aparegut 
molt al final de la meva tesis però aquest últim any t’has convertit en una gran amiga. Merci per 
els bon àpats, les bones xerrades, l’iniciació al món del cine i la música moderneta i per tot el 
que m’has aportat i sé que continuaràs aportant. Vull donar també les gracies als que m’heu 
 
VIII 
 
 aguantat més aquest últims mesos durant els dinars: “Cate, Miquel i Astrid lunch time with all of 
you have been really tasty and full of chocolate.”  
El laboratori d’Enginyeria de Teixits va íntimament lligat al de Biomaterials. Tot i tenir estires i 
arronses que ens han fet la vida més interessant he trobat grans persones i amics en aquest 
laboratori que compartim: Pri, Sejin, Pau, Ingrid, Pere, Mariana, Oscar, Leti i als que segur que 
em deixo. Hem passat grans moments junts després d’hores de feina. Els petits moment de 
cafetons, cervesetes, festetes i activitats variades han sigut tots i cada un d’ells especials a la 
seva manera i sé que els trobaré molt a faltar. No em vull oblidar de els bioquímics amb qui més 
he tractat i he pogut recórrer en tot moment, i especialment a la Victoria i la Cristina. Vic merci 
per ser-hi en tot (i quan dic tot vull dir tot) moment en tots els àmbits i instants de la meva vida.  
Fora del laboratori també hi ha moltes persones que m’han aguantat amb paciència i que han 
sigut amb mi des de que ens hem creuat en el camí de la vida. Als Lloretencs i especialment la 
Mimar, en Cesc, la Moni, la Yaiza i la Clàudia els vull agrair el ser-hi sempre i, tot i divergir 
camins, aparèixer quan se’ls fa falta. Als companys de carrera, que tot i trobar-nos poc 
aconseguim mantenir-nos al dia i es preocupen pel que faig i com em va. M’encanta que a 
aquestes altures, després de tant anys i dels tombs que dóna la vida pugui dir que encara us tinc 
al meu costat. Gracies a tots els que m’heu recolzat i animat en algun moment. A en Javi li vull 
agrair el temps que hem compartit en tots els aspectes i especialment parlant de ciència i 
animant-nos l’un a l’altre a continuar endavant quan tot plegat semblava que no tenia sortida.  
Vull acabar fent un incís especial a la meva família, a tots i cada un d’ells, els que hi son i els 
que ja han marxat però que sempre s’han preocupat tant per mi, per com em van les coses i que 
m’han recolzat en totes les meves decisions. Els que sempre han estat i sé que sempre estaran al 
meu costat passi el que passi. Especialment als meus pares que han fet grans esforços perquè jo 
sigui on soc ara i que han tingut la paciència d’educar-me per arribar-hi. I al meu germà li he 
d’agrair com li treu ferro als meus suposats problemes, com m’ajuda a deixar d’ofuscar-me per 
les coses que no tenen solució i com em fa riure en tot moment. Gràcies per fer-me veure les 
coses des d’un altre punt de vista quan ho necessito.  
Iaia, ho he aconseguit, he acabat el llibre. 
Moltes gràcies a tots, 
CRIS 
Aquesta tesis ha sigut possible gràcies al projecte europeu del 7º programa marco RECATABI y el pressupost del 
IQS per al laboratori d’Enginyeria de Teixits. 
  
 
IX 
 
   
 
X 
 
  SUMMARY 
The irreversible necrosis of heart muscle (myocardial infarction, MI) occurs when ischemia exceeds a critical 
threshold and overwhelms myocardial cellular repair mechanisms. After MI, myocardial tissue lacks the 
ability to significantly regenerate itself and as a consequence, ischemia might cause moderate or severe tissue 
death. Tissue Engineering is an emerging interdisciplinary field focused on the obtaining of three-
dimensional (3D) constructs with two different purposes: provide a set of biomedical tools with potential 
applicability in tissue replacement, repair and regeneration; or enable the in vitro study of cardiac human 
physiology and physiopathology more accurately. In this work, we have developed and analyzed a 3D in 
vitro model based on RAD16-I self-assembling peptide and a bioactive implant for cardiac tissue repair in 
the framework of RECATABI European Project. 
3D models can help us to study the biophysical, biomechanical and biochemical parameters that regulate cell 
differentiation. In this thesis, we have developed a 3D in vitro model to analyze the behavior of subcutaneous 
adipose derived progenitor cells (subATDPCs) in terms of viability, growth, and gene expression, under 
different stimuli. Moreover, a novel and simple method to study the effect of electrical stimulus on cells 
growing in the 3D model has been achieved. The goal of these in vitro models is to better understand the 
behavior that these cells could have after their in vivo implantation with the hope to improve their 
performance in terms of regeneration or repair of the infarcted tissue. 
Stem cells have been previously proposed to be grafted into the infarcted area to contribute to the generation 
of new myocardial tissue. We hypothesize that this mechanism could be enhanced by the application of a 
bioactive implant that could maintain the cells in the implanted site, afford the mechanical heart behavior 
and, at the same time, provide to the implanted cells a proper microenvironment. Therefore, we have 
prepared a composite obtained from the combination of RAD16-I included within microporous of 
elastomeric membranes. The goal of the present study is to evaluate cell survival and growth, seeding 
capacity and gene expression of subATDPCs in the new synthetic composite scaffold platform. We have 
described the development and characterization of bioimplants based on two different elastomeric 
membranes: poly(ethyl acrylate) (PEA), and poly(caprolactone 2-(methacryloyloxy)ethyl ester, (PCLMA). 
Both biomaterials are a good support for cell delivery and elastic enough to withstand the stresses arising 
from the heartbeat. Additionally, the developed composites equally facilitated the propagation of electrical 
pulses and maintained subATDPCs gene expression. We have proposed that the bioactive implants 
(elastomeric membranes with self-assembling peptide, and subcutaneous adipose tissue derived progenitor 
cells) could increase the efficacy of future cardiac cell therapy by improving cell immobilization and survival 
at the affected site. 
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  RESUMEN 
La necrosis irreversible del músculo cardíaco se conoce como infarto de miocardio (MI) y se da cuando la 
isquemia supera el umbral crítico y rebasa los mecanismos celulares de reparación. Después de un MI, el 
tejido cardíaco no tiene la capacidad suficiente de autoregeneración y como consecuencia, la isquemia puede 
causar la muerte, moderada o severa, del tejido. La ingeniería de tejidos es un campo emergente 
interdisciplinar enfocado a obtener cultivos tridimensionales (3D) con dos propósitos distintos: aportar 
herramientas biomédicas con potencial aplicación en la substitución, reparación y regeneración del tejido; o 
permitir el estudio in vitro de la fisiología y la patofisiología de manera más precisa. En la presente tesis se 
ha desarrollado y analizado un modelo in vitro 3D basado en el péptido autoensamblable RAD16-I y un 
implante bioactivo para la reparación del tejido cardíaco dentro del marco del proyecto europeo RECATABI.  
Los modelos 3D pueden ayudarnos a estudiar los parámetros biofísicos, biomecánicos y bioquímicos que 
regulan la diferenciación celular. En esta tesis, hemos desarrollado un modelo 3D para analizar el 
comportamiento de células progenitoras derivadas de tejidos adiposo subcutáneo (subATDPCs) en términos 
de viabilidad, crecimiento y expresión génica, bajo la influencia de diferentes estímulos. Por otro lado, se ha 
desarrollado un método simple y novedoso para el estudio del efecto de un estímulo eléctrico en células 
encapsuladas en el modelo 3D. El objetivo final de este modelo in vitro es entender mejor el comportamiento 
que estas pueden tener células in vivo después de su implantación. De esta manera se espera poder mejorar su 
actuación en términos de regeneración o reparación del tejido infartado.  
Se ha propuesto con anterioridad que el injerto de células progenitoras en el área infartada puede contribuir 
en la generación de un nuevo tejido de miocardio. Nuestra hipótesis se basa en que este mecanismo puede ser 
mejorado con la aplicación de un implante bioactivo que pueda mantener las células en la localización de 
implantación, soportar el comportamiento mecánico del corazón y a la vez proporcionar un microambiente 
adecuado a las células implantadas. Con estos objetivos se preparó un material combinado consistente en la 
inclusión del RAD16-I dentro de los microporos de membranas elastoméricas. El objetivo de este estudio es 
evaluar la capacidad de siembra de esta plataforma y la supervivencia, crecimiento y expresión génica de las 
subATDPCs. Se describe el desarrollo y caracterización de bioimplantes basados en dos membranas 
elastoméricas: poli etil acrilato (PEA) y policaprolactona 2-metacriloxiloxi etil ester (PCLMA). Ambas son 
buenos materiales de soporte para la implantación de células y también son suficientemente elásticas para 
soportar los esfuerzos resultantes del latido del corazón. Se ha observado que los dos materiales compuestos 
facilitan la propagación de los impulsos eléctricos y permiten el mantenimiento de la expresión génica de las 
subATDPCs. Se propone que los implantes bioactivos (membranas elastomérica con péptido 
autoensamblable y subATDPCs) pueden mejorar la eficacia de futuras terapias celulares, aumentando la 
inmovilización y supervivencia de las células en el área afectada.  
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  RESUM 
La necrosi irreversible del múscul cardíac es coneix com infart de miocardi (MI) i es dóna quan la isquèmia 
supera el llindar crític y depassa els mecanismes cel·lulars de reparació. Després d’un MI, el teixit cardíac no 
té la capacitat suficient d’autoregeneració i com a conseqüència, la isquèmia pot causar la mort, moderada o 
severa, del teixit. L’enginyeria de teixits és un camp emergent interdisciplinari enfocat a l’obtenció de cultius 
tridimensionals (3D) emprats per a dos propòsits diferents: aportar eines biomèdiques amb potencial 
aplicació en la substitució, reparació i regeneració del teixit; o permetre l’estudi in vitro de la fisiologia i la 
fisiopatologia de manera més precisa. En aquesta tesi s’ha desenvolupat i analitzat un model 3D in vitro basat 
en el pèptid autoensamblant RAD16-I, i un implant bioactiu per a la reparació del teixit cardíac dins del marc 
del projecte europeu RECATABI.  
Els models 3D poden ajudar-nos a estudiar els paràmetres biofísics, biomecànics i bioquímics que regulen la 
diferenciació cel·lular. En la present tesis, s’ha desenvolupat un model 3D per analitzar el comportament de 
cèl·lules progenitores derivades de teixit adipós subcutani (subATDPCs) en termes de viabilitat, creixement i 
expressió gènica, sota la influència de diferents estímuls. Per una altra banda, s’ha desenvolupat un mètode 
simple i innovador per a l’estudi de l’efecte de l’estímul elèctric en cèl·lules cultivades en el model 3D 
proposat. L’objectiu final d’aquest model in vitro és entendre millor el comportament que poden tenir 
aquestes cèl·lules in vivo després de ser implantades. D’aquesta manera s’espera poder millorar la seva 
actuació en la regeneració o reparació del teixit infartat.  
S’ha proposat amb anterioritat que l’empelt de cèl·lules progenitores en l’àrea afectada pot contribuir en la 
generació d’un nou teixit de miocardi. La nostra hipòtesi es basa en que aquest mecanisme es pot millorar 
amb l’aplicació d’un implant bioactiu que pugui mantenir les cèl·lules en la localització d’implantació, 
suportar el comportament mecànic del cor i a la vegada proporcionar un micoambient adequat per a les 
cèl·lules implantades. Amb aquest objectius, es va preparar un material combinant consistent en la inclusió 
del RAD16-I dins dels microporus de membranes elastomèriques. L’objectiu d’aquest estudi és avaluar la 
capacitat de sembra d’aquesta plataforma i la supervivència, creixement i expressió gènica de les 
subATDPCs en el material combinat. Es descriu el desenvolupament i caracterització de bioimplants basats 
en dues membranes elastomèriques: polietilacrilat (PEA) i policaprolactona 2-metacrilociloxi etil ester 
(PCLMA). Ambdues són bons materials de suport i també són suficientment elàstiques per a suportar els 
esforços resultants del batec del cor. A més, ambdós materials compostos faciliten la propagació dels 
impulsos elèctrics i permeten el manteniment d’expressió gènica de les subATDPCs. Es proposa doncs que 
els implants bioactius (membranes elastomèriques amb pèptid autoensamblant i subATDPCs) poden millorar 
l’eficàcia de futures teràpies cel·lulars augmentant la immobilització i supervivència de les cèl·lules en l’àrea 
afectada.  
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PREFACE: A little of history 
 
 
3 
 
Overview 
The aim of this section is to introduce the field in which all the work presented in the next 
chapters will be enclosed, the Tissue Engineering (TE) field. The investigation within this 
radically new concept for the treatment of disease and injury has increased during the last 
decades. It involves the use of molecular and cell biology technologies combined altogether 
with material science with the hope to promote mechanisms of tissue regeneration in situations 
where evolution has determined that adult humans no longer have this privilege
1
. In this brief 
introduction, I will present an abridged journey through the history describing the main players 
and their seminal discoveries that lead to the founding of the field. 
A little of history 
“The tails of lizards and of serpents, if they be cut off, will grow again” 
Aristotle, History of Animals, Book II, Chap 17, 508b 4-7 
 
Throughout history, the generation of artificial tissues, organs or even more complex organisms 
from simpler pieces has been deeply embedded in people's imagination and considered a myth 
or dream. There are many examples that reflect the human desire to be able to create, by 
themselves, living individuals or at least parts of them. Just 278 years AD, Fra Angelico painted 
“The Healing of Justinian” (Figure 1A, a), which illustrates the legend of St. Cosmas and St. 
Damien replacing an injured leg for a homograft onto a soldier. From the time of the ancient 
Romans, and until the 19
th
 century, it was generally accepted that some life forms arose 
spontaneously from non-living matter (spontaneous generation). During the transition from the 
Middle Ages to the Renaissance in Europe, the hope and belief that living organisms could be 
generated by alchemy took Theophrastus von Hohenheim (Figure 1, d) to attempt the creation 
of human life by mixing chemical substances in a defined environment. Later on, as science and 
medicine progressed, the idea that life could be created by scientific means was represented in a 
multitude of stories, paintings and films. A remarkable example in literature and cinema is the 
history of Frankenstein (Figure 1A, b), which describes the vitalization of a creature 
reassembled from different body parts
2
. The creation of live from inert material was decisively 
dispelled during the 19
th
 century by Louis Pasteur, who enlarges the work performed by 
investigators such as Francesco Redi and Lazzaro Spallanzani. Finally, advances in germ theory
I
 
and cell theory
II
 definitely displaced the ideas of spontaneous generation
3
. 
                                                     
I
GERM THEORY (Girolmo Fracastoro): States that certain diseases are caused by microorganisms. Proposed in the 
mid-16th century and gained widespread credence when sustained by scientific discoveries of the 17th and late 19th 
century. 
II
 CELL THEORY (Matthias Schleiden and Theodor Schwamm). States that: (1) all living organsims are composed 
of one or more cells, (2) the cell is the more basic unit of life, and (3) all cells arise from pre-existing living cells 
PREFACE: A little of history 
 
 
4 
 
The creative and curious nature of humans, along with our endless imagination are the engines 
that push us to envision beyond the limits of science; rationality and progress then, take those 
dreams into reality. 
A determined observation of nature shows a high diversity of organisms capable of growing 
new parts of their bodies with the aim to replace those that are damaged (Figure 1B).  
 
Figure 1: The origin and inspiration of Tissue Engineering. (A) Remarkable artistic references of the desire to 
create: (a) “Healing of Justinian” Fra Angelico (1455, Roma), (b) Frankenstein by Mary Shelley (1818, London), (c) 
Sanskrit text (3000-2500 BC, India) and (d) Theophrastus von Hohenheim (1493-1541, German-Swiss alchemist and 
physician) (B) Nature inspiration. Important examples of organisms capable to regenerate: (a) Zebrafish (b) Lizard 
(c) Deer Antler (d) Newt (e) Shark teeth (f) Planarian (g) Axolotl (h) Starfish (i) Annelid (j) Spotted salamander (k) 
Hydra (l) Sea cucumber.  
Regeneration can be defined as the process of renewal, restoration, and growth that makes 
genomes, cells, organisms, and ecosystems resilient to natural fluctuations or events that cause 
disturbance or damage
4
. It is a fundamental attribute of all living organism and can be complete, 
when the new tissue results the same as the lost one, or incomplete when it takes place healing 
by fibrosis (e.g. scar formation). Complete tissue regeneration occurs through the activation of 
developmental processes to restore the missing or damaged structures. It has long been observed 
that, even though there is a great diversity in the regeneration ability among different animals, 
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many of the developmental molecules are shared by organisms as different as hydras and 
humans. This suggests that the underlying molecular machinery is probably the same. These 
facts have drawn the attention to the study of animal regeneration. Apart from being a 
fascinating biological issue, the acquired knowledge on how regeneration takes place naturally 
can provide very important insights into the creation of new functional tissues for eventual 
medical use
4
. The idea is to recreate in vitro the biological, biophysical and biomechanical 
conditions that occur in regeneration environments to draw out the intrinsic ability of 
differentiated cells to develop a tissue-like structure
5
.  
 
Figure 2: Important outcomes in the field of Tissue Engineering. 
In terms of scientific progress, the first tissue-based therapies were skin grafting techniques 
performed by Hindus in 3000-2500 BC, which were documented in Sanskrit texts (Figure 1A, 
c). More recently, in 1794 the first autologous skin grafting was reported, and almost 100 years 
later the first cadaveric skin allograft was prepared. During the 20
th
 century TE and regenerative 
medicine have advanced, grown and developed by leaps and bounds. Between 1954 and 1976 
transplantations of kidney, liver, lung, pancreas, bone marrow, and heart were achieved. At 
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cellular level, cryopreservation at subzero temperatures was developed in 1949 and  10 years 
later, the purification of different cell types to produce monolayer cultures of single cell types 
was accomplished. Also during this century the production of synthetic substitutes was 
gradually developed. Additionally, several tissue-engineered skin and subsequently cartilage 
products were successfully commercialized
6
 (see Figure 2).  
Tissue Engineering 
“ Tissue Engineering is the application of the principles and methods of engineering and life sciences toward the 
fundamental understanding of structure-function relationships in  normal and pathologic mammalian tissue and the 
development of biological substitutes to restore, maintain, or improve function”. 
National Science Foundation (NSF) – 1987 
 
After its official definition in 1987 by NSF, the field of TE becomes a rapidly growing scientific 
area mainly focused on the development of tissue and organs substitutes, but also a useful tool 
for the obtaining of in vitro models (see Figure 3).  
 
Figure 3: Tissue Engineering principles. Cells are isolated from human or animal sources and expanded on two-
dimensional cultures. Next, cells are embedded in an extracellular matrix analogue (scaffold), which facilitates proper 
cellular organization. This engineered tissue is implanted in the patient to promote regeneration of damaged tissue. 
Alternatively, it can be used in vitro to study human physiology and pathophysiology more accurately than with two-
dimensional cultures. Castells-Sala et. al. 2013. 
It is well known that biological tissues consist of cells, extracellular matrix (ECM) and signaling 
systems. The combination of these three components plays a crucial role in the differential 
activation of genes or cascades of genes responsible for signaling tissue building and 
differentiation
7
. By learning from nature, TE uses combinations of cells, scaffolds and/or 
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biologically active molecules to develop the desired substitute. In most cases a three-
dimensional (3D) construct is produced allowing the control of biological, biophysical and/or 
biomechanical parameters in the laboratory
8
. Not surprisingly, TE is an interdisciplinary field 
that brings together specialists from as different areas as cell and developmental biology, basic 
medical and veterinary sciences, biophysics and biomechanics, transplantation science, 
biomaterials and biomechanical engineering. 
The obtained 3D constructs are used for two purposes, each one independently useful, yet 
related between one another: 
Provide a set of biomedical tools with potential applicability in tissue replacement, repair, and 
regeneration 
Yearly, millions of people suffer tissue loss or end-stage organ failure, and it is one of the most 
frequent, devastating, and costly problems for healthcare nowadays. Current treatments are 
associated with transplants, mechanical devices, surgical reconstructions or supplementation of 
metabolic products. Although these therapies have saved and improved countless patient lives, 
they still present associated problems
9
: 
- Organ transplants show important limitations such as transplant rejection and lack of 
donors to cover the worldwide demand.  
- Mechanical devices are not capable of accomplishing all tissue functions and cannot 
prevent progressive deterioration or be compatible with tissue/organ growth.  
- Surgical reconstruction can result in long-term difficulties since the organs used for the 
replacement consist of different tissue and cannot properly function in the new 
environment. 
- The supplementation of metabolic products does not solve the lack of physiological 
feedback mechanisms, which may lead to acute or long-term complications. 
Therefore, TE arises from the need to provide more definitive solutions to tissue repair in clinic. 
This is achieved by the development of in vitro devices that could repair the damaged tissue in 
vivo
10
. 
Enable the in vitro study of human physiology and physiopathology more accurately 
Knowledge of human physiology and physiopathology is of great interest for medicine 
professionals in order to find the best procedure when a particular health problem is faced. 
Unfortunately, the complexity of the human body makes it difficult to analyze each factor 
separately. To solve these issues, TE uses 3D constructs, which allow the study of human 
physiology and physiopathology in vitro
8,11
.  
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In vitro human models help to identify and comprehend the factors that drive cellular processes. 
In particular, the idea is to deconstruct the complex cellular microenvironment into simpler 
systems in order to analyze the role of different chemical, mechanical and/or physical factors. In 
fact, these models fulfill the need for reductionist approaches to understand the in vivo 
molecular mechanisms, which rule human physiological as well as pathological processes and 
in turn, better predict the effect of drugs and medical therapies. A lot of research is focused on 
the study of different disorders such as arrhythmia
12
, skin fibrosis
13
 and wound healing
14,15
, and 
the comprehension of the biological function and development of healthy organs such as skin
16–
19
, blood-brain barrier
20
, and mammary gland
10,21
. 
Tissue Engineering components 
TE involves three basic elements: cells, scaffolds and biomolecules. It is necessary to carefully 
choose which combination better fits the desired application. The mix of the three elements 
produces a very complex structure, while simpler than in vivo, it is still very challenging to 
design properly. To fully understand the parts that make up these structures the individual 
blocks are described here shortly: 
Cells 
It has been demonstrated that the use of living cells results in a higher degree of tissue function 
than the use of chemotactic agents, growth factors (GFs) or hormones to stimulate development. 
Cells are able to create or recreate functional structures using pre-programmed information and 
signaling. Today, there are still much needs to be learned in regard to their behavior for the 
creation of body structures before its medical use can become a reality
7
.  
Some TE approaches are focused on a guided regeneration of tissue using materials that serve as 
templates for ingrowth of host cells and tissues, while others implant cells as a part of the 
engineered device. One of the most important issues is the selection of the cell source 
depending on the final application. This step becomes critical, especially when the strategies 
mentioned above are designed to be clinically applied. In general, cells should fulfill a basic 
requirement: to be integrated in the specific tissue and segregate GFs and cytokines that activate 
the endogenous tissue regeneration program. The first approach in cell-based techniques is the 
use of native resident cells (progenitor and/or functional); unfortunately, some specific cell 
types are difficult to obtain and grow in large amounts in vitro. As a consequence stem cells 
have emerged as a promising alternative
22
. 
Stem cells are unspecialized cells that maintain the ability to preserve developmental potential 
and are capable of renewing themselves through mitotic cell division. They are able to undergo 
a diverse range of cell specialization through a process called differentiation, which is induced 
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by certain physiologic or experimental conditions. Intrinsic factors of the cells (signals inside 
the cells, gene expression) as well as extrinsic ones (signals from outside, chemicals, physical 
contact and certain molecules) that trigger each stem cell undergo differentiation are just 
beginning to be understood. Nevertheless, it is known that the action of these signals causes the 
DNA to acquire concrete epigenetic marks that can be passed on through cell division, and 
direct the specific genes to be expressed and transcribed at protein level for each cell type
23
. 
Stem cells can be divided into two big groups: Embryonic Stem Cells (ESCs) and Adult Stem 
Cells (ASCs). ESCs are pluripotent cells that are able to differentiate into any lineage while 
ASCs are multipotent. Although ESCs have higher capacity to differentiate than ASCs, their use 
is highly restricted due to ethical controversies and their potential to produce teratomas. As a 
consequence, ASCs seem to be more appropriate for TE
24,25
. For instance, ASCs and tissues 
derived from them are currently believed to be less likely to initiate rejection after 
transplantation
26
. Research on ASCs is progressing rapidly and up today, they have been 
isolated from different tissues including bone marrow
27
, muscle and adipose tissue
28
, and 
umbilical cord
29,30
. 
There is still much work to be done in order to understand stem cells capabilities, but their 
unique regenerative abilities can offer new insights into the TE field. Therefore, one of the 
challenges the scientific community has to cope with is to understand the principles of cell 
biology to apply the knowledge with the aim to obtain better tissue or organ substitutes.  
Concurrently, it is also important to develop techniques to maintain alive the large masses of 
cells needed both in vitro and in vivo. In this aspect enormous challenge in which significant 
advances have already been made is still under development. For example in vitro flow 
bioreactors for maintenance of cell mass have improved during the recent years. 
Although this work will be mainly focused on the use of ASCs, it is important to briefly 
mention induced pluripotent stem cells (iPSCs). This type of cells were presented in the 
scientific community by Yamanaka and collaborators in 2006
31,32
. Basically, iPSCs are somatic 
cells that have been reprogrammed to a pluripotent state through the introduction of a defined 
set of transcription factors. The main advantages of these cells are their autologous character, 
their differentiation capacity and the robustness and simplicity of the reprogramming procedure. 
However, there are several barriers to overcome before extensively using iPSCs in TE. 
Specifically, the molecular mechanisms underlying reprogramming should be precisely 
characterized before its use in clinical applications
33,34
.  
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Scaffolds 
The second major goal of TE field is the design of scaffolds able to recreate the in vivo milieu of 
cells, which is mainly provided by the ECM. Due to the huge diversity of TE potential 
applications, the task to develop a biomaterial to be used as cell scaffold results to be quite 
arduous. The designed material can be permanent or biodegradable, natural, synthetic or hybrid 
and need to be compatible with the living system in vitro and in vivo. Moreover, these structures 
should incorporate the appropriate biophysical, biomechanical and biochemical cues that guide 
cell proliferation, differentiation, maintenance, and function
35
. The difficulty lies in the fact that 
each design should focus in the specific considered therapy and therefore different scaffolds 
with different properties need to be delineated.  
Regarding biophysical signaling, an essential function of the ECM is to give anchorage and 
mechanical signaling to cells. For this reason, the understanding of the interface between the 
cells and the implant site is an important assessment for the optimization of the scaffold.  
Interestingly, the ECM highly porous nanostructure provides the cells a proper 3D 
microenvironment and imparts biochemical signaling through two mechanisms: (i) the binding 
of a wide variety of soluble GFs, enzymes and other effector molecules controlling their 
diffusion and local concentrations and (ii) the exposure of specific motifs that are recognized by 
cellular adhesion receptors. As a result, ECM is dynamically integrated with the intracellular 
signaling pathways regulating gene expression and participating in cell phenotype 
determination
36–39
. Additionally, the cells are able to sense the matrix stiffness, which also 
results in mechanical signaling. Cells routinely contract to pull on the milieu where they are 
attached, generating internal tension. This mechanical stimulus is translated into a chemical 
response through a process known as mechanotransduction, which has been reported to directly 
influence cell function (e.g. proliferation, differentiation, maintenance, survival)
40–42
. Due to the 
complexity and interaction among all these cues, TE focuses on mimicking the most relevant 
ECM properties to develop custom-tailored scaffolds depending on the tissue to be 
recreated
36,43,44
. Specifically, parameters as scaffold pore size, chemical signaling motifs and 
stiffness should be carefully examined. 
Besides particular parameters, an ideal biomaterial designed for clinical applications should 
fulfill a serial of requirements. First of all, biocompatibility and biodegradability are required to 
allow scaffold replacement by proteins synthesized and secreted by native or implanted cells
44–
46
. Additionally, the material must be clinically compliant (that means, covering Good 
Manufacturing Practice standards, GMP) to minimize inflammatory and immunological 
response avoiding further tissue damage
44
. Moreover, since cell degradation products are toxic 
to other cells, it would be important for the material to allow host macrophages to infiltrate and 
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remove cellular debris
47
. Finally, material production, purification and processing should be 
easy and scalable
35,48
.  
Scaffolds for TE can be divided in natural and synthetic, depending on their origin. Natural 
scaffolds are readily accessible and provide a broad range of cues that during an in vivo assay 
participate in the process of morphogenesis and function acquisition of different cell types. 
However, its composition strongly depends on the specific animal origin as well as on the 
isolation and purification procedures, compromising assay reproducibility
8,44
. On the other hand, 
synthetic scaffolds can be custom-tailored to mimic specific ECM properties, providing 
controllable cellular environments. Paradoxically, this advantage makes this class of 
biomaterials far more challenging because a wide range of factors needed to be identified and 
precisely incorporated. Indeed, unless the application of surface-modifications (adhesion of 
peptides or biological molecules), synthetic scaffolds only serve to hold and guide cells in a 3D 
space until they produce their own physiological matrix environment
8,47,49
. 
Biomolecules 
Besides an appropriate scaffold and cell source, signaling molecules represent an interesting 
tool in TE to modulate several aspects of cell biology, from proliferation capacity to specific 
phenotypic features of fully differentiated cells
43,50,51
. In the cellular milieu, the presence and 
gradient of soluble factors such as GFs, chemokines and cytokines play an important role in 
biological phenomena such as chemotaxis, morphogenesis and wound healing. In particular, 
these signals are tightly controlled and unique to each organ and for this reason what happens to 
a cell depends on their location
7
. 
Signaling molecules used in TE can be added to the culture media as soluble factors or attached 
to the scaffold by means of covalent and non-covalent interactions. First of all, the direct 
delivery of these molecules into the media is frequently used to in vitro evaluate the effect of 
these cues. However, these biomolecules are rapidly degraded and deactivated by some cell-
secreted enzymes, responsible for their short biological half-live. For this reason, for clinical 
application, the bounding of these factors to the matrix is highly extended with the aim to 
protect them from degradation
52
. Additionally, the controlled release of different factors from 
scaffolds allows their constant renewal, having a great potential to direct tissue regeneration and 
formation. Several matrix systems, microparticles and encapsulated cells have been reported to 
locally deliver bioactive factors and to maintain effective concentrations for their use in the 
application areas, such as musculoskeletal, neural and hepatic tissue
53–55
. 
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1.1 BACKGROUND 
1.1.1 Overview 
According to the World Health Organization, cardiovascular diseases (CVDs) are the number 
one cause of death worldwide. CVD is an overarching term that refers to a group of diseases 
involving the heart and blood vessels. An estimated 17.3 million people died from CVDs in 
2008, representing 30 % of all global deaths, and this number is predicted to increase and reach 
24 million people by 2030
1,2
. Over 80 % of these deaths take place in low- and middle-income 
countries and occur almost equally in men and women
2
. CVDs include coronary heart disease 
(CHD) (heart attacks)
i
, cerebrovascular disease (stroke)
ii
, hypertensive heart disease
iii
, 
peripheral arterial disease
iv
, aortic disease
v
, rheumatic heart diseasevi, and congenital heart 
disease
vii
. Significantly, heart attacks and strokes account for nearly the 80 % of deaths as can 
be observed in Figure 1.1-1. 
 
Figure 1.1-1: Cardiovascular diseases prevalence3. CVDs claim more lives than anything else, accounting for 
nearly one-third of deaths worldwide. Coronary heart disease results in the most fatal cardiovascular disorder. Data 
recorded from World Health Organization. 
In 2010, the global cost of CVDs was estimated at USD 863 billion (an average per capita cost 
of USD 125), and it was estimated to rise to USD 1,044 billion in 2030
4
. About 80 % of 
coronary heart and cardiovascular cases are directly caused by behavior risk factors, including 
unhealthy diet, obesity, physical inactivity, tobacco, and harmful use of alcohol
2
.  Therefore, the 
corrections of life habits can reduce premature death, clinical events, and public costs. Reducing 
                                                     
i Coronary heart disease: Blocking of heart’s blood supply. 
ii Cerebrovascular disease: Disturbing of blood supply to the brain.  
iii Hypertensive heart disease: Complications of systemic arterial hypertension or high blood pressure. 
iv Peripheral arterial disease: Blockage in the arteries of the limbs (usually legs). 
v Aortic disease: Weakening of aorta wall and formation of bulges outwards. 
vi Rheumatic heart disease: damage to the heart muscle and heart valves due to rheumatic fever, caused by streptococcal bacteria.  
vii Congenital heart disease: malformations of heart structure existing at birth. 
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the incidence through lifestyle changes can save thousands of dollars, but in any case it is 
crucial to develop new strategies to treat this family of diseases. 
CVDs encompass different illnesses with a variety of casuistry, so it is essential to focus on 
specific ailments. In this work, we will direct our attempts to the latest complication of CHD: 
the narrowing of the blood vessels that supply blood and oxygen to the heart. The blocking of 
blood supply to the heart leads to different diseases such as angina, heart attacks, arrhythmias, 
and at the end stage heart failure. The subject of our study will be the heart tissue damage 
produced due to heart attack (medically known as myocardial infarction, MI). 
Current therapies for the treatment of MI include percutaneous coronary intervention (PCI), 
coronary artery bypass grafting (CABG), dynamic latissiumus dorsi cardiomyoplasty, cardiac 
bio-assist mechanical support, and pharmacological intervention. These therapies are capable of 
increasing patients’ life expectancy a few years after MI, reducing early mortality.  Despite the 
improved medical care and acute management of MI, survivors are susceptible to an increased 
prevalence of chronic heart failure due to muscular tissue death, which develop scarring, 
followed by ventricular remodeling and dilatation
5
.  The removal of damaged heart tissues by 
ventriculoplasty results in the loss of a substantial portion of nondiseased myocardium, so this 
treatment is suitable only for severe dilated cardiomyoplasty
6
. To avoid heart failure, the last 
and only available treatment option with good long-term results is heart transplantation. 
Unfortunately, this treatment is limited due to the lack of donors and complications associated 
with immunological response. In this context, the design of new strategies that maintain the 
structural support necessary for effective cardiomyocyte (CM) contraction is of high interest. 
The need for new therapies has grown in parallel to the evidence that heart muscle is capable of 
regeneration through the activation of cardiac stem cells or recruitment of stem cells (SCs) from 
other tissues
7
. Although this regenerative capacity is not enough to compensate the large-scale 
tissue lost after MI, the concept has opened a new field in heart therapies: cell transplantation. 
The major aim of cellular therapy is the recovery of cardiac function in the infarcted heart by 
regenerating lost myocardial tissue as well as its associated vasculature
8
. Current treatments 
under study consist in cellular cardiomyoplasty, where cells are directly injected or encapsulated 
in scaffolds and grafted into ischemic ventricles wall. These strategies show beneficial effects 
but are not fully developed yet. The exact beneficial mechanism of cell therapy in ischemic 
heart disease is not yet fully understood but possible mechanisms involve paracrine secretion of 
growth factors (GFs) and cytokines, improving neovascularization and angiogenesis
9
 
In this context, a small consortium (RECATABI) was created with the objective to obtain a 
novel clinical platform to regenerate necrotic ischemic tissues after MI with a simple patch 
technology application. The consortium aimed to achieve this goal by manofacturing nanoscale 
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engineered biomaterials and scaffolds that mimic as much as possible the biomechanical and 
biophysical requirements of the implanted tissue. To accomplish this objective, it was needed 
the close collaboration of an interdisciplinary group of experts. In particular, the consortium was 
formed by experts in areas such as material sciences, tissue engineering (TE), stem cell 
technologies, clinical cardiovascular research, and industry: 
- Dr. Manuel Monleón-Pradas (Center for Biomaterials and Tissue Engineering, Universitat Politècnica de 
València (UPV), València, Spain) 
- Dr. Antoni Bayés-Genís (Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Research 
Institute Germans Trias i Pujol (IGTP), Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona, 
Spain) 
- Dr. Alexander Deten (Fraunhofer institute for Cell Therapy & Immunology, Leipzig, Germany) 
- Dr. Juan Carlos Chachques (Department of Cardiovascular Surgery, Pompidou Hospital, Paris, France) 
- Franck Tricot (Creaspine SAS) 
- Dr. Carlos E. Semino (Department of Bioengineering, IQS-School of Engineering, Ramon Llull University, 
Barcelona, Spain) 
The present thesis is enclosed within RECATABI European project and specifically focused on 
the in vitro work developed in Dr. Semino’s group. Chapter 2 and Chapter 3 describe the 
development of in vitro models for the characterization of cardiomyogenic potential of 
subATDPCs. On the other hand, Chapter 4 is focused on the assembling and analysis of a 
bioactive device for the treatment of ischemic tissue after MI. An overview of the most relevant 
results obtained during RECATABI project is also provided at the end of Chapter 4. 
1.1.2 Heart physiology 
The heart is a muscular organ, about the size of a fist, which lies in the center of the thoracic 
cavity encased in a double-walled membrane sac called the Pericardium
10,11
. Pericardium 
contains a layer of pericardial fluid that lubricates the external surface of the heart as it beats. 
The heart is responsible for pumping blood throughout arteries and veins supplying nutrients 
(picked up from the intestine) and oxygen (collected from the lungs) all over the body. 
Functionally, it is divided into left and right halves by a central wall (septum). Each half 
functions as an independent pump that consists of an atrium and a ventricle. These two pumps 
promote pulmonary circulation (flow within the lungs through the pulmonary vein) and 
systemic circulation (flow within the rest of the body through the aorta artery). A scheme is 
presented in Figure 1.1-2.  
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Figure 1.1-2: Cardiovascular system function12. Anterior (frontal) view of the opened heart. White arrows indicate 
normal blood flow. Blood containing low oxygen concentration circulates through the vena cava (VC both superior 
and inferior) that flows into the right atrium (RA). From there, the blood passes to the right ventricle (RV) which 
pumps the blood through the pulmonary artery (PA) to the lungs where it is re-oxygenated. Blood with high oxygen 
concentration returns to the heart through the pulmonary vein to the left atrium (LA) and the left ventricle (LV) 
pumps it all along the body through the aorta (Ao). Running across the surface of the ventricles, there are shallow 
grooves containing the coronary arteries and coronary veins, which supply blood to the heart muscle. Original image 
created by Eric Pierce and licensed under the creative Commons Attribution Share-Alik 3.0 license. 
Cardiac cycle 
A single cycle of cardiac activity can be divided into two movements: systole (muscular 
contraction) and diastole (muscular dilatation) as it is graphically observed in Figure 1.1-3. A 
lower pressure in the ventricles than in the atria produces the opening of atrioventricular valves 
(tricuspid and mitral valves), and consequently the blood flows into the relaxed ventricles. At 
this point, the contraction of the atria (atrial systole) completes the ventricular filling. 
Subsequently, the ventricular contraction causes the atrioventricular valves to close, signaling 
the beginning of ventricular systole. The semilunar valves (pulmonary and aortic) remain closed 
during this period, but the increase of ventricular pressure due to contraction causes their 
opening. When ventricles relax, and the pressure decreases, the semilunar valves close and the 
ventricular diastole begins. The atrioventricular valves remain closed until the pressure in the 
ventricles is lower than in the atria and the cycle re-starts. Since ventricles are responsible for 
pumping the blood out of the heart, their walls need to be strong; therefore, they include most 
part of cardiac muscle cells
10,11
.  
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Figure 1.1-3: Cardiac cycle. A single cycle of cardiac activity can be divided into two movements: systole 
(muscular contraction) and diastole (muscular dilatation). The stiffness of heart muscle is 10KPa at the beginning of 
diastole and up to 200-500 KPa at the end of diastole. Image from Mosby's Medical Dictionary, 8th edition. © 2009, 
Elsevier. 
Heart at cellular level 
The cardiac wall is divided in three layers (see Figure 1.1-4): Epicardium, Myocardium and 
Endocardium. 
 
Figure 1.1-4: Cardiac muscular tissue layers. Cardiac muscular tissue is divided into three layers: epicardium, 
myocardium and endocardium. Myocardium is formed by cardiomyocytes that are faintly striated, branching, 
mononucleated cells connected by means of intercalated disks to form a functional network. Intercalated disks are 
anchoring structures containing gap junctions. This tissue is irrigated by coronary arteries with branches to the 
myocardium.  The heart itself is contained in a sac called pericardium which plays roles such as fix the heart, limit its 
motion, prevent overfilling, lubricate and protect from infection. Image adapted from ©Mayo Foundation for Medical 
Education and research. 
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- Epicardium: Outer layer of the heart composed of connective tissue and covered by 
epithelium. It provides an outer protective layer for the heart. 
- Myocardium: It is the muscular tissue of the heart wall and rests between epicardium 
and endocardium.  
- Endocardium: Thin serous membrane that lines the interior of the heart. It is composed 
of loose connective tissue and simple squamous epithelial tissue. 
In this work we will fix our attention on myocardium. It is composed of cells surrounded by an 
extracellular matrix (ECM) spatially organized into a complex 3D architecture to allow 
coordinated contraction and electrical pulse propagation. The cells that form the heart tissue can 
be divided into two major categories: excitable and non-excitable. The excitable ones are able to 
produce action potentials and include cardiac myocytes, pacemaker cells, Purkinje cells, and 
smooth muscle cells. On the other hand, non-excitable cells do not generate action potentials 
and include fibroblasts, endothelial cells, and adipocytes. Cardiac myocytes are organized 
within muscular fibers with changing orientation across the ventricular wall up to 180º (cardiac 
bundles). At the same time, these muscular fibers are organized into myocardial laminas 4-6 
myocytes thick separated from neighboring laminas by extracellular collagen. The particular 
arrangement of the ventricular myocytes influences the mechanical and electrical function of the 
heart and small changes can lead to severe damages in these functions
13
. 
Heart beating 
Heart beating is conducted by the contraction and relaxation of cardiac muscles. This 
involuntary beating is guided by a network of nerve fibers obtaining an efficient wave-like 
pumping action (Figure 1.1-5). Pacemaker cells are responsible for initiating this contraction: 
these cells have specialized membrane that allows sodium, calcium, and potassium to cross, 
causing cell depolarization. This depolarization is the moving force that initiates the sending of 
electrical impulses through heart wall, which triggers each heartbeat. Pacemaker cells are 
localized in the right atrium, in an area known as sinoatrial node (SA node). The impulse 
generated spreads through the atria to the atrioventricular node (AV node), situated in the lower 
portion of the right atrium. The AV node in turn sends an impulse through the nerve network to 
the ventricles initiating the contraction of the ventricles and creating a delay of 0.1 seconds to 
ensure that all the blood from the atria has been ejected to the ventricles before their contraction.  
The nerve network is formed by Purkinje fibers, specialized CMs that conduct cardiac action 
potentials more quickly and efficiently than any other cells in the heart. This cycle occurs 
approximately 70 times per minute. Electromechanical coupling of CMs is crucial for their 
synchronous response to electrical pacing signals
14
. 
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Figure 1.1-5: Electrical conduction system. (1) Stimulus originates in the Sinoatrial (SA) node and travels across 
the walls of the atria, causing them to contract. (2) Stimulus arrives at the Atrioventricular (AV) node and travels 
along the AV bundle. (3) Stimulus descends to the apex of the heart through the bundle branches. (4) After stimulus 
reaches the Purkinje fibers, the ventricles contract. Image adapted from www.melbourneheartcare.com. 
1.1.3 Myocardial Infarction  
MI
15,16
 is the irreversible necrosis of the heart muscle. It occurs when ischemia exceeds a critical 
threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal 
operating function and homeostasis. Coronary arteries transport the essential nutrients to the 
heart and its steady supply allows the heart to pump blood continuously to the rest of the body. 
Concerning to the pathological process, most MI are caused by a disruption in the vascular 
endothelium associated with an unstable build-up of plaque. This stimulates the formation of an 
intracoronary thrombus, which results in coronary artery blood flow occlusion. If such an 
occlusion persists for more than 20 minutes, irreversible myocardial cell damage and cell death 
will occur. Nearly 70 % of MIs involve left ventricle (LV), in part because it has the most part 
of muscular mass and is more sensitive to oxygen supply.  
The accumulation of this plaque over time is known as atherosclerosis, and it occurs over a 
period of years to decades. Research suggests that CHD begins with damage to the lining and 
inner layers of coronary arteries, and continues with the deposition of calcium, fatty substances, 
cholesterol, cellular waste products, and other cellular substances in the inner lining of an artery. 
It is important to notice that these products are present in healthy individuals, but its quantity is 
critical. Several factors have been reported to contribute to the coronary arteries damage 
including smoking (even secondhand smoke), high amount of certain fats and cholesterol in the 
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blood, high blood pressure, high amounts of sugar in the blood, and blood vessel inflammation, 
between others.  
 
Figure 1.1-6: Myocardial infarction. (A) Heart presenting necrotic heart muscle caused by heart attack. (B) Cross-
section of a coronary artery with plaque build-up and blood clot. Image adapted from 
https://www.nhlbi.nih.gov/health/health-topics/topics/heartattack/ 
Reduced blood supply leads to cell death. It first occurs in the area of muscular wall most distal 
to the arterial blood supply: the endocardium. As the duration of the occlusion increases, the 
area of myocardial cell death enlarges, extending from the endocardium to the myocardium and 
ultimately to the epicardium. The area of myocardial cell death then spreads laterally. Generally, 
after a 6- to 8-hour period of coronary occlusion, most of the distal myocardium has died. The 
severity of a MI depends on three factors: the level of the occlusion in the coronary artery, the 
length in time of the occlusion, and the presence or absence of collateral circulation. In general 
it can be pustule that: 
- The more proximal the coronary occlusion, the more extensive the amount of 
myocardium that will be at risk of necrosis.  
- The larger the necrotic area, the greater the chances of death because of mechanical 
complication or pump failure.  
- The longer a vessel occlusion persists, the higher the chances of irreversible myocardial 
damage distal to the occlusion. 
The goals of therapies to be used immediately after MI include the expedient restoration of 
normal coronary blood flow and salvaging as much functional myocardium as possible. These 
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goals can be achieved by a number of medical interventions and adjunctive therapies. In any 
case, after the restoration of blood flow, as an adult heart is not able to repair the damaged 
tissue, a scar is formed on the damaged cardiac tissue. Scar formation is crucial for rapid 
handling and seclusion of the lesion from healthy tissue, preventing a cascade of uncontrolled 
deleterious events
17
. However, the newly formed tissue does not have contractile, mechanical, 
and electrical properties of normal myocardium, which reduce the pumping efficiency of 
ventricles. Different compensatory mechanisms are activated in response to reduced cardiac 
output, maintaining initially acceptable levels. Ultimately, these compensatory systems place an 
extra burden on the weakened heart muscle, initializing a downward spiral of cardiac function 
which leads to heart failure
18
. Heart failure after a MI is often progressive. After CMs’ death, 
macrophages, monocytes, and neutrophils migrate into the infarct area, initiating the 
inflammatory response. Subsequently, matrix metalloproteases (MMPs) are activated and the 
infarct starts to expand due to the weakening of the collagen scaffold. The damaged wall 
undergoes progressive remodeling, wall thinning, and chamber dilatation, with CMs slippage 
and fibroblast proliferation
19
. This increase of fibrillar, cross-linked collagen deposition helps to 
resist the deformation and rupture
20
, but interferes in the migration and engraftment of the cells. 
Additionally, the ischemic heart results to be a hostile environment for the cells due to local 
hypoxia, acidosis, lack of substrates, and accumulations of metabolites
21
. New therapies are 
required to prevent the progression of pathological remodeling and cell death, as well as to 
induce tissue recovery in the affected areas
22
.  
Regenerative medicine aims to achieve the restoration of tissue structure and organ function, 
thus delaying or preventing disease progression. The desired outcome would be the maintenance 
of normal ventricular function and anatomy, replacement of lost CMs post-MI, prevention of 
LV wall thinning, and improvement in overall cardiac output towards physiological levels 
(average of 5.6 L/min for human males and 4.9 L/min for human females). With the aim to 
achieve these goals, Cardiac Tissue Engineering (CTE) is nowadays under study as an approach 
to support cell-based therapies and enhance their efficacy
22
. 
1.1.4 Cardiac Tissue Engineering 
Regenerative medicine is undergoing experimental and clinical trials in cardiology, in order to 
limit the consequences of MI
23
. Its ultimate aim is to protect the infarcted heart from the 
progressive increase in cavity dilatation, decrease in wall thickness, and deterioration of 
ventricular function along time
17
. This can be fulfilled from different approaches:  
1. Direct injection of isolated cell suspensions24–27. 
2. Biomaterials application to restrain ventricular cavity dilatation. 
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3. Injection of biomaterials with or without cells and/or growth factors (GFs) 28–34 into the 
myocardium to create in situ engineered cardiac tissue. 
4. In vivo implantation of in vitro engineered cardiac tissue with or without cells and/or 
GFs
19,35–38
.  
The direct delivery of cell suspensions is known as cellular cardiomyoplasty. It is well 
established that this technique has the potential to influence in the reconstruction of 
myocardium in situ
19
. Resident stem cells or exogenous progenitor cells administrated in the 
proximity of the lesion can modify the microenvironment by secreting cytokines that favor cell 
homing, growth, and differentiation
17
. Many benefits have been reported: (1) reduction of size 
and fibrosis of infarct scars; (2) limitation of adverse post-ischemic remodeling; and (3) 
improvement of diastolic function
23
. Unfortunately, direct cell loading in the affected tissue 
presents many problems related to low cell engraftment (blood pumping washes out most of the 
injected cells from the target site), and poor cell survival (approximately 90 % of delivered cells 
die). Therefore, after many years of cardiomyoplasty trials the efficacy of the benefits observed 
resulted to be very limited due cell engraftment and survival efficiency.  
To improve the efficiency of cellular therapy, an efficient cell delivery system is essential. CTE, 
which includes de use of biomaterials, emerged as an interesting approach. There are three 
primary strategies: (1) in situ TE where cells and biomaterials are directly injected in the 
myocardium; (2) in vitro TE that embeds the cells in 3D scaffolds to develop tissue constructs 
for in vivo implantation; and (3) scaffold free TE (cell sheets, cell bodies, core shell, and 
aggregates)
39,40
. The association of cells with biomaterials could provide an appropriate milieu 
where cells can grow in a 3D fashion and at the same time offer a support for the implantation 
step. The proper design, fabrication, and characterization of the material required to guide tissue 
development, and in some cases, support the organ, is required
18
. The right microenvironment  
as well as mechanical and topological cues may even reverse remodeling and boost cardiac 
regeneration
41
. Specifically, the milieu provides physical (e.g. dimensionality, topology), 
chemical (e.g. GF, cytokines, cell-adhesion complexes), and mechanical (e.g. stiffness) cues, 
facilitating cells integration and further cardiac regeneration
42
. 
Thus, CTE approach constitutes an attractive alternative since it provides the opportunity to 
deliver a large number of cells that are already organized in a natural or artificial ECM. The 
expectation of CTE lies in the repair of damaged tissues and organs, and also the production of 
relevant in vitro tissues for successful implantation
43
. Major issues still need to be solved, and 
bed-to-bench follow-up is paramount to foster clinical implementations
44
. The development of 
these therapies requires a multidisciplinary approach in order to optimize cell source, 
scaffolding design, and interaction of soluble biomolecules with and extracellular milieu
45
. 
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Cells for Cardiac Tissue Engineering 
It has been reported that MI involves the loss of 1-1.5 billion (10
9
) CMs, compromising 
considerable amounts of myocardial cell mass
46
. For this reason, many CTE approaches are 
based on using new cells to replenish the damaged myocardium. Cell implantation strategies for 
heart failure have been designed to replace damaged cells or to produce new fibers creating 
contractile tissue
23
. But which kind of cell is the best candidate? Several stem and progenitor 
cells types from autologous and allogeneic donors are being tested to find the most appropriate 
candidate (Figure 1.1-7). Interestingly detailed reviews have been published regarding 
advantages, drawbacks, and different advances developed in this issue
7,19,47–52
. Here, a short 
overview of the cell types under study is provided. 
 
Figure 1.1-7: Cells under study for their application in Cardiac Tissue Engineering. Different cell types have 
been analyzed clinically with good results in terms of security, but heterogeneous results in terms of efficacy. 
Different regenerative mechanisms of implanted cells have been described: (1) transplanted cells could directly 
transdifferentiate into CMs; (2) paracrine effects could induce the growth of resident CMs; (3) resident endogenous 
myocardial stem cells may be stimulated; and (4) cell fusion between transplanted cells and resident CMs could be 
induced5. 
CARDIAC MYOCYTES
53
: They are the major cell type of cardiac muscle tissue. The primary 
goal of cardiac cell therapy consists in increasing the number of contractile cells in the necrotic 
zone to improve systolic heart function. Consequently, CMs were the first obvious source of 
cells due to their natural electro-physiological, structural, and contractile properties. These cells 
are able to engraft successfully in the resident myocardium improving its contractility. 
However, differentiated CMs dissociated from heart tissue are difficult to obtain and expand 
since they depend on heart biopsies or donations.  
SKELETAL MYOBLATS
53,54
: Skeletal muscular fibers harbor an endogenous reservoir of tissue-
committed precursor cells. Their use in cardiac repair is motivated by their clinically attractive 
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characteristics: (1) autologous origin with easy accessibility and without immune rejection or 
ethical concern, (2) high degree of scalability, (3) myogenic lineage that reduces the risk of 
tumor formation, and (4) high resistance to ischemia. However, they do not functionally 
integrate with the host cardiac tissue due to their incapability to form the appropriate gap 
junctions as a result, they can produce arrhythmias. 
CARDIAC STEM CELLS (CSCs)
55
: The identification of a reservoir of resident stem cells in the 
heart appeared as a huge promise for cardiac regeneration since they are tissue specific and pre-
committed to a cardiac fate. These cells are capable of differentiating into CMs, vascular 
smooth muscle cells, and endothelial cells. However, isolating and expanding them from cardiac 
biopsies represents a challenge. 
EMBRIONIC STEM CELLS (ESCs): They are pluripotent, undifferentiated cells and, therefore, 
have the ability to differentiate into different specialized cells. They are able to grow and divide 
indefinitely, but their cellular mechanisms and signaling pathways are not fully understood. 
Although their cardiomyogenic potential, implanting ESC (or its cardiogenic derivate) in vivo 
might have the risk of producing teratomas
19,43,56,57
 or/and induce arrhythmias
52,58
. Additionally 
to the biologic drawbacks, the clinical use of ESCs is severely limited due to ethical concerns 
and political discussion.  
INDUCED PLURIPOTENT STEM CELLS (iPSCs)
59
: The main benefits of these cells are (1) 
their autologous character, (2) their differentiation capacity, and (3) the robustness and 
simplicity of reprogramming procedure
7,60
. Additionally, they are free of political and ethical 
debate. In mice hearts, these cells reduced cardiac cell loss, decreased fibrotic scar formation, 
and significantly improved cardiac function
5,25
. However, there are many barriers to overcome 
before its clinical use can be envisioned. Recent studies have revealed that iPSCs contain 
epigenetic features that indicate either incomplete or aberrant reprogramming. Additionally, 
some established iPSCs are genetically unstable, exhibiting large-scale genomic rearrangement, 
copy-number variation and abnormal karyotype
61
. 
ADULT STEM CELLS (ASCs): An adult stem cell is an undifferentiated cell found among 
differentiated cells in a tissue or organ that can self-renew and produce a progenitor cell. These 
cells can differentiate to yield some or all of the major specialized cell types of the tissue or 
organ in question. The primary role of ASCs in a living organism is to maintain and repair the 
tissue in which they are found. They have been isolated from a range of sources including bone 
marrow
62
, muscle tissue, adipose tissue
63
, and umbilical cord
64,65
. Principal advantages of ASCs 
are based on their autologous character, avoiding immunogenic reactions and tumor formation. 
Indeed, most of the research in cardiovascular regenerative therapies has been conducted using 
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bone marrow-derived stem cells, a specific type of ASC. It has been demonstrated that their 
administration can improve cardiac function in animal models of MI and develop 
vasculogenesis in ischemia models. Mesenchymal stem cells (MSCs)
66
 is a subpopulation of 
bone-marrow stem cells
5
, which have been reported to be capable of forming cardiac lineage 
cells in vitro and in vivo. Interestingly, MSCs can be obtained from other sources, such as 
adipose tissue, placenta, and umbilical cord
51
. They are easy to isolate and cultivate. 
Importantly, it has been reported that their therapeutic potential resides in the ability to directly 
differentiate into cardiac tissue, and exert paracrine signaling through the release of soluble 
biomolecules such as GFs
19
. 
It is not trivial to choose the most adequate cellular type for CTE. At microscopic level, the 
engrafted cells have to survive, and migrate from the seeding site to the border of damaged area, 
invade the infarcted zone, grow and differentiate. For this purpose, cells need the formation of 
adherent and gap junctions with the resident cells to anchor properly to the host myocardium. 
Interaction between integrin receptors on progenitor cells and ECM proteins is fundamental for 
cell loading, division, and maturation
17
. On the other hand, technically speaking, finding the 
best cell source for cardiac repair remains a major obstacle because of the difficulty on isolating 
and expanding autologous sources, ethical issues surrounding certain cell types and the inability 
of one cell source to fully replenish all necessary cell types
20
.  Ideally, for clinical application, 
the cells used for CTE must accomplish the subsequent requirements 
67,68
: 
1. Amenability to large-scale expansion. Recent advances in large-scale 
bioreactor technologies adequately address this issue, being operable in 
accordance to good manufacturing practice (GMP) regulations. 
2. Feasibly engrafting within damaged areas. 
3. Migration potential. 
4. Capability to differentiate into new CMs coupled electromechanically with 
neighboring cells and other mature cell types such as endothelial cells or 
fibroblasts. 
5. Avoid tumor formation and arrhythmias induction. Tumorigenicity may be 
controllable by stringent selection of terminally differentiated somatic 
derivatives. Conversely, arrhythmogenicity appears more difficult to control
40
. 
 
In this project, adipose-derived progenitor cells (ATDPCs) were selected. These cells can be 
easily isolated and cultured in vitro. Interestingly, they express markers associated with MSCs 
and maintain their multipotenciality to differentiate into chondrocytes, osteoblasts, endothelial 
cells, and CMs. The differentiation capacity and paracrine activity of these cells make them an 
optimal candidate for the treatment of a diverse range of diseases. Four different possible fates 
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of ADPCs are described by Choi et al.
69
: (1) differentiating into cardiac muscles by direct 
contact with adjacent resident CMs; (2) differentiating into smooth muscle cells that have 
migrated to and surrounded immature vessels; (3) adipogenic differentiation and (4) secreting 
pro-angiogenic factors to recruit endogenous endothelial cells
19
. MSCs were discarded because 
although they can partially transdifferentiate into cardiomyogenic lineage, they rapidly undergo 
senescence during in vitro expansion. 
Biomaterials for Cardiac Tissue Engineering 
In ischemic disease, ECM is both chemically and morphologically modified. Therefore, the 
development of a milieu that closely mimics the native tissue architecture is of high interest
23,52
. 
There are various critical aspects to address for the design of the material: (1) cell anchorage in 
the scaffold, (2) nutrients and other small molecules diffusion, (3) vascular integration, (4) 
cellular organization, and (5) vascularization to enhance cell survival of the engrafted cells
18,70
. 
The selected biomaterial for CTE must accomplish the subsequent basic requirements:  
1. Biomimetism: mimic the ECM and fit the structural and mechanical properties of the 
native myocardium. In particular, it should be stress and strain-resistant, but elastic 
enough to transmit contractile forces
71
, due to the constant expansion and contraction of 
the heart tissue. Additionally, the material must integrate with the endogenous electrical 
pattern of the heart, propagating the internal wave front. 
2. Biocompatibility: avoid rejection or immune response, presenting a good interaction 
with the host.  
3. Biodegradability: in case to be biodegradable, the degradation products must be non-
toxic and readily removed from the body.  
4. Cell friendly: enhance cell survival, adhesion and rapid vascularization7,72. Additionally 
it must allow host macrophage infiltration in order to remove cellular debris
8
.  
5. Cost effective: easily accessible and reasonably affordable. 
Biomaterials give cells multiple physical, mechanical and chemical cues to guide their growth, 
function, self-renewal and differentiation. In order to design a suitable biomaterial, there are 
large number of parameters to be considered
19,45
. Regarding physical signaling, scaffold internal 
structure (e.g. size and interconnectivity of pores) determines the transport of nutrients, 
metabolites and regulatory molecules
19,43
, and at the same time the accommodation of the cells, 
and their organization into functional tissues. For instance, it has been largely demonstrated that 
extremely large pores could avoid vascularization (endothelial cells are not capable of bridging 
pores larger than their diameter), but pores smaller than 100 µm can influence diffusion. From 
the chemical perspective, the scaffold has an important role in cellular attachment and 
differentiation. Specifically, it has been reported that properties such as wettability, charge, 
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chemistry, roughness and stiffness play an essential role in determine whether cells are able to 
adhere. Finally, its elasticity must be precisely controlled because it should not negatively affect 
heart performance. Besides, a compromise between the complete degradation and the 
mechanical support is needed. Biomaterials have been successfully used to constrain the post-
MI failing heart, preventing it from further remodeling and dilatation
18,41
. 
CTE uses both natural and synthetic materials. Up to date, most research is focused on natural 
biomaterials due to their early commercial availability and the potential advantage of biologic 
recognition
7
. Nevertheless, the use of synthetic scaffolds is also of high interest. This type of 
materials has a wide diversity of properties, which can be tailored with respect to mechanical, 
chemical and physical signaling. The most important quality of this group of materials is that 
the synthesis conditions can be fixed to get defined properties without batch-to-batch variations 
and with known composition (desired porosity, mechanical stability and degradation 
properties). However, their origin leads to limited cellular interactions. Some examples of 
materials used nowadays in CTE are presented in Table 1.1-1. 
Table 1.1-1: Materials currently used in Cardiac Tissue Engineering73. Image from Castells-Sala et. al. 
 
Besides material composition, the methodology used for its implantation is also important. In 
this field, injectable scaffolds have been widely studied as vehicles for cell delivery with the aim 
to maximize cell retention, and survival in the ischemic area. Injectable therapies are beneficial 
to avoid invasive chirurgical treatments, but their major challenge resides in the demanded 
properties. For practical reasons, the material needs to remain liquid until its injection and then 
solidify quickly after delivery, presenting the features described above. The difficulty of this 
technique falls on the continuous contraction-relaxation cycles present in the heart, and, 
therefore, the integration of muscular, vascular and connective tissue compartments between 
graft and host is really challenging. Although injectable biomaterials seem like a more desirable 
approach from the chirurgic point of view, the need to maintain the material in a liquid phase 
until injection made of non-injectable materials an interesting alternative
74
. Several studies have 
been focused on the scaffold itself. Many materials are able to induce a cellular response from 
the host tissue
52
, but they also serve as a 3D environment and a vehicle for cells
18
. A scheme of 
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different biomaterials platforms is presented in Figure 1.1-8, and examples of both kinds of 
materials are presented on Table 1.1-1.                                             
 
Figure 1.1-8: Biomaterials platforms mainly used in Cardiac Tissue Engineering73. Natural and artificial 
biomaterials are used in the development of injectable and non-injectable biomaterial platforms to assist cardiac 
tissue repair and regeneration after acute or chronic MI. Injectable systems usually are composed of a liquid material 
(hydrogel) scaffold, whereas non-injectable biomaterials are composed of solid materials with tuned stiffness values 
as well as variable mesh and porous sizes. Both platforms could include the use of GFs and cytokines (triangle, 
square, and circle dots), cells (star-like shape), or both. From Castells-Sala et. al. 2012. 
RECATABI project bets on a combination of two synthetic biomaterials: an elastomeric 
microporous membrane to provide mechanical support to cells and a self-assembling peptide 
(SAP) nanofiber gel to provide an adequate microenvironment within the membrane’s pores. 
The results obtained combining these materials for cell culture and further in vivo application 
are presented in Chapter 4. 
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1.1.5 Cardiac markers analyzed 
Heart is the first organ to form and function in the embryo. Its development requires cell 
specification, cell differentiation, cell migration, morphogenesis, and interaction among cells. 
This process can be divided in three steps: (1) determination of the cardiac field in the 
mesoderm; (2) differentiation of cardiac precursor cells; and (3) heart maturation. The identity 
of the progenitor cells during early cardiogenesis is regulated by tightly coordinated, spatially 
and temporally active signaling pathways and molecular mechanisms. This leads cells to a 
progressive restriction of undifferentiated progenitors to the different cardiovascular lineages 
(Figure 1.1-9). The molecular identity of these inductive signals is not well understood, but 
various transcription factors that may regulate cardiac commitment and differentiation have 
been isolated. The understanding of this molecular basis could facilitate the investigation of 
stem cell-based regenerative therapies, since it would allow the development of more extensive 
strategies in CMs differentiation or even the identification of new cell types with CM 
potential75. 
 
Figure 1.1-9: Sequential steps in cardiac differentiation in vitro from pluripotent stem cells to functional 
cardiomyocytes75. Cardiac development starts with the commitment of undifferentiated pluripotent stem cells of the 
inner cell mass of blastocysts to mesodermal restricted derivatives during embryonic development. Typical markers 
and characteristics for the different cell types are indicated. Structural and functional maturation is not well 
understood. Maturation might be provoked by hormones, organization in 3D engineered heart tissues (EHTs), and 
electrical and mechanical stimulation. Image adapted from Cyganek 2013. 
In this thesis the cardiomyogenic potential of the cells cultured in different conditions (2D and 
3D environment) and stimulation protocols (chemical and electrical) is assessed by analyzing 
the expression of early and definitive cardiac markers. A brief description of the analyzed 
markers is presented below: 
Early cardiac markers 
- GATA binding protein 4 (GATA4). GATA factors comprise a small family of highly 
conserved zinc finger transcription factors that play critical roles in gene activation in 
multiple cell lineages. They are involved in the development of the cardiovascular, 
hematopoietic, digestive, and reproductive systems. GATA4 is an essential transcription 
factor for normal heart morphogenesis that regulates the survival, growth, and 
proliferation of CMs
76
. It is one of the earliest transcription factors expressed in 
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developing cardiac cells, and continues to be expressed in CMs. Its function consists on 
binding to DNA and determining which genes get active or shut off. 
- Myocyte Enhancer Factor-2 Polypeptide-C (MEF2C). Member of the MADS box 
transcription enhancer factor 2 (MEF2) family proteins, which play a key role in 
myogenesis
77
. MEF2 family of transcription factors has long been associated with 
regulation of myocardial-expressed genes, including cardiac alpha-actin (ACTN1) and 
myosin heavy chain (MHC)
78
. The encoded protein, MEF2C, has both trans-activating 
and DNA binding activities. It is possible that this protein plays a role in maintaining 
the differentiated state of muscle cells. It is also involved in vascular development. 
- NK2 Transcription Factor Related Locus-5 (NKX2.5). Also called Csx, this gene encodes a 
homeobox-containing transcription factor that functions in heart formation and 
development. NKX2.5 is the earliest known marker of vertebrate heart development. 
The overexpression or loss-of-function mutations studies in frogs, zebrafish, mice and 
humans have demonstrated that NKX2.5 can induce myocardial gene expression, and 
that it is necessary for the specification of the right ventricle, heart looping and atrial 
septation
79
. It is also involved in the AV node function and intimately cooperates with 
GATA4 for the differentiation into beating CMs. NKX2.5 has been shown to interact 
with TBX5
80
.  
- T-box Transcription Factor 5 (TBX5). TBX5 belongs to the T-box gene family. Its 
members share a highly conserved 180-amino- acid domain required for DNA binding 
81
. TBX5 gene is critical for the development of the heart. The encoded protein 
regulates the activity of other genes by attaching to specific regions of DNA. In situ 
hybridization studies in mouse, chick and humans show that it is expressed in the 
cardiac crescent early in the developing heart and subsequently in an asymmetric 
fashion in the left ventricle and on the left side of the ventricular septum
82
.The T-box 5 
protein is also critical for the formation of the electrical system that coordinates 
contractions of the heart chambers. It has been shown to interact with NKX2.5, GATA4 
and MEF2C to synergistically activate target genes expression in CMs 
83
. 
Definitive cardiac markers 
- Alpha-actin 1(ACTN1). Alpha actin belongs to the spectrins gene superfamily, which 
represents a diverse group of cytoskeletal proteins. It is a marker of mature CMs, but it 
is also expressed in cardiac progenitor cells. Therefore, it could be also considered an 
early cardiac marker. This type of actin is specifically expressed in myoblast 
cytoskeleton and is the major constituent of the contractile apparatus
84
.  
- Connexin43 (Cx43) or gap junction protein, alpha 1 (GJA1). GJA1 is a member of the 
connexin gene family. It encodes for a protein component of gap junctions, which are 
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composed of arrays of intercellular channels that provide a route for the diffusion of low 
molecular weight materials from cell to cell. Gap junctions mediate electrical coupling 
between cardiac myocytes, forming the cell-to-cell pathways for propagation of the 
precisely orchestrated patterns of current flow that govern the regular rhythm of the 
healthy heart. The encoded protein is the major protein of gap junctions in the heart. It 
has been established unequivocally that mammalian CMs express Cx40, Cx43, and 
Cx45, but different tissues of the heart express different amounts and combinations of 
these connexins. The major cardiac gap junction protein, Cx43, is expressed in atrial 
and ventricular muscle
85
. 
 
Figure 1.1-10: Cardiac gap junctions. Specialized intercellular connection between two cells, that allows 
the pass of molecules and ions, freely. (a) A 3D drawing showing the interacting plasma membranes of two 
adjacent cells connected by gap junctions. The lipid bilayers (red) are penetrated by protein assemblies 
called connexons (green). (b) The connexons are composed of 6 connexins. The connexons can be 
homomeric or heteromeric, and the intercellular channels can be homotypic or heterotypic. Several gap 
juncions channels (hundreds) assemble within a macromelecular complex called gap junction plaque. Image 
adapted from Molecular Biology of the Cell. 4th edition86. 
- Myosin Heavy Chain (MHC). Myosins are a family of ATP-dependent protein well 
known for their role in muscle contraction and their involvement in a wide range of 
eukaryotic motility processes. Muscle myosin contains 2 heavy chain subunits, 2 alkali 
light chain subunits, and 2 regulatory light chain subunits. This gene encodes the heavy 
chain subunit of cardiac myosin predominantly expressed in normal human ventricle. 
The abundance of this protein correlates with the contractile velocity of cardiac 
muscle
84
. 
- Troponin. It is a 3-unit complex of troponin T (tropomyosin binding), I (inhibitory) and 
C (calcium binding). This thin filament is associated with the regulatory complex of the 
contractile system of skeletal and cardiac muscle. The principal role of this complex is 
to control the calcium mediated interaction between actin and myosin. Troponin C 
binds calcium released out of the sarcoplasmic reticulum after stimulation; Troponin T 
(cTnT) connects the troponin complex to tropomyosin regulating muscle contraction in 
response to alteration in intercellular calcium concentration; and Troponin I (cTnI) 
prevents the connection between actin and myosin without stimulus. In contrast with 
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other multigene families, the skeletal and cardiac proteins are not derived from 
alternative splicing of exons from a single gene 
87
, therefore, they have, theoretically, 
the potential of being unique to the myocardium. Indeed, cTnI has only been identified 
in the myocardium
88
.  
 
Figure 1.1-11: Arrangement of Troponins I, C and T with tropomyosin and actin in the heart muscle 
fibers. These are located at regular intervals along the length of actin filaments and play a key role in 
muscle contraction. Image adapted from Chaikhouni A et. al.89. 
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1.2 MOTIVATIONS AND GENERAL AIMS 
From their beginnings, the Tissue Engineering Laboratory directed by Dr. Semino has been 
fully immersed in the study of three-dimensional (3D) environment effect on cell behavior. The 
principal hypothesis of the group is that the recreation of key biological, biophysical and 
biomechanical parameters of a healthy tissue would allow a damaged tissue function recovery. 
The system used in our laboratory is based on the synthetic matrix of self-assembling peptide 
RAD16-I
90
 (see Chapter 2), that allows studying different aspects of cellular behavior such as 
proliferation, maintenance, and acquisition of complex cellular structures with characteristics of 
tissues and organs.
91
. Additionally, these 3D systems achieve to mimic the in vivo milieu, 
recreating structural patterns that allow proper organization of the ECM and increasing cell 
capacity of differentiation and proliferation. In this context, during the last years, the group has 
obtained a series of study models working with adult cells: MC3T3
92
 (cells of mouse calvaria), 
MEF
93,94
 (Mouse Embryonic fibroblasts), hNDF
95
 (normal human dermal fibroblasts); and 
embryonic stem cells: mESC
96
 (Mouse Embryonic stem cells). 
Meanwhile, the RECATABI European project coordinated from our laboratory proposed to 
develop a bioengineering platform to implant subcutaneous Adipose Tissue-Derived Progenitor 
Cells (subATDPCs) in the damaged tissue of the heart after MI, with the aim to promote 
function recovery. The 3D mentioned systems provide the cells great freedom of migration, 
leading to the formation of intracellular contacts and resulting in the appearance of emergent 
properties of self-organization acquisition. However, their mechanical performance is not 
suitable for their direct introduction in a highly stressed tissue such as the heart. Therefore, the 
combination of RAD16-I with elastomeric membranes (to provide mechanical support) was 
proposed for the culture of subATDPCs and subsequent implantation of the platform in animal 
models (mice and sheep). 
Thus, the general objectives of the present thesis, which will be addressed separately in the next 
three chapters, are the following: 
 
- To obtain an in vitro model to study the behavior of subATDPCs in a truly 3D 
environment for the understanding of key biological, biophysical and biomechanical 
parameters regulating the cardiac differentiation process (Chapter 2). 
 
- To obtain a system to analyze the effect of electrical stimulation in the developed in 
vitro 3D model (Chapter 3). 
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- To evaluate innovative combinations of scaffolds and cells for novel cell-delivery 
system to ensure high cell survival and enhanced tissue integration after implantation 
(Chapter 4). 
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2.1 BACKGROUND 
2.1.1 Overview 
After myocardial infarction (MI), the principal purpose of medical practice is to reconstitute the 
blood flow towards the affected area as soon as possible, to avoid at the maximum extent the 
formation of necrotic tissue. Unfortunately, it is not always possible, and the prolonged 
ischemia produces a high degree of cardiomyocyte (CM) death, which leads to a reduction of 
heart normal function. With the aim to restore this function, big efforts are being focused in the 
delivery of cells to the damaged site. Although the present clinical trials of cell therapy to 
provide a “proof of concept” of its viability, the encouraging results observed have a limited 
success in damaged myocardium regeneration1. Valuable lessons can be learnt from human 
myocardium and stem cell (SC) biology that would help scientists to develop new effective, safe 
and affordable regenerative therapies. Therefore, in vitro and in vivo models are nowadays 
being widely studied. 
Humans heart is one of the organs with lowest regenerative capacity, but hearts innate ability to 
regenerate has been extensively reported in amphibians2, fish, and recently in developing 
mammals3. Zebrafish4 in vitro model is one example of particular importance in Cardiac Tissue 
Engineering (CTE) due to its ability to regenerate approximately 20 % of its resected ventricular 
mass two months following heart injury3,5. Interestingly, this heart muscle regeneration does not 
make use of SC, instead, mature heart muscle cells regress to SC-like state and re-differentiate. 
Whereas, in adult mammals the situation seems to be different. Typically, mammalian hearts 
respond to injury by scarring, whereby the damaged cardiac muscle is replaced by fibrotic scar 
tissue6.  
In vivo models are of high interest, but their high-complexity limit the possibility to analyze 
specific factors. Although the long-term goal of tissue engineering (TE) is to enhance in vivo 
regeneration, it also allows developing strategies to study such factors in a more controlled 
manner. Therefore, in a short-term approach TE can help to improve our understanding of how 
cells respond biochemically and in terms of spatial organization to the features found in their 
native environment, and to specific induction factors. These in vitro models also provide 
accurate approaches that may guide the creation of three-dimensional (3D) engineered cell 
aggregates. In this sense, innovations in the fields of biomaterials scaffolds, tissue matrix 
environment, and chemical or biological scaffolds are under development to understand the 
cellular response7. 
Cells introduced in the infarcted myocardium are hoped to induce angiogenesis, inhibit 
apoptosis, help to recover hibernating myocardium, activate endogenous repair mechanisms, 
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and create a new contractile tissue8. There is a strong possibility that implanting undifferentiated 
SC in vivo lead to a low engraftment and as a consequence to limited myocardial regeneration 
effect. Therefore, it is possible that some degree of cardiomyogenic differentiation of SC in 
vitro prior to transplantation would help to solve these issues. Additionally, this pre-
differentiation may also alleviate the probability of spontaneous differentiation of SC into 
undesired lineages and reduces the risk of teratoma formation9. Moreover, it is likely that, 
without previous differentiation, only a small fraction of the transplanted cells would 
differentiate into the cardiomyogenic lineage, thus reducing the efficacy of the therapy. The 
development of efficient protocols for directly cardiomyogenic differentiation in vitro is thought 
to provide a much more amenable model to molecular characterization and genetic 
manipulation1. 
In this chapter, we describe an in vitro model of subcutaneous adipose tissue derived progenitor 
cells (subATDPCs) in a 3D system with the aim to analyze its cardiogenic potential before 
implantation in animal models. 
2.1.2 In vitro models 
The major process to reverse the left ventricular remodeling would be the enhancement of CMs 
regeneration as well as stimulation of neovascularization within the affected area of the 
myocardium. While animal models clearly have shown benefits of SC therapy to improve 
cardiac function after MI and ischemic heart failure, clinical trials in humans have shown to 
provide restricted benefits10. Animal models display the integrated responses that result from 
complex interactions between tissues and organs. Nonetheless, they fail to capture important 
facets of human responses, and they are very costly, time-consuming, and ethically 
controversial11–13. However, it has been widely proposed that understanding the underlying 
biology is the first step to a successful breakthrough in the development of new and efficient 
therapies. To achieve this goal the complex cellular microenvironment needs to be 
deconstructed into simpler and predictable systems. Decompose 3D microenvironments and the 
associated processes into adhesive, mechanical, and chemical components will aid in the 
understanding of the fundamental mechanisms that guide these processes14. Additionally, it 
would help researchers to identify and analyze the role of specific critical factors in human 
physiology and pathophysiology, or regulate SC fate. These approaches have already provided 
useful tools for controlling cell differentiation with potential clinical application and could also 
be precious to accelerate translational research11.  
Life is not entirely flat: the milieu is a crucial fate determinant 
Functional systems consist of cells growing in two dimensions (2D) and cells growing in 3D 
structures. Both environments are in close contact and interact one to each other. A high 
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percentage of in vivo cells are organized in a 3D microenvironment (provided by the 
extracellular matrix, ECM), but their study in vitro has mostly been performed in 2D Petri 
dishes. Studies in standard cell cultures have produced many important conceptual advances. 
However, the change from a 3D in vivo milieu to a 2D tissue culture substrate, could lead to a 
differential cell behavior. Specifically, they can differ considerably on their morphology, cell-
cell and cell-ECM interactions, and gene expression patterns from those growing in more 
physiological 3D environment (see Figure 2.1-1)11,12,14. This fact can be explained due to the 
unnaturally polarization found in 2D platforms for cells that are used to grow in a 3D milieu. In 
these systems cells have one side attached to a rigid and flat substrate and the other one exposed 
to culture media, what reduce cell-cell and cell-ECM interactions15. Additionally, the 
accessibility to the soluble factors (cell secreted factors and exogenous added factors) in 2D 
systems is quite easy since they are free to mix convectively through the medium, leading to a 
rapid equilibration. Therefore, conventional 2D cell cultures, in which cells grown in 
physiological constrained conditions, do not mimic adequately in vivo systems, which limits 
their potential to predict the cellular responses of real organisms12,16. 
The 3D in vitro models were developed to recreate the in vivo cellular environment offered by 
the ECM and neighboring cells. This new milieu provides unique perspectives on the behavior 
of the cells, developing tissues and organs11. During the last two decades, significant discoveries 
have shown that ECM plays an important role in the behavior of biological tissues. The 
interactions between cells and the ECM can determine whether a given cell undergoes 
proliferation, differentiation, apoptosis or invasion15,16. Additionally, it has been widely reported 
the great importance of the direct connection between cells and the ECM through integrin 
receptors. 
In this context, 3D models, which are constituted by cells, 3D matrices (natural or synthetic) 
and effector molecules, fulfill the need for reductionist approaches to understanding in vivo 
molecular mechanisms (see Figure 2.1-1)11. These models have the potential to improve the 
physiological relevance of cell-based assays and advance the quantitative modeling of 
biological systems from cells to organisms12. They allow the cells to integrate many external 
cues (including those that arise from various ECM components, mechanical stimulation, and 
soluble signals from adjacent and event distant cells) to generate a basal phenotype and respond 
to perturbations in their environment. Additionally, these models mimic the limited access to the 
soluble factors due to structural features such as pore size, interconnectivity, gel dimensions, 
cell density, and solute size and charge14. The 3D structure also allows having adhesions 
distributed in all three dimensions without prescribed polarity. 
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Figure 2.1-1: Cell and tissue organization in 2D vs. 3D cultures. The cues encountered by a cell are strikingly 
different between an ECM- coated glass or plastic surface (2D) and a typical 3D ECM. a) A cell growing on 2D flat 
surface. b) Cell cultured in 3D in vitro model mimicking the natural ECM. c) Biological function comparison of cells 
growing on 2D surface vs. 3D system. Image adapted from Baker et. al. 2012 11,14 
In vitro 3D approaches enable a more accurate study of the molecular mechanisms underlying 
human diseases and better prediction of drugs and therapies effect, compared to 2D systems15,17–
20. In any 3D model system, the particular cellular and matrix microenvironment provided to 
cells can substantially influence the experimental outcome. 
Extracellular matrix 
Within the most part of pluricellular organisms, the cells are organized in cooperative groups 
called tissues. The cells secrete various macromolecules that interact one to each other forming 
a complex network known as ECM. This structure is involved in the maintenance of the tissue 
structure and possesses a reticular organization where the cells can migrate and interact one to 
each other (Figure 2.1-2)21. There is a serial of essential components found in ECM, which 
composition varies between tissues. From merely structural point of view, collagens provide 
strength to the tissues, elastin ensures tissue flexibility, and glycoproteins maintain tissue 
cohesiveness. Another important element is the ground substance that fills the gaps between 
protein fibers of the ECM. This gel-like substance is composed of different types of 
polysaccharides, mainly glycosaminoglycans (GAG), and to a less extent some adhesion 
glycoproteins. This complex structure controls the bulk and local mechanical environment. 
Additionally, it contributes to the microenvironment through their own signaling moieties and 
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their ability to bind growth factors (GFs), cytokines, enzymes, and other diffusible molecules. 
This property to bind soluble effector molecules significantly slows their diffusion and 
therefore, serves to fine tune their local concentrations and gradients11,13. Therefore, both the 
molecular composition and physical properties of the ECM are necessary for the control of 
fundamental cell processes. Additionally, ECM integral role in regulating the spatial distribution 
of nutrients, gases, and soluble effector molecules also play an essential role14. It is also 
important to mention that cells secrete their own ECM, which becomes incorporated into the 
local environment13. 
 
Figure 2.1-2: Extracellular matrix. The composition, architecture, and degree of crosslinking dictate the 
mechanical properties of ECM and control the transmission of mechanical forces to cells. Collagen fibers resist 
tensional and compaction forces, while proteoglycans (PGs) control hydration. PGs also hinder protein transport by 
their high, fixed charge density. Matrix composition also controls cell adhesion and migration. Furthermore, its 
sensibility to proteolytic enzymes will determine the ability of the cell to remodel the matrix and migrate through it. 
Image adapted from Griffith et. al. 200613. 
Cell-ECM interactions: integrin and non-integrin receptors 
Cell adhesion is fundamental for tissue formation and integrity. Moreover, for TE strategies it is 
essential to know how cells can interact with the ECM and transduce the information received 
by extracellular molecules into an intracellular event22. Adhesion molecules are functional 
receptors expressed in the cellular membrane that actively participate in physiologic and 
pathologic phenomena. Their underlying characteristic is their capacity of transducing signals 
and modulate signaling cascades. Cell surface possesses two kinds of receptors: integrin and 
non-integrin receptors. 
Integrins are heterodimeric transmembrane receptors and the major group of adhesion receptors 
that connect cells to components of the ECM (Figure 2.1-3)23. In the case of human cells, it has 
been identified 18 α-subunits and 8 β-subunits which gives rise up to 24 distinct integrin 
heterodimers24. Both the integrin α and β subunits are type I transmembrane glycoproteins with 
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large extracellular domains followed by single-spanning transmembrane domains, with the 
exception of β4, which has a short cytoplasmic domain25. 
The cytoplasmic domains of both subunits are connected to the actin cytoskeleton of the cell via 
associated proteins also known as adaptor proteins23. This particular structure connects cells 
mechanically with their surrounding environment acting as “cellular sensors”. Integrins work in 
a bidirectional signaling manner24. On one direction, the adhesiveness of integrins can be 
dynamically regulated in response to cytokines, chemokines or other stimuli in a process known 
as inside-out signaling. On the other direction, specific ligand binding as well as mechanical 
forces generate outside-in signals that trigger intracellular signal transduction cascades23,25. 
These signal transduction cascades play a crucial role in a wide number of cellular processes 
both physiological23,26 and pathological26–28. In conclusion, cell surface integrin receptors and 
the contractile cytoskeleton pull against the ECM to sense the stiffness of the 
microenvironment, which initiate specific cellular responses by, for example, modulating 
changes in gene expression. 
 
Figure 2.1-3: Integrin scheme. Transmembrane integrin receptors mediate cell adhesion. The extracellular head 
region generally binds ECM basement membranes or connective tissue, but it also can bind neighboring cells, 
bacterial polysaccharides, or viral coat proteins. Through all these interactions, integrins mediate different processes: 
(1) stable adhesion to basement membranes, (2) formation of ECM and migration on such matrices, (3) formation of 
platelet aggregates, (4) establishment of intercellular junctions in the immune system, and (5) bacterial and viral entry 
during infectious diseases. Furthermore, integrin-mediated adhesion modulates signaling cascades in control of cell 
motility, survival, proliferation, and differentiation. Image adapted from Pearson Education Inc.29. 
Non-integrin receptors are a wide range group of cell surface receptors not as widely studied as 
integrins. Proteoglycans, CD36, and laminin-binding proteins belong to this group and are the 
most analyzed. Among proteoglycans, syndecan and CD44 are the most widely studied. The 
first one is a transmembrane proteoglycan which GAG side chains are represented by 
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chondroitin sulfate and heparin sulfate22. Syndecan surface receptors bind to collagens, 
fibronectin, thrombospondin, and other ECM receptors22. CD44 is a cell surface glycoprotein 
which carries N- and O-linked sugars and GAG side chains22. It binds to type I and IV collagens 
and hyaluronan playing a vital role in cell adhesion and movement22. On the other end, CD36, 
also known as FAT (fatty acid translocase) is an integral membrane protein found on the surface 
of many cell types. It binds many ECM ligands including collagen, thrombospondin, anionic 
phospholipids, and oxidized LDL. Additionally, it directly binds to long chain fatty acid acids 
and may function in the transport and/or as a regulator of fatty acid transport30. In the case of 
laminin-binding proteins it is known that cells express many proteins (integrin receptors 
between them) that bind to laminin. The non-integrin receptor most amply studied is the 67 kDa 
laminin receptor (67LR) since it is an important molecule both in cell adhesion to the ECM and 
in signaling transduction following this binding event. This protein also plays critical roles in 
the metastasis of tumor cells31. 
Cell-cell interactions 
Mammalian cells are in close contact and communicate one to each other. They are able to 
coordinate their behavior sending and receiving a variety of chemical signals. This ability is the 
hallmark of multicellular organisms. Therefore, cell-cell communication refers to the direct 
interaction between cell surfaces32, which allow them to communicate in response to changes in 
their environment. Cell-cell communication via cell adhesion is critical for assembling cells into 
tissues, controlling cell shape and cell function. The major cell-cell adhesion sites are: tight 
junctions, anchoring junctions, and communication junctions. This division is based upon the 
function they serve21,32.  
Also called occluding junctions, tight junctions form the closest contact between adjacent cells, 
preventing small molecules from leaking between the cells and through the sheet (Figure 
2.1-4a). This allows the sheet of cells to act as a cellular filament space wall within the organ, 
keeping molecules on one side or the other. Anchoring junctions mechanically attach the 
cytoskeleton of one cell to the cytoskeletons of other cells or to the extracellular matrix. They 
are commonest in tissues subject to mechanical stress, such as muscle and skin epithelium32,33. 
Anchoring junctions are multiprotein complexes found in all cell types where they stabilize the 
cells position, provide stability and rigidity, and support tissue integrity by holding cell sheets 
together (Figure 2.1-4b). Additionally, anchoring junctions regulate the motility of both single 
cells and cellular masses through their substrates. These anchor points are highly dynamic, 
primarily associated with actin filaments, and come in many different forms34. Anchoring 
junctions called desmosomes connect the cytoskeletons of adjacent cells while 
hemidesmosomes anchor epithelial cells to the basement membrane. Proteins called cadherins, 
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most of which are single-pass transmembrane glycoproteins, are responsible for creating the 
critical link32. 
 
Figure 2.1-4: Types of cell junctions. These three models represent current thinking on how the structures of the 
major types of cell junctions facilitate their function. (a) Tight junction, (b) Anchoring junction, and (c) 
Communication junction. From Biology. Chapter 7: Cell-cell interactions32. 
The third group of cell-cell adhesion sites is communicating junctions, which allows the direct 
transfer of a chemical signal from one cell to an adjacent one (Figure 2.1-4c). In animals, these 
direct communication channels between cells are called gap junctions. Gap junctions are 
aggregates of intercellular channels composed of connexons, which are constituted by six 
identical transmembrane proteins (see Figure 1.1-10). The proteins within a connexon (called 
connexins) are arranged circularly to create a channel. A gap junction is formed when the 
connexons of two cells align perfectly, creating an open channel spanning the plasma 
membranes of both cells. These channels establish direct physical connections that link the 
cytoplasm of two cells together. The direct connection allows the transfer of small substances 
such as salts, sugars and amino acids, but prevent the passage of larger molecules such as 
proteins. The ability of adjacent cells to share ions through low-resistance pathways is 
fundamental to the function of electrically excitable cells, such as neurons, heart, and smooth 
muscle32,35. 
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2.1.3 Self-assembling peptides as three-dimensional scaffolds 
An overwhelming number of biomaterials have been developed to study, as well as to direct, 
cellular interactions in 3D14. Not only the theoretical base but also the technical procedure needs 
to be widely analyzed. These systems typically begin with a liquid precursor containing 
suspended cells, which gels or solidifies in a cytocompatible and hydrated manner14. The 
resulting gels might be porous to enable nutrient and waste exchange, and need to possess 
sufficiently mechanical properties to be self-supporting. Nanomaterials are emerging as the 
principal candidates to ensure the achievement of a proper instructive cell niche with good drug 
release/administration properties36. 
The discovery and development of self-assembling peptides (SAPs) revolutionized the TE 
community. By definition, self-assembly is the spontaneous organization of molecules into 
structurally well-defined arrangements, under thermodynamic equilibrium conditions, due to no 
covalent interactions37,38. Self-assembly is ubiquitous in nature. It has been observed that under 
variety of conditions, amphiphilic molecules spontaneously assemble into aggregates with 
tunable size and structure in response to change in their physical properties39. The nanofibers are 
1000-fold smaller than synthetic polymer microfibers and similar in scale to ECM. This 
property allows mimicking better the 3D environment found in vivo. A widely studied SAP was 
EAK16-II, a 16 amino acid peptide found as a segment in the yeast protein, Zuotin. Its 
peculiarity is the alternating alanine (A, neutral charge), charges of glutamic acid (E, negative 
charge), and lysine (K, positive charge) with regularity: Ac-AEAEAKAKAEAEAKAK-NH2. 
This particularity creates a secondary bipolar structure that induce the self-assembly in high 
ionic strength medium. The interactions obtained after the self-assembly are weak and non-
covalent (hydrogen bonds, ionic bonds, hydrophobic interactions, van der Waals interactions, 
and water-mediated hydrogen bonds)40. This type of nanofiber structure is stable under changes 
in temperature (T), pH, concentration of denaturing agents (urea, guanidinium hydrochloride), 
and degradation by proteolytic enzymes in vitro39,41. 
SAPs can be classified in three main blocks: (1) Type I, which forms β-sheet structures, (2) 
Type II, which forms both β-sheet and α-helix structures, and (3) Type III, which forms 
monolayers on surfaces. SAPs included in the first group are subclassified according to the 
scheme of repeating residues in each face of the peptide. Depending on the alternating 
positively and negatively charged arrangement of amino acids, peptides are divided in several 
moduli: (I) -+-+-+-+, (II) --++--++, and so on. The number following the peptide name is the 
modulus that belongs to. The most hopeful property of EAK16-II is its apparent lack of toxicity. 
Other SAPs models have been discovered with the same properties as EAK16-II. In this work, 
we focus our attention in RAD16-I41. 
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PuraMatrixTM / RAD16-I Self-assembling peptide 
RAD16-I (AcN-RADARADARADARADA-CNH2, R= Arginine (positive charge); A= Alanine 
(neutral charge); and D= Aspartic Acid (negative charge)) is a 16-residue peptide, member of 
the ionic self-complementary oligopeptide family. This type of oligopeptides consists of 
internally periodic repeats of alternating ionic hydrophilic and hydrophobic residues forming a 
β-sheet. The structure of the β-sheet present two differentiated surfaces: 1) one polar surface 
with regular repeating charged ionic side chains and, 2) a non-polar surface with alanine 
residues. Due to this structure, all charged amino acids lie on the same side providing them the 
capacity of self-assemble in the presence of monovalent cations. The self-assembly ends in the 
development of a nanofiber network with pores of 5-200 nm in diameter and over 99 % water 
content (Figure 2.1-5)37,38. The ionic side chains, complementary one to each other, form 
intermolecular ionic bonds, while methyl groups of alanine residues form hydrophobic β-sheet 
interactions (Figure 2.1-5c). Other features, like the intermolecular hydrogen bonds in 
conventional β-sheet, contribute to the formation and stability of the structure42.  
 
Figure 2.1-5: Self-assembling process of RAD16-I peptide. (a) Molecular model of the RAD16-I molecular 
building block. (b) Molecular model of RAD16-I molecules undergoing self-assembly. (c) RAD16-I peptide is 
formed by alternating hydrophilic and hydrophobic amino acids forming an antiparallel β-sheet configuration that 
self-assembles into nanofiber network. Increasing the ionic strength and adjusting pH to neutrality the peptide easily 
turns into a gel43. (d) The self-assembling peptide is examined by using scanning electron microscopy. (Scale bar, 
500 nm.)44. 
It has been reported that the ionic strength (within a range) increase the stability of β-sheet 
structure inducing some order, and leads the self-assembly into a peptide matrix45. Monovalent 
ions do not have a particular position in the matrix structure, but their role is important because 
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they are the driving force that stimulate the self-assembly. These matrices are chemically and 
physically stable under physiological conditions and do not dissolve with heat neither in acidic 
or alkaline solutions nor dissolve upon addition of guanidine hydrochloride, SDS/urea or a 
variety of proteolytic enzymes46,47. Additionally, it has been demonstrated that RAD16-I 
produces no noticeable immune response, nor inflammatory reaction in animals, nor 
cytotoxicity41. 
Although RAD16-I has been shown to support attachment and/or differentiation of a variety of 
cell types, it does not contain any specific peptide signaling motif. Therefore, this environment 
can be defined as “non-instructive” milieu from the point of view of cell receptor 
recognition/activation48.  
During the last years, Semino and collaborators have been studying the effect of three-
dimensional milieu based on RAD16-I in the behavior of different cell types. Indeed, Garreta 
et.al. cultured mouse Embryonic Stem Cells (mESC) and Mouse Embryonic Fibroblasts (MEFs) 
encapsulated in RAD16-I with the aim to analyze the differentiation into osteoblast-like cells. It 
was shown that mESCs acquired an osteoblast-like phenotype when cultured both in 2D and 3D 
conditions, but MEFs only underwent osteoblast differentiation when cultured in 3D RAD16-I 
system and induced with osteogenic inductors49,50. Another approach using this peptide scaffold 
is the one proposed by Quintana et.al. to study MEFs de-differentiation. Following Garreta et 
al.’s work, MEFs were cultured in RAD16-I, and it was detected that they only underwent 
osteogenesis after osteogenic induction whereas adipogenesis and chondrogenesis occurred with 
and without adipogenic/chondrogenic induction. Therefore, they concluded that MEFs cultured 
in 3D lost their fibroblastic phenotype and became chondrocyte-like cells51. Fernandez-Muiños 
et.al. continued the study analyzing the influence of matrix on the differentiation process as well 
as the potential participation of genes involved in early tissue organization. Interestingly, cells 
only underwent chondrogenic differentiation under certain mechanical conditions, characterized 
by low stiffness (G’ ~ 0.1 kPa)52. Also in this area, Bussmann et. al. reported the development 
of chondrocyte-like constructs using human normal dermal fibroblasts (hNDFs)53. In parallel, 
Genové et. al. reported the functionalization of RAD16-I to enhance the formation of confluent 
cell monolayers of human aortic endothelial cells (hAEC)38, and Sieminski et. al. demonstrated 
the ability of RAD16-I to support robust capillary morphogenesis48,54. Genové et al. also 
assessed a new way to culture rat hepatocytes preserving their distinct functionality55 and Wu et. 
al. demonstrated the capacity of sandwich cultures with modified instructive self-assembling 
peptides to promote cell-matrix interaction56. In addition, recent studies developed by Alemany-
Ribes et.al. have shown that cells respond differently to photodynamic therapy in 2D and 3D 
microenvironments based on RAD16-I (the effect in 3D is dramatically lower). Therefore, it 
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was confirmed that this 3D system aptly reproduces one of the most important factors limiting 
the efficacy of photodynamic therapy in clinical practice.  
These results lead Dr. Semino’s laboratory to hypothesize that this 3D-matrix would allow 
dedifferentiating adult cells into early precursors and/or into other lineages if the surrounding 
conditions were appropriate. Peptide scaffold provides a favorable microenvironment for 
normal progenitor cell kinetics and enhances cell differentiation57. It was also demonstrated the 
significance of the mechanical strength of peptides materials, which is proportional to the 
peptide concentration. Interestingly, collagen type I gel show similar stiffness at these 
concentrations, suggesting that both materials have similar mechanical properties, so it is 
possible that cells respond in a similar way growing in both scaffolds43. 
2.1.4 Study of specific factors effect on cell behavior 
In vitro studies of cell behavior in different tailored environments may help to improve cell 
survival under low nutrient and oxygen conditions. In addition, this can enhance cell 
differentiation58 in the infarcted tissue59,60. In this chapter, 3D systems of RAD16-I with various 
modifications and distinct chemical inductions are analyzed to evaluate the effect on cell 
maintenance and differentiation towards the cardiac phenotype. 
Matrix modification 
Biomaterial science has taken a step forward with designed nanofibers to render more 
biomimetic scaffolds. In this sense, tailored SAPs have been designed. A novel and promising 
strategy combines SAPs with functional motifs. These hydrogels have been modified with 
dextran macromolecules, laminin and collagen motifs, integrin-binding sequence, laminin 
receptor binding sequence, and heparin-binding sequence. These modifications could be useful 
to better mimic cardiac environment or even for further in vivo implantation to improve cardiac 
function after MI. It is strongly believed that the attachment of functional motifs to the 
nanofibers of the engrafted scaffold combined with cell delivery could have a beneficial effect. 
Several peptide motifs have been described to improve myogenic activity with the aim to 
maintain phenotype, allow cell-cell contact, establishment of gap-junctions, as well as cellular 
viability38. The cell-adhesion motif RGD (R: arginine, G: glycine, D: aspartic acid) that derives 
from fibronectin is, by far, the most characterized and often employed functionalization system. 
This recognition motif has shown to display high biological activity on cell anchoring, growth, 
migration, survival, and differentiation of encapsulated cells61. Focusing on the obtaining of a 
functionalized matrix scaffold, RAD16-I peptides were blended with small proportions (1-5 %) 
of RAD16-I peptides modified to contain the RGD motif. These modified peptides were 
synthesized by extension of RAD16-I sequence at the amino terminal (RAD-RGD peptide, 
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Table 2.1-1). Additionally, in order to keep the active sequence free and active, two glycines 
were added between the main chain and the new sequence. 
Table 2.1-1: RAD16-I / RADRGD. Sequences of RAD16-I and RAD16-I modified with RGD. 
PEPTIDE SEQUENCE 
RAD16-I AcN-RADARADARADARADA-CONH2 
RADRGD AcN-GPRGDSGYRGDS-GG-RADARADARADARADA-CONH2 
The binding domains of heparin, that has numerous important biological roles associated with 
its interaction with diverse proteins, are also interesting motifs to analyze. The presence of 
heparin can allow better control of local gradients of matrix-binding molecules such as GFs, 
chemokines or others, which can be maintained in the matrix and later released 
proteolytically13,62,63. Heparin is widely used as an anticoagulant, but its real physiological role 
remains unclear64. It is a linear polydisperse sulphated polysaccharide consisting mainly of 
repeating units of 1→4-linked pyranosyluronic acid and 2-amino- 2-deoxyglucopyranose 
(glucosamine) residues. The presence and frequency of these saccharide units vary with the 
tissue source from which heparin is obtained (Figure 2.1-6). It possesses the highest negative 
charge density of all known biological macromolecules with an average of 2.7 negative charges 
per disaccharide provided by sulfonic and carboxyl groups. Consequently, the most common 
binding interaction between heparin and proteins is through ionic interactions. However, non-
electrostatic interactions such as hydrogen bonding and hydrophobic interactions can also 
contribute to the stability of heparin–protein complexes65,66. The sequestering of GFs helps to 
localize their activity, protect them from degradation, and in some cases enhance their binding 
to a cell surface receptors67. Moreover, heparin can participate in the modulation of various 
cellular functions such as cell growth, differentiation, morphology, and migration68. For this 
reason, and due to their functional resemble the native ECM polymeric GF delivery systems 
based on heparin are widely used69. Similar strategies report the binding of heparin with other 
types of materials through covalent interaction with polymers such as alginate, polycaprolactone 
and collagen or entrapped within chitosan62,70–73. 
 
Figure 2.1-6: Heparin structure. Heparin is a linear polysaccharide with variable composition consisting on 
repeating units of disaccharides with its primary sequence contains an uronic acid residue and a glucosamine residue. 
Its composition varies depending on the tissue.(X= H or SO3-; Y= Ac or SO3-). Image adapted from Murugesan et al. 
2008 65. 
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Chemical and biological induction 
Enhancement of cardiomyogenic differentiation has been extensively assessed on different 
sources of human SCs by exposure to several chemical and biological stimuli1. ESCs are 
capable of spontaneously differentiate into cardiomyogenic lineage in vitro (even in the absence 
of cytokines and GFs)1. However, in the case of adult stem cells (ASCs) there is no evidence of 
differentiation in the absence of stimulation of exogenous cytokines and GFs. However, it has 
been reported that specific biological activity and interactions can be facilitated through the 
addition of soluble or insoluble factors and biological domains14. 
The members of transforming growth factors beta superfamily (including TGF-β1 itself, and 
bone morphogenic protein 2 (BMP-2) and 4 (BMP-4)) have been extensively reported to induce 
cardiomyogenic differentiation in ESCs. Other GFs implicated in cardiomyogenic 
differentiation are insulin-like growth factor I (IGF-I), platelet-derived growth factor (PDGF), 
basic fibroblast growth factor (bFGF), oxytocin, and erythropoietin. They have been reported to 
regulate cardiac specification of mesodermal progenitors and trigger expression of cardiac 
proteins. In addition, a number of chemical compounds have been reported to induce 
cardiomyogenic differentiation in vitro. Chemicals result to be less labile, with longer active 
half-life in solution than proteins, and are easily manufactured. Therefore, they are structurally 
and chemically more defined compared to proteins. Some of the synthetic chemicals known to 
promote cardiomyogenic differentiation in vitro are 5-azacytidine (5-aza), dimethyl sulfoxide 
(DMSO), L-ascorbic acid 2-phosphate (Aa 2-P), and retinoic acid (Ra). 5-aza is a nucleoside 
used as inhibitor of DNA methylation and said to be a potent inducer of cardiomyogenic 
potential of ESCs and ASCs (in particular bone marrow mesenchymal stem cells (BM-MSCs)). 
DMSO has shown effective differentiation on ESCs74,75, the same as Aa 2-P and Ra which are 
derivatives of vitamin A. Finally, the most effective strategy, reported until now, to enhance the 
transdifferentiation of SCs is its co-culture with freshly isolated CMs58.  
RECATABI consortia used the protocol described by Smits and coworkers to induce 
cardiogenesis and CM differentiation in vitro. In this protocol, a combination of 5-aza 
treatment, followed by TGF-β1 and Aa 2-P stimulation was used to achieve a high-
differentiation efficiency in 2D cultures of human CM progenitor cells76. Recently it has been 
reported to also induce cardiomyogenic differentiation of adipose-derived stem cells77. 5-aza 
induces the expression of cardiac-specific proteins, but the mechanism by which the expression 
of these specific markers is increased is unclear. Unfortunately, this treatment is not suitable for 
further use in patients. Demethylation is not specific for early cardiac genes, but their effects are 
random. So, this is possible that this treatment leads to tumorigenic cells. 
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TGF-β1, transforming growth factor-beta 1, is a key molecule in the regulation of the 
differentiation switch. It simultaneously inhibits adipogenesis and activates myogenesis, 
enhancing cardiomyogenic differentiation. Aa 2-P, a stable form of vitamin C, increases the 
expression of muscle-specific glucose and ion transporters. Vitamin C can promote muscle 
differentiation likely through the increase of myogenic expression, which may in turn regulate 
muscle differentiation in vivo. Both, hormones and GFs are important regulators of myogenic 
cell differentiation, but little is known about the effect of vitamins on muscle differentiation and 
development78.  
Induction cardiac medium used was prepared with Iscove’s Modified Dulbecco’s Medium and 
HAMF12 Nutrient Mix, GlutaMAXTM supplement. The first one is a highly enriched synthetic 
media well suited for rapidly proliferating, high-density cell-cultures. The second one contains a 
wide variety of components (zinc, putrescine, hypoxanthine, and thymidine between others), 
and it is highly recommended to reduce the serum concentration. The combination of these 
media was supplemented with insulin-transferrin-selenium (ITS), minimum essential media, 
alpha (α-MEM), horse serum (HS), TGF-β1 and vitamin C. ITS has been reported to be required 
for optimal performance of serum-free media: insulin promotes glucose and amino acids uptake, 
lipogenesis, intracellular transport of proteins and nucleic acids; transferrin is an iron carrier and 
it may also help to reduce toxic levels of oxygen radicals and peroxide; and selenium, as sodium 
selenite, is a co-factor for glutathione peroxidase and other proteins, used as an anti-oxidant in 
media. About HS, it is known to contain twice the protein content and low concentration of 
trace elements than fetal bovine serum. It has been widely used for CMs maintenance and 
differentiation. With the aim to increase cell growth and viability, α-MEM was also added to 
supplement the medium. 
This protocol does not reach the high Good Clinical or Manufacturing Practice requirements 
because of the use of 5-aza. However, the proposed system could provide a framework for 
clinical adaptation76. Our working hypothesis sustains that providing a “non-instructive” 3D 
microenvironment with the nanometric scaffold RAD16-I would replace the role of 5-aza in the 
cardiogenic medium. Therefore, we suggest that seeding subATDPCs in a proper 3D 
environment together with some cardiogenic induction could promote enhancement of cardiac 
lineage. 
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2.2 PREVIOUS RESULTS 
2.2.1 Combination of RAD16-I and heparin 79 
One of the general aims of the RECATABI European Project was to design and fabricate a new 
biomaterial nanofiber matrix for controlled release of cell/tissue-inducing factors. This work 
was developed by Dra. Maria Teresa Fernández-Muiños, and was presented in her thesis 
entitled “Effect of the microenvironment in the in vitro chondrogenic and osteogenic 
differentiation of mouse embryonic fibroblasts”. 
Briefly, she evaluated the possibility of combining self-assembling peptide (RAD16-I) with 
heparin in different blended ratios in order to obtain a new biomaterial composite with good 
mechanical, structural and biological properties. The chemical and structural stability of the mix 
were assessed observing the formation of homogeneous hydrogels. Moreover, scanning electron 
microscopy (SEM) and circular dichroism (CD) results showed that the presence of heparin 
does not interfere in the nanofiber formation. 
Once analyzed the influence of heparin in the self-assembling process and nanofiber formation, 
it was tested the capacity of the composite to be used as a drug delivery hydrogel. For this 
purpose, a non-cumulative quantification of the vascular endothelial growth factor 165 
(VEGF165) angiogenic factor released by the composite and the control RAD16-I self-
assembling peptide was performed. Two different kinetics releases were observed for each 
scaffold. Interestingly, in the case of peptide-heparin composite a gradual release of VEGF165 
over time was observed during the 36 hours of experiment (Figure 2.2-1b). These results clearly 
indicate that the self-assembling-heparin hydrogel is a good composite biomaterial to bind and 
release physiologically significant quantities of VEGF165 in vitro during the first 24-36h, which 
could be used to promote a pro-angiogenic effect in an in vivo model. 
In order to know if the released GF was biologically active, a functional study was performed, 
with human umbilical vein endothelial cells (hUVECs). The results showed that the released GF 
have an effect of on hUVECs survival, maintenance and proliferation. Control groups without 
GF presented high mortality (Figure 2.2-1b). These results confirm that VEGF165 maintained 
their biological activity after being released from the hydrogels. No significant differences, in 
terms of cell number, were found between the GFs released from RAD16-I or the composite. 
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Figure 2.2-1: Analysis of RAD16-I and heparin combination effect. (a) Schematic process of the binding and 
release experiments. Gels were prepared and incubated with VEGF165 in binding buffer for 3 hours at 37 ºC. Then, 
the GF solution was removed, and the gels were incubated with binding buffer to allow the release of VEGF165. (b) 
Noncumulative release of VEGF165. After taking each sample, all the media was removed, and new media was added 
to the gels. (c) Effect of heparin and VEGF165 in cell proliferation. (d) Functional study of released VEGF165. 
VEGF165 maintains its biological activity after being released by the gel. (e) DAPI cell count for the functional study 
of released VEGF165. Cell number was significantly higher for samples supplemented with the VEGF165, released by 
the gels. 
2.2.2 Cells used in RECATABI project 
The cells used in this thesis were the ones designed for the RECATABI European Project. One 
of the candidates were BM-MSC which are able to transdifferentiate partially into 
cardiomyogenic lineage, but they were discarded because they rapidly undergo senescence 
during in vitro expansion 80. As we would need a large cell number, adipose tissue-derived 
progenitor cells (ATDPC) appear as a possible candidate. These cells have similar surface 
markers as BM-MSC81 and can be easily isolated and expanded in vitro. Dr. Antoni Bayés-
Genís group IGTP isolated ATDPCs from fad pads between skin and sternum from patients 
undergoing cardiac surgery. These cells were carefully characterized for their superficial antigen 
profile, proliferative properties, and gene and protein expression. These cells will be referred as 
subcutaneous ATDPCs (subATDPCs). 
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SubATDPCs superficial antigen profile and proliferative properties analysis 
A standard protocol for subATDPCs isolation and expansion was defined and validated by Dr. 
Carolina Soler-Botija in Hospital Germans Tries i Pujol (IGTP). The protocol was approved by 
the local Ethics Committee and informed consent was obtained from all patients. The study 
protocol conformed to the principles outlined in the Declaration of Helsinki. 
 
Figure 2.2-2: Subcutaneous ATDPCs superficial antigen profile. SubATDPCs express CD105, CD166, CD29, 
CD44 and CD90; reveling a mesenchymal stem cell (MSC)-like pattern both at passage 2 and passage 5. 
SubATDPCs were characterized using immunophenotipycal analysis to define the cells based 
on the molecules present on their surface. BM-MSCs were used as control cells. The clusters of 
differentiation analyzed were: CD105, CD44, CD166, CD29, CD90, CD117, CD106, CD34, 
CD45, and CD14. Flow cytometry levels of each antigen were defined by the ratio between 
specific antibody and IgG isotype control (1 = no difference). The results obtained showed that 
BM-MSCs express CD105, CD44, CD166, CD29, and CD106 (data not shown), while 
subATDPCs express CD105, CD44, CD166, CD29, and CD90; reveling a MSC-like pattern 
(Figure 2.2-2). SubATDPCs were also demonstrated to be capable of differentiate towards an 
adipogenic and osteogenic phenotype as it can be observed in Figure 2.2-3. 
 
Figure 2.2-3: In vitro characterization of subATDPCs cultured in monolayer. (a) Oil Red O staining of 
subATDPCs cultured in adipogenic differentiation medium showing lipid droplets depositions (red). (b) Von Kossa 
staining of subATDPCs cultured in osteogenic differentiation medium with the presence of calcium depositions (red). 
Scale bars 100μm. 
 
    
 
64 
 
Chapter 2 –PREVIOUS RESULTS: Cells used in RECATABI project 
 
On the other hand, proliferative analysis was carried out. The assay was performed in samples 
from six different patients to confirm reproducibility. The assay revealed subATDPCs 
duplication time was 3.1 days (Figure 2.2-4). 
 
Figure 2.2-4: Subcutaneous ATDPCs duplication time. Cell number per cm2 of two different pools of 
subATDPCs. 
Compilation of data from cardiac-specific genes, establishment of a gene profile and protein 
analysis 
The cardiomyogenic potential of subATDPCS was assessed by IGTP group. Part of his work 
was to analyze gene and protein cardiac profile by qRT-PCR, western blot and 
immunocytofluorescence staining. The expression of sarcomeric α-actinin (ACTN1), 
Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 (SERCA2), Gap Junction Protein 
alpha 1 (GJA1 - also known as Connexin-43, Cx43), Transcription Box Transcription Factor 5 
(TBX5) transcripts, Myosin Heavy Chain (MHC), cardiac Troponin I (cTnI), Insulin Gene 
Enhancer protein (ISL1), GATA binding protein 4 (GATA4), and NK2 Transcription Factor 
Related Locus-5 (NKX-2.5) were analyzed. 
The results of qRT-PCR revealed that subATDPCs expressed ACTN1, SERCA2, GJA1, and 
TBX5 transcripts, whereas no gene expression of MHC, cTnI, ISL1, GATA4 and NKX-2.5 was 
observed (Figure 2.2-5A). Protein expression was assessed by Western blotting showing 
expression of ACTN1, SERCA-2, and GJA1 at passage 5 (Figure 2.2-5B). 
Immunocytofluorescence at passage 5 was also performed to determine cell distribution of the 
cardiac markers GATA4, SERCA2, cTnI, TBX5, NKX2.5, ACTN1, MHC, and GJA1. 
Immunostainings were performed with samples from four different patients. The 
immunocytofluorescence results (Figure 2.2-5C) show expression of ACTN1, SERCA2, and 
GJA1 as well as a weak signal of TBX5 transcription factor. No expression of GATA4, cTnI, 
MHC or NKX2.5 was detected. 
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Figure 2.2-5. Study of cardiac specific genes expressed by subATDPCs. (A) SubATDPCs gene expression profile 
at passage 2 and 5 by qRT-PCR. (B) SubATDPCs cardiac protein expression profile by western blotting. (C) 
Immunocytofluorescence staining of subATDPCs. (a) TBX5 (green) and GJA1 (red) expression. Arrows indicate 
nuclear TBX5 signal. (b) ACTN1 (red) expression. (c) SERCA2 (green) and GATA4 (red) expressions. (d) MHC and 
cTnI immunostaings. Nuclei were counterstained with Hoescht 33342 (blue). 
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2.3 SPECIFIC AIMS 
In vitro models are of great interest to analyze specific factors of human physiology or 
pathophysiology. These systems provide a simplistic way to examine individual factors as 
compared to animal models, and better mimic the reality than 2D models. In this sense, the 
primary objective of this chapter is to better understand subATDPCs behavior when they are 
encapsulated in a the 3D environment provided by RAD16-I self-assembling peptide. Thus, the 
specific aims for this chapter are the following: 
- To evaluate subATDPCs viability and behavior in the self-assembling peptide scaffold 
RAD16-I peptide as a function of peptide concentration and cell number. Determine the 
best conditions to seed these cells in RAD16-I matrix for further analysis (section 
2.5.3). 
 
- To study the effect in subATDPCs viability and behavior of RGD motif and heparin 
polysaccharide modifications in RAD16-I matrix (section 2.5.4 to 2.5.6). 
 
- To assess the potential of subATDPCs to undergo proliferation in RAD16-I 3D cultures 
prepared with and without RGD and heparin polysaccharide modifications, under 
different conditions (section 2.5.7). 
 
- To study gene and protein expression of subATDPCs in RAD16-I 3D cultures prepared 
with and without RGD and heparin polysaccharide modifications, under different 
conditions (section 2.5.8). 
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2.4 MATERIALS AND METHODS 
2.4.1 Cell culture 
Subcutaneous adipose tissue-derived progenitor cells  isolation: SubATDPCs were isolated 
from fat pads between skin and sternum from patients undergoing cardiac surgery by Dr. Antoni 
Bayés-Genís in Hospital Germans Trias I Pujol (IGTP). Informed consent was obtained from all 
subjects, and the study protocol conformed to the principles outlined in the Declaration of 
Helsinki. Adipose tissue biopsy samples were processed as previously described 82,83. Briefly, 
samples were rinsed with phosphate buffer saline (PBS - Sigma; D8537-500mL) and cut into 
small pieces, removing visible blood vessels; thereafter, cells were isolated by collagenase II 
(Gibco; 17101-015) digestion. Adhered cells were grown under standard conditions (37 °C in 5 
% CO2 humidified atmosphere) in Minimum Essential Medium, alpha (α-MEM - Sigma; 
M4526) supplemented with 10 % fetal bovine serum (FBS - Lonza; DE14-801F; Lot 1SB003), 
1 % (v/v) penicillin-streptomycin (P/S - Labclinics; P11-010), 1 % L-glutamine (Labclinics; 
M11-004) and 5 µg/mL plasmocin (InvivoGen; ANT-MPT).  
Subcutaneous adipose tissue-derived progenitor cells culture: Culture flasks obtained for each 
patient were maintained for two passages to assure viability, correct growing and mycoplasma 
contamination. Unlike bacterial or fungal contaminations, mycoplasma contaminations cannot 
be detected by visual inspection and may not noticeably affect cell culture growth rates. 
However, mycoplasma infection has been shown to alter DNA, RNA and protein synthesis, 
introduce chromosomal aberrations and cause alterations or modifications of host cell plasma 
membrane antigens. For this reason, this step is important for further analysis.  
At passage 2, when cell density was about 20,000 cells/cm2, they were detached using Trypsin-
EDTA 0.05 % - 0.02 % (Invitrogen; 25300-062) and pools from 5 different patients were 
prepared. Each pool was registered with a letter, expanded during 3 more passages, and frozen 
at passage 5. Each passage was performed when a high level of confluence was reached (90 % 
approx.). The velocity to reach a confluent culture depends on the cellular type and the passage 
of the cells (number of cell divisions), in this case, the confluence was obtained after one week 
of culture. The medium was changed on alternate days.  
Subcutaneous adipose tissue-derived progenitor cells freezing and thawing: SubATDPCs 
(passage 5) were detached using Trypsin-EDTA 0.05 % - 0.02 % (Invitrogen; 25300-062) and 
counted to be resuspended at a final concentration of 1 million cells/0.5 ml. The freeze medium 
(used at 4 ºC) was based on FBS with 5 % of dimethyl sulfoxide tissue culture tested (DMSO  - 
Sigma; D2650). DMSO acts as a cryoprotector in order to avoid cellular membrane fracture by 
reducing the formation of intracellular water crystals. The freezing process was performed 
slowly by decreasing the temperature of the cells suspended in freezing medium from 4 ºC to     
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-80 ºC in several hours (24 hours). Aliquots of 0.5 mL per cryotube were prepared. SubATDPCs 
were maintained at -80 ºC up to a year. On the other hand, the thawing process must be 
completed quickly. As the cryotube was taken out -80 ºC freezer, it was directly submerged in a 
bath at 37 ºC until only a little part of cell suspension remained frozen. Then, the cellular 
suspension was mixed carefully with 10 ml culture medium pre-warmed at 37 ºC. The cells 
were centrifuged at 1,000 g during 5 minutes, and the supernatant suctioned to eliminate the 
remaining DMSO. The pellet was resuspended and seeded in T75 flasks. The fast thawing 
process avoids the osmotic exchanges through the plasmatic membrane between the cells and 
the medium. 
2.4.2 RAD16-I self-assembling peptide preparation 
Four different peptide variations of RAD16-I were analyzed: RAD16-I 0.3 % (w/v) without 
modifications, RAD16-I/RADRGD (95:5) 0.3% (w/v), RAD16-I 0.3% (w/v) with heparin 
(570:1) and RAD16-I/RADRGD (95:5) 0.3 % (w/v) with heparin (570:1). Shortly, 1 % 
nanofiber peptide (PURAMATRIXTM - Corning; 354250), was diluted to obtain a solution of 
0.3 % RAD16-I in sucrose 10 % (Sigma; S1888) as follows: 300 µL of RAD16-I were 
combined with 300 µL of sucrose 20 % and 400 µL of sucrose 10 %. In parallel, 30 µL of 1 % 
water solution RADRGD (synthesized by Peptide 2.0) was combined with 30 µL of sucrose 20 
% and 40 µL of sucrose 10 % to obtain a solution of RADRGD 0.3 %. Afterwards, RAD16-I 
0.3 % and RADRGD 0.3 % were mixed in a blend ratio of 95:5. To obtain the peptide with 
heparin, RAD16-I 0.3 % and RAD16-I/RADRGD 0.3 % were mixed with heparin 0.01 % in a 
blend ratio of 95:5. 
2.4.3 Three-dimensional cultures 
Assembly using cell culture insert: SubATDPCs pools were thawed at passage 5 and expanded 
until passage 7. At passage 7, cells were trypsinized, washed with sucrose 10 %, and 
resuspended in sucrose 10 % to render 1.6·105 cells in 40 µL (the experiments with different 
cell densities were adapted). All 3D cultures (encapsulations) start at passage 8. Three-
dimensional constructs for each peptide variation, previously described, were prepared mixing 
equal volume of the cell suspension and nanofiber peptide obtaining a final cell suspension 
containing 2·106 cells/mL. The mixture was thoroughly mixed by pipetting, and 80 µL were 
loaded into each 9-mm-diameter cell culture insert (PICM01250, Millipore, Billerica, MA) 
already placed inside a 6-well culture plates with 500 µL of media outside the insert to wet the 
membrane51. The medium penetrated in the insert from the bottom membrane inducing a 
bottom-to-top self-assembly of RAD16-I and thus the formation of a gel with cells suspended 
inside. Medium was added carefully in sequential steps on the top of the hydrogel and allowed 
to infiltrate, to wash out the remaining sucrose. Finally, 500 µL were loaded inside the insert 
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and 2.5 mL in the well. On alternate days, 500 µL of medium was discarded from the well and 
500 µL of fresh medium was added carefully on the wall of the insert until the end of the 
experiment. Incubation was performed, in the same way, as in 2D cultures (37 ºC, 5 % CO2). A 
scheme of the defined protocol is presented in Figure 2.4-1. 
 
Figure 2.4-1: Three-dimensional cultures assembly scheme. Firstly 2D cultures were trypsinized and expanded 
until passage 7. RAD16-I 0.3 % was mixed with cell solution (4·106 cells/mL) in a blend ratio of 1:1. The mixture 
was loaded inside a 9-mm-diameter cell culture insert already placed in 6-well culture plates with 500 µL of media 
outside the insert to wet the membrane. In the case of the protocol where the assembly was performed without cell 
culture insert, the mixture was loaded inside 48-well plates previously filled with 150 µL of medium. 
Assembly without cell culture insert: With the aim to avoid the use of cell culture inserts, an 
alternative protocol was established. Previous steps to the loading of the mixture were 
performed, in the same way, as with cell culture inserts. In this case, cell culture inserts were 
discarded and instead of 6-well plate, 48-well plates without treatment for cell culture 
(Labclinics; PAA30048X) were used. Each well was filled with 150 µL of medium, and the 
mixture of RAD16-I and cells was loaded quickly but carefully in the middle of the well. The 
viscosity of the RAD16-I and the low volume of medium allow maintaining the two liquid 
phases immiscible. The ionic strength of the medium induces RAD16-I self-assembling and 
thus the formation of a gel with cells encapsulated. It is important to load the mixture in one 
step carefully and assure not to touch the medium with the end of the tip. Medium was added 
and removed carefully in sequential steps, to wash out the remaining sucrose. Finally, all wells 
were filled with 800 µL of medium. On alternate days, 400 µL of medium was discarded from 
the well and 400 µL of fresh medium was added carefully until the end of the experiment. 
Incubation was performed, in the same way, as in 2D cultures (37 ºC, 5 % CO2). 
3D cultures maintaining: All 3D constructs were maintained in control medium during 4 days, 
when the medium was completely replaced. Half of the 3D constructs were induced with 
cardiac induction medium while the other half of the samples was refilled with control medium. 
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Samples were picked 2 and 4 weeks after induction for their analysis, and cells seeded in 2D 
cultures were taken as control. 
Control medium was based on α-MEM and supplemented with L-glutamine and 10 % FBS. 
Two formulations of α-MEM were tested: α-MEM from Sigma and α-MEM from Labclinics. 
The cardiac induction media used was based on the culture media described by A. Smits et. al.76 
with slightly differences. Induction cardiac medium was prepared using Iscove’s Modified 
Dulbecco’s Medium (IMDM - Gibco; 2198032), and HAMF12 Nutrient Mix, GlutaMAXTM 
supplement (Gibco; 31765027). The combination of these media was supplemented with ITS 
(Gibco, 41400-045), α-MEM 100x (Lonza, BE13-114E), HS (Sigma, H1138-100mL), Aa 2-P 
(Sigma, A4403), and TGF-β1 (Millipore, GF111). 
Both media (control and cardiac) were treated for possible contaminations of bacteria or 
mycoplasma. Penicillin/Streptomycin (P/S) was used to avoid bacterial contamination against 
gram-positive and gram-negative bacteria. Regarding on mycoplasma contamination 
Plasmocin™ was added to the medium. This product contains two bactericidal components. The 
first component acts on the protein synthesis machinery by interfering with the ribosome 
translation, and the other one acts on DNA replication. These two specific and separate targets 
are found in mycoplasma and many bacteria, but are entirely absent in eukaryotic cells. In 
contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas 
and intracellular forms. 
The composition of both media is presented in Figure 2.4-2. 
 
Figure 2.4-2: Culture media. Two culture media were prepared for the in vitro experiments. Control medium do not 
contain induction factors while cardiac induction medium was supplemented with various factors known to induce 
cardiac differentiation in different cell types. Both media were protected again bacterial and mycoplasma 
contamination with P/S and Plasmocin™, respectively. 
2.4.4 Macroscopic and microscopic analysis of 3D cultures 
With the aim to analyze the macroscopic behavior of 3D constructs, all samples were analyzed 
under Stereoscopic microscope Nikon digital Slight DS-2MV, while network formation was 
followed using Nikon Eclipse TE2000-1 microscope. 
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2.4.5 Congo Red staining 
Congo Red staining was performed to analyze the presence of the β-sheet structure 
characteristic of the self-assembling peptide RAD16-I. Samples were incubated with 0.1 % 
(w/v) Congo Red in water for 5 minutes and washed several times with PBS. Finally, the 
samples were analyzed under Stereoscopic microscope Nikon digital Slight DS-2MV. 
2.4.6 Toluidine Blue staining 
Toluidine Blue staining was performed to analyze the presence of highly negative charges 
provided by the heparin molecules. Briefly, samples were washed with PBS, incubated with 
Toluidine Blue 0.05 % (w/w) in water during 20 minutes, and washed several times with water. 
Finally, the samples were analyzed under Stereoscopic microscope Nikon digital Slight DS-
2MV. 
2.4.7 Live and dead staining (L&D) 
The viability of the cells cultured in 3D cultures was assessed using two-colour fluorescence 
cell viability assay based on intracellular esterase activity and plasma membrane integrity 
(LIVE/DEAD® Cell Viability Assays, Invitrogen; L-3224). Calcein AM presents an uniform 
green fluorescence in live cells by detecting intracellular esterase activity while, ethidium 
homodimer-1 bromide (EtBr) produces a bright red fluorescence by entering in dead cells with 
damaged membranes and binding to nucleic acids. Shortly, medium was removed, and 3D 
samples were rinsed with PBS (Labclinics; H15-002). After washing the encapsulations were 
immersed in PBS containing 1 µL calcein AM and 2 µL EtBr of the stock kits. After 15 minutes 
the staining solution was removed, and the samples were washed three times with PBS for 30 
min. Images were taken with Zeiss AxioVert 200M / ApoTome Microscope. 
2.4.8 Dapi and phalloidin staining (D&P) 
Cells were double stained using DAPI [4’,6-Diamidino-2-phenylindole] (Sigma; D9542) and 
Phalloidin–tetramethylrhodamine B isothiocyanate (Sigma; 7418). Briefly, the 3D constructs 
were fixed for 30 min using 2 % paraformaldehyde (PFA) diluted in PBS followed by 3 washes 
with PBS. Cell membranes were permeabilized in 0.1 % Triton x-100 (Sigma; X100-500mL) 
solution with soft shaking during 30 min, followed by 3 PBS washes. The samples were 
incubated with Phalloidin-TRITC at a final concentration of 1 µg/mL in PBS for 25 min. DAPI 
solution (1µg/mL in PBS) was added into the previous solution and incubated for 5 minutes to 
counterstain the nucleus. Samples were carefully washed 3 times with PBS to eliminate the 
background and examined under Zeiss AxioVert 200M / ApoTome Microscope.  
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2.4.9 MTT viability assay 
MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a colorimetric 
test based on the reduction of MTT to formazan crystals, giving purple color. This reaction only 
takes place when cellular reductase enzymes are active and, therefore; conversion is often used 
as a measure of viable cells. First, a MTT stock solution (10 mg/mL) was prepared with water, 
filtered through a 0.2 µm and stored at -20 ºC. Briefly, the medium was aspirated from the 
culture and MTT reagent (Sigma; M5655-1G) was added to a final concentration of 0.5 mg/mL 
in culture medium. The samples were incubated for 3 hours at 37 ºC in the dark. After the 
incubation, the solution was aspirated, and the constructs were lysed using DMSO (Sigma, 
D8418) to resuspend the formazan crystals. All samples were analyzed in triplicate. The 
absorbance was read at 550nm using microplate reader, Biotek ELX808. 
2.4.10 RNA extraction, purification, and quantification 
2D and 3D cultures were washed with PBS. Then, the samples were lysed, and RNA was 
extracted using PeqGold Total RNA kit (Peqlab; 12-6634-02). Briefly, the lysis was performed 
using RNA lysis buffer (Peqlab; 12-6834-02) with immediate inactivation of endogenous and 
exogenous RNases. Samples were disrupted by pipetting up and down with the micropipette 
(3D constructs growing in control medium) or a pestle (3D constructs growing in cardiac 
induction medium) and stored at -80ºC. Each 3D sample was constituted by two 3D 
encapsulations due to limited genetic material. The purification with PeqGold Total RNA kit 
provided a quick method for total RNA isolation based on the reversible binding characteristics 
of RNA to Perfect-Bind silica filters in centrifugation columns.  
Table 2.4-1: Equations for RNA purity calculation and RNA quantification. 
 EQUATIONS 
Relationship between nucleic acids and chemical 
impurities* (range 2-2.4) 
A260/A230 = (A260 – A320) / (A230 – A320) 
Relationship between nucleic acids and proteins** 
(range 1.8-2.1) 
A260/A280 = (A260 – A320) / (A280 – A320) 
 
RNA concentration 
[RNA] / μg·ml-1 = (A260 – A320) x (1/0.025) x dilution 
factor 
*Absorbance at 320 nm corrects light scattering due to dust particles. It provides information about contamination by 
chemicals: alcohol, phenol and guanidinium from the lysis buffer.  
**Absorbance at 280 nm provides information about protein contamination.  
 
RNA amount and purity was determined by measuring samples absorbance at 230 nm, 260 nm, 
280 nm and 320 nm with the Helios Alpha UV-Vis Spectrophotometer. The quantification by 
this technique may be affected by scattering of light and impurities such as protein, phenol or 
other contaminants that also absorb near 260 nm. For this reason, some correction parameters 
are introduced (see Table 2.4-1). 
 
73 
 
Chapter 2 –MATERIALS AND METHODS 
 
2.4.11 cDNA synthesis  
The material obtained was used for cDNA synthesis using Quantitect Reverse Transcription Kit 
(Qiagen; 205311) according to manufacturer’s protocols. Briefly, 500 ng of purified RNA was 
treated with gDNA Wipeout Buffer during 2 min at 42 ºC to eliminate DNA contamination. The 
treated samples were transcribed to cDNA using Quantiscript Reverse Transcriptase incubated 
during 15 min at 42 °C. Finally, an inactivation step of 3 min at 95 °C to inactivate the reverse 
transcriptase was performed. The samples were aliquoted and stored at -80 ºC until gene 
analysis. 
2.4.12 Primers selection 
Primers were designed using Primer Blast software from National Center for Biotechnology 
Information (NCBI). The following parameters were taken into consideration: a melting 
temperature around 60 oC, maximum of CG content of 60 % (optimum between 40-50 %), 
ending with cytosine or guanine bases, maximum of 3-4 dimers and hairpins, 15-30 base pair of 
primer length and 250-80 base pair of PCR product length. Primers sequences of the designed 
primers are shown in Table 2.4-2. 
Table 2.4-2: Primers for RT-PCR and qRT-PCR. Early and definitive cardiac markers were analyzed 
 
2.4.13 Study of gene expression by RT-PCR  
Reverse transcription polymerase chain reaction (RT-PCR) was performed to analyze 
qualitatively gene expression in 2D and 3D cultures. RT-PCR reaction was carried out using 30 
ng of cDNA in a final volume of 25 μL containing 1X ThermoPol Reaction Buffer (stock 10X), 
0.42 units of TAQ DNA polymerase (Sigma; D1806), 200 μM of dNTPs (Sigma; DNTP100) 
and 0.3 μM primers (synthesized by Sigma). The RT-PCR took place under the following 
conditions: 3 min at 95 ºC (activation) followed by 35 cycles of 20 s at 94 ºC, 30 s of annealing 
(Tm dependent on primer pair, see Table 2.4-2) and 30 s at 72 ºC. Final extension step was 
performed at 72 ºC during 15 min. RT-PCR products were size fractionated by 2 or 4 % agarose 
gel electrophoresis, depending on the expected fragment size. 
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2.4.14 Study of gene expression by qRT-PCR 
Real Time RT-PCR reactions were performed with LightCycler® 480 Real-Time PCR System 
(Roche), using the iQ™ SYBR® Green Supermix (Bio-Rad;170-8882) as a fluorescent reporter. 
SYBR® Green binds to double-stranded DNA and upon excitation emits fluorescence.  
Real-time RT-PCR was run with the following parameters: 1 cycle of 10 minutes at 95 oC in 
order to activate the hot-start iTaq™ DNA polymerase, 50 cycles consisting in 15 seconds at 94 
oC for denaturation of the double stranded cDNA, 15 seconds for primer annealing (Tm 
dependent on primer pair, see Table 2.4-2), and 15 seconds at 72 oC for extension. Finally 
melting curve analyses were performed to test the specificity of PCR products, together with 
agarose electrophoresis. Relative gene fold variations were all determined by the comparative 
CT method (2-ΔΔCt) and expression of the target genes was normalized to the housekeeping gene 
(ribosomal protein 22L, RPL22).  
2.4.15 Western Blotting for protein analysis 
Protein extracts were obtained using RIPA buffer (Sigma; R0278) containing proteinase 
inhibitor cocktail (Roche; 11836153001) from 2D and 3D cultures of subATDPCs at passage 8. 
Two 3D cultures constituted each sample for western blotting and they were lysed with the help 
of pestles to crush the samples. All samples were centrifuged to eliminate the debris and stored 
at -20 ºC until analysis. Protein content was quantified from the supernatant using Micro 
BCATM Protein assay kit (Pierce-Thermo Scientific; 23225). Equal amounts of total protein (5 
µg) were denatured with SDS (Sigma; L5750-500G) and β-mercaptoethanol at 95 ºC during 10 
min. Subsequently, the proteins were separated by electrophoresis on 10 % SDS–PAGE gels at 
150 V during 1 h 30 min. Proteins were blotted onto PVDF membrane (Invitrogen; LC2005) 
during 2 h at 40 V using wet transference. The membranes were blocked with 5 % non-fat milk 
buffer during 2 h at room temperature and incubated with rabbit polyclonal anti-GATA4 1 
µg/mL ( Santa Cruz; sc-9053) or rabbit polyclonal anti-GJA1 1 µg/mL (Santa Cruz; sc-9059) at 
room temperature during 1h. After 3 short washes with PBST (Phosphate Buffered Saline 
(Gibco; 18912-014) supplemented with Tween-20 (Sigma; P-1379)) and an overnight PBST 
wash the blots were incubated with peroxidase-conjugated to rabbit IgG goat polyclonal 
secondary antibody 1µg/mL (Abcam; ab97051). The protein bands were detected after 
incubation with SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific; 
34080) using ImageQuant LAS 4000 mini equipment. Goat polyclonal anti-Actin antibody 
(Santa Cruz; sc-1615) was used to normalize with peroxidase-conjugated to goat IgG rabbit 
polyclonal secondary antibody (Abcam; ab97100).  
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2.4.16  Dynamic mechanical analysis 
Viscoelastic properties of 3D constructs were analyzed by dynamic mechanical analysis 
(DMA). This technique consists of applying a force (stress) to the culture and measure the strain 
generated by the material when it is displaced. As a result, storage modulus (G’) was obtained. 
Measures were picked at 2 and 4 weeks from subATDPCs cultured in each condition [RAD16-I 
peptide 0.3 % (w/v) without modifications, RAD16-I/RADRGD (95:5) 0.3 % (w/v), RAD16-I 
0.3 % (w/v) with heparin (570:1) and RAD16-I/RADRGD (95:5) 0.3% (w/v) with heparin 
(570:1)] in control and cardiac induction medium. Four samples of each condition were 
analyzed. A compression assay with DMA Multi-Frequency-Strain mode and a frequency 
sweep test was applied to each sample with a DMA Q800 (TA Instruments). The construct was 
deformed (oscillated) at constant amplitude (strain) over a constant frequency, and the 
mechanical properties were measured. The conditions of the assay were: Amplitude= 1, Preload 
force= 0.03 N and Frequency= 1 Hz. Construct diameter and thickness were variable depending 
on the dimension of the construct. Results were obtained with TA Instrument Explorer software 
and analyzed with TA Universal analysis software.  
2.4.17 Statistics 
GrapPad Prism version 5.oo Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com was used for statistical analysis. The results are presented as mean ± SD as 
obtained of three independent values per group. Two-way analysis of variance performed 
comparison of means in qRT-PCR and Western blotting with Bonferroni’s posttest. Comparison 
of assays was made by correlation and linear regression analysis. Differences were considered 
significant if p < 0.05. 
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2.5 RESULTS AND DISCUSSION 
2.5.1 Cell behavior in 2D cultures 
SubATDPCs were isolated and expanded by IGTP group, who also defined the basic 
requirements of these cells in 2D cultures. Figure 2.5-1 shows the general behavior of 
subATDPCs growing on flat surfaces. As it can be observed, the morphology highly depends on 
the culture medium. SubATDPCs growing in control medium presented an elongated, 
individual morphology, but the addition of cardiac induction medium promoted a star-shape 
morphology and the formation of clusters. On the other hand, proliferation test with MTT assay 
(Figure 2.5-1b) showed that control medium allowed slow, but constant proliferation. 
Meanwhile, the cardiac induction medium stopped the proliferation presumably due to a 
differentiation process. 
 
Figure 2.5-1: SubATDPCs growing on flat surfaces. (A) Phase contrast of subATDPCs growing in control 
medium (a-10X augments and c – 20X augments) and in cardiac medium  (b-10X augments and d – 20X augments. 
(B) MTT assay of 2D cultures growing in control (blue) or cardiac (red) medium. 
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After assessing the best conditions for 2D cultures, subATDPCs were de-attached from flat 
surfaces to be embedded in the 3D milieu provided by the self-assembling peptide RAD16-I. 
Different cell types encapsulated in this material have been reported to be able to migrate and 
contact one to each other in a truly 3D environment. The first aim of this work was to evaluate 
subATDPCs viability and behavior in RAD16-I self-assembling peptide as function of peptide 
concentration and cell number. Therefore, we determined the best conditions (culture media, 
cell density, and peptide concentration) for subATDPCs to grow in this environment. We based 
our decisions on cell viability (L&D assay), network formation (D&P staining), and construct 
diameter reduction (macroscopic analysis). Network structure is intimately related to construct 
diameter reduction since as denser is the network; more strain is exerted by the cells, thus 
reducing the overall diameter of the system. 
2.5.2 Media selection 
The basic component of basal media (used for 2D cultures and control medium for 3D cultures) 
was α-MEM. The slight differences observed in the formulation of this medium, between two 
suppliers, lead us to test different media for 3D cultures (constructs) maintenance: α-MEM from 
LabClinics and α-MEM from Sigma were analyzed. Both media tested were the most enriched 
α-MEM medium of each supplier, with only slightly differences between their concentrations of 
amino acids, salts and vitamins. The most important difference lied in the presence of L-
glutamine, ribonucleosides, and deoxyribonucleosides in Labclinics medium.  
Constructs of subATDPCs encapsulated in 0.15 % RAD16-I (cell density = 2,000 cells/µL, the 
standard conditions currently used in our laboratory with other cell types) were performed as 
follows: half of the encapsulations were cultured with α-MEM from LabClinics, and the other 
half with α-MEM from Sigma. Figure 2.5-2 presents the results obtained after 12 days of 
culture. Significant differences were found in construct diameter reduction (Figure 2.5-2a) and 
in the L&D assay (Figure 2.5-2b). A decrease in diameter was observed for the constructs 
cultured in Sigma medium; however, constructs cultured in LabClinics medium did not show 
any change in construct diameter. Consequently, the samples cultured with Sigma α-MEM 
presented a higher condensation after 12 days of culture (nearly 2 mm of diameter) than the 
samples with LabClinics medium (about 9 mm of diameter). This suggests that Labclinics 
medium did not allow subATDPCs to properly elongate to form an intricate network. This 
hypothesis was corroborated by cell viability test that showed more cell density and number of 
live cells in the construct growing with Sigma medium (Figure 2.5-2b). For all these reasons, 
thereafter encapsulations with subATDPCs were cultured with α-MEM media from Sigma. 
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Figure 2.5-2: SubATDPCs behavior depending on α-MEM supplier. (a) Construct diameter reduction progression 
during 12 days depending on basal media used. (b) L&D staining of 3D cultures using Sigma or Labclinics α-MEM 
basal media. Live cells stained in green and dead cells in red. 
 
2.5.3 SubATDPCs cultured in a 3D system. 
In this chapter, we aimed to analyze subATDPCs behavior in 3D environments, and therefore 
the first step was to define the best conditions of peptide concentration and cell density for this 
in vitro model.  
Regarding cell density, the values must favor cells free movement by allowing an intimal 
contact between them and the ECM-analog, avoiding overcrowding. Figure 2.5-3 shows the 
effect of cell density in 3D cultures of RAD16-I 0.15 %. Two cell densities were tested (2,000 
cells/µL and 4,000 cells/µL), and construct diameter reduction, cell network and viability were 
analyzed. No significant diameter reduction was observed independently of cell density, but a 
clear difference appeared in network formation. The first day cells remained round-shaped (red 
arrows) in both cases, but after some days of culture cells growing in constructs of 2,000 
cells/µL gently started to elongate, to contact one to each other, and to form a cellular network 
(blue arrows). Constructs of 4,000 cells/µL presented the formation of amorphous clusters 
(yellow arrows), and L&D staining showed a large number of dead cells. Constructs of 2,000 
cells/µL presented high viability and proper network formation after 7 and 9 days of culture. 
respectively. Therefore, as we were looking for a good 3D environment to analyze subATDPCs 
behavior in vitro we decided to work with a cell density of 2,000 cells/µL. 
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Figure 2.5-3: SubATDPCs at different cell density encapsulated in RAD16-I self-assembling peptide 0.15 %. 
(a) Macroscopic view of construct diameter reduction depending on cell density during a period of 10 days of culture. 
(b) Cell network depending on cell density during a period of 9 days of culture (Red arrows point out round shaped 
cells, blue arrows point out elongated cells, and yellow arrows point out cluster formation) and L&D staining after 7 
days of encapsulation. Live cells stained in green and dead cells in red. Scale bar 100µm. 
Typically, these 3D structures were prepared using a constant volume of 80 µL, which means 
that each construct contains 160,000 cells. With the aim to increase cell number for further 
analysis steps, we prepared 3D constructs doubling their volume. It was known that this would 
affect medium and oxygen diffusion, so it was important to firstly test how this modification 
could affect cell behavior in terms of network formation. Figure 2.5-4 shows cell network 
formed after 5 and 7 days of culture in constructs of 160 µL at different peptide concentration 
taking as a control subATDPCs growing in RAD16-I 0.15 % at 2,000 cells/µL. The increased 
construct volume (at same cell density and peptide concentration) led to a poor network 
formation as compared with the control. After 7 days of culture, construct of 80 µL presented an 
intricate network, but only some elongated cells could be observed in constructs of 160 µL. 
Additionally, the increase in peptide concentration was shown to prevent the network formation 
and less elongated cells could be observed. At the view of these results, we decided to maintain 
the typical peptide volume (80 µL) and cell density (2,000 cells/µL). Therefore to obtain enough 
material for further analysis two constructs were used per experimental point. 
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Figure 2.5-4: Effect of construct volume and peptide concentration in the behavior of subATDPCs 
encapsulated in RAD16-I. Increase of volume of the construct implies a slowing down of the network formation. 
The increase of peptide concentration worsens the situation. 
The final step to decide the best conditions for 3D cultures of subATDPCs in RAD16-I peptide 
was to test different peptide concentrations, using a cell density of 2,000 cells/µL. Figure 2.5-5 
shows cell viability (Figure 2.5-5a) and construct diameter reduction (Figure 2.5-5b) depending 
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on peptide concentration. Additionally, the effect of the cardiac induction medium (or cardio 
medium) in the construct morphogenesis and cell viability was analyzed. Cardiac induction 
medium in vitro was used to test the potential of these cells to differentiate towards a cardiac 
phenotype.
 
Figure 2.5-5: SubATDPCs growing in different RAD16-I self-assembling peptide concentration. (a) L&D 
staining of subATDPCs growing in different RAD16-I self-assembling peptide concentration depending on culture 
medium. Live cells stained in green and dead cells in red. (b) 3D cultures diameter reduction depending on peptide 
concentration and culture medium. 
All peptide concentrations (equally for control or cardiac induction medium) showed a high 
degree of viability (Figure 2.5-4a). As expected, higher peptide concentration led to a lower 
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reduction in construct diameter. Interestingly, it was observed that at high concentration of 
peptide (from 0.2 to 0.3 %) subATDPCs growing in control medium were not able to elongate 
properly. Therefore, the construct did not condense (all constructs maintained more or less the 
diameter of 9 mm). On the other hand, the addition of cardiac induction medium allowed the 
cells to elongate and diminish the diameter of the construct. After 18 days almost all constructs 
growing in cardiac induction medium, indistinctly of peptide concentration, presented a 
diameter between 2 and 4 mm. This effect was not observed in constructs growing in control 
medium.  
At the view of all these results, it was concluded that the most appropriate conditions to analyze 
subATDPCs behavior using RAD16-I to emulate a 3D model in vitro were: RAD16-I 0.15 % at 
cell density of 2,000 cells/µL with α-MEM enriched media from Sigma. In Figure 2.5-6 an 
overview of subATDPCs behavior in this conditions is presented.  
 
Figure 2.5-6: SubATDPCs growing at a cell density of 2,000 cells/µL in RAD16-I 0.15 %. (a) Macroscopic 
structure. Construct diameter reduction. (b) D&P staining presenting network formation. Nuclei stained in blue and 
actin filaments in pink. (c) L&D staining shows the viability after 14 and 20 days of culture depending on culture 
medium. Live cells stained in green and dead cells in red. (d) GATA4 and GJA1 protein expression after 4 days, 1, 2, 
and 3 weeks of 3D culture in control, or cardio medium. 
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After encapsulation, all constructs were maintained in control medium until cells started to 
elongate at the 4th day of culture (Figure 2.5-6b), then half of the constructs were induced with 
cardiac induction medium. The morphogenic process of construct diameter reduction was faster 
for constructs growing in cardiac induction medium, but constructs growing in control medium 
also displayed this condensation (Figure 2.5-6a). Importantly, cells remained alive in both 
conditions after 20 days of culture and interestingly, cardiac induction medium induce some 
kind of cell alignment (Figure 2.5-6c). Finally, protein expression after 4 days, and 1, 2, and 3 
weeks of culture were analyzed. It was observed that GATA4 (early cardiac marker) and GJA1 
(definitive cardiac marker) were expressed in both control and cardio medium. 
2.5.4 RAD16-I self-assembling peptide with RGD and heparin modifications 
As explained previously, RAD16-I peptide provides a non-instructive microenvironment, which 
means that it does not present cues that guide cells to a particular commitment. This fact 
provides an opportunity to analyze different signals independently, by functionalizing RAD16-I 
with biologically active motifs that trigger different cells responses. Several peptide motifs have 
been described to improve myogenic activity. It is, therefore, feasible to prepare a new series of 
self-assembling peptide carrying functional motifs that activate and maintain myogenic 
properties. The ECM-analog RAD16-I with heparin-like motifs described in previous results 
and modified with RGD-based integrin binding domains were tested84. Hence, RAD16-I were 
used as a base to design three new sets of self-assembling peptide scaffolds. RAD16-I 
modification with heparin was pretended to promote the binding of GFs by naturally interacting 
with its heparin-like domain for further release. On the other hand, the modification with RGD 
motif aimed to promote cell maintenance and viability. 
Initial efforts in this block of experiments were directed to the preparation of self-assembling 
peptide with the combination of RADRGD and heparin modifications. RAD16-I self-
assembling peptide organize itself into structurally well-defined arrangements as a result of an 
increase of ionic strength. Therefore, it was important to assure that the proposed modifications 
did not interfere in the process. The subsequent mixtures were prepared: RAD16-I/RADRGD 
(95:5), RAD16-I with heparin (570:1), and RAD16-I/RADRGD (95:5) with heparin (570:1). All 
samples were stained with Congo Red (analysis of β-sheet structures formation), and Toluidine 
Blue (analysis of heparin binding) using RAD16-I as control. 
Congo Red Staining in Figure 2.5-7 shows that all the modifications suggested allow RAD16-I 
peptide to gel forming β-sheet structures. Toluidine Blue staining show little purple structures 
inside the gel corresponding to the presence of heparin polysaccharide. Therefore, these 
nanofiber peptides in principle maintained all the structural features needed to culture 
subATDPCs even in the presence of RGD motif and heparin polysaccharide. However, first of 
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all it was necessary to ensure the behavior and viability of these cells encapsulated in the 
nanofiber peptides. 
 
Figure 2.5-7: Analysis of RAD16-I proposed modifications in the self-assembling process. Congo Red Staining 
stains β-sheet structures and Toluidine Blue staining stains polysaccharides, in this case Heparin. (a) RAD16-I 
without Heparin – Congo red staining; (b) RAD16-I without Heparin – Toluidine Blue staining; (c) RAD16-I/RGD 
without Heparin – Congo red staining; (d) RAD16-I/RGD without Heparin – Toluidine Blue staining; (e) RAD16-I 
with Heparin – Congo red staining; (f) RAD16-I with Heparin – Toluidine Blue staining; (g) RAD16-I/RGD with 
Heparin – Congo red staining; (h) RAD16-I/RGD with Heparin – Toluidine Blue staining. 
2.5.5 SubATDPCs encapsulated in RAD16-I with and without heparin 
In the context of RECATABI European project the development of a new biomaterial able to 
promote vascularization of ischemic areas after myocardial infarction was studied by 
Fernandez-Muiños et.al.79. RAD16-I was combined with heparin, which has high GF binding 
capacity. As a consequence, the RAD16-I peptide-heparin composite (RAD16-I+Hep) could 
bind soluble GFs localizing their activity into the RAD16-I scaffold, protecting them from 
degradation, and in some cases, enhancing their binding to cell surface receptors67. RAD16-
I+Hep was observed to be able to bind and release physiologically significant quantities of 
VEGF165 (chemical signal produced by cells that stimulates the growth of new blood vessels) in 
vitro during the first 24-36h (see 2.2.Preliminary Results). This system was demonstrated to be 
a useful tool for drug delivery system for vascularization. In this work, we aim to test its ability 
to support survival and maintenance of subATDPCs. Additionally, we wanted to analyze the 
effect of VEGF165 presence in the culture media on cell behavior. 
3D cultures of subATDPCs were prepared using self-assembling peptide scaffolds of RAD16-I 
or RAD16-I+Hep (570:1). Half of them were cultured in control medium with VEGF165 (Figure 
2.5-8a). After five days of culture, D&P staining showed that subATDPCs growing in media 
containing VEGF165 presented higher proliferation and better cell network formation than cells 
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growing without this GF. The most interesting aspect was that cells encapsulated in RAD16-
I+Hep hydrogel presented an aligned growth while the samples that did not contain this 
polysaccharide showed a disordered pattern (Figure 2.5-8b). 
The viability was analyzed using L&D assay. As it can be observed after 13 and 21 days of 
culture (Figure 2.5-8c and d, respectively), despite there were some dead cells in all samples the 
most part of them remained alive. Interestingly, after 13 days of culture it could be seen that 
subATDPCs growing in RAD16-I+Hep scaffolds showed a high ordered pattern regardless of 
the presence of VEGF growing factor. On the other hand, cells growing without heparin did not 
show this aligned pattern; instead the cells were completely disordered. The same results could 
be found after 21 days of culture 
 
Figure 2.5-8: Effect of heparin in 3D cultures of subATDPCs. (a) Preparation of 3D constructs of RAD16-I with 
or without heparin. Half of each pool was cultured with VEGF and the other half without VEGF. (b) D&P staining 
after 5 days of culture. Nuclei stained in blue and actin filaments in pink. (c) L&D staining after 13 days of culture. 
(d) L&D staining after 21 days if culture. Live cells stained in green and dead cells in red. 
. 
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2.5.6 SubATDPCs encapsulation in RAD16-I with and without peptide 
modifications 
RAD16-I self-assembling peptide containing the motif RGD (RADRGD = AcN-
GPRGDSGYRGDS-GG-(RADA)4) for cell integrin-receptor recognition and signaling was 
tested to support subATDPCs culture, using the RAD16-I peptide without modifications as 
control. This new peptide was blended with regular RAD16-I (typically the ratio RAD16-
I/RADRGD = 95:5 was used). Behavior and viability of subATDPCs encapsulated in RAD16-I 
peptide containing RADRGD with or without heparin was analyzed at macroscopic and 
microscopic level. As it can be clearly seen in the fluorescent images (Figure 2.5-9b) scaffolds 
composed of RAD16-I/RADRGD motifs presented a higher cell number as compared to 
RAD16-I peptide alone. Cells encapsulated in RAD16-I constructs resulted to be more isolated 
and less connected compared to constructs with the modified peptide. So, we suggest that RGD 
motif was indeed enhancing the connections and migration of the cells. In the case of heparin, 
we founded different cell behaviors. The combination of heparin with only RAD16-I enhanced 
the elongation of the cells, but in combination with RGD motif, cells formed more clusters and 
looser networks. Therefore, from de point of view of cellular network formation, we concluded 
that heparin could have an adverse effect. In terms of viability, although L&D assay showed 
some death cells in all conditions, the majority of them were alive. Additionally, in order to 
assess whether the network correlated with the construct diameter reduction, the diameter of the 
different constructs was measured. The condensation effect depending on the presence or not of 
peptide RGD motif and heparin is shown in Figure 2.5-9a. It has to be highlighted that the 
constructs that presented RGD motifs condensed more than the constructs without it.  
On the other hand, as it can be seen in Figure 2.2-1 (see 2.2 Previous Results) heparin itself 
could promote the capture of GFs improving their accessibility through heparin binding 
domains. This behavior could be useful for further in vivo applications, therefore heparin 
modification was not discarded and both RGD motif and heparin polysaccharide will be 
included in further experiments.  
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Figure 2.5-9: SubATDPCs encapsulated in RAD16-I nanofiber peptide and RAD16-I with modifications. A) 
Macroscopic structure of subATDPCs encapsulated in RAD16-I with and without modifications from day 1 to day 11 
of culture. B) L&D staining after 11 days of culture (live cells stained in green and dead cells in red) and D&P 
staining after 9 days of culture (nuclei stained in blue and actin filaments in pink). a) RAD16-I without Heparin – 
L&D staining; b) RAD16-I without Heparin – D&P staining; c) RAD16-I/RGD without Heparin – L&D staining; d) 
RAD16-I/RGD without Heparin – D&P staining; e) RAD16-I with Heparin – L&D staining; f) RAD16-I with 
Heparin – D&P staining; g) RAD16-I/RGD with Heparin – L&D staining; h) RAD16-I/RGD with Heparin – D&P 
staining.
2.5.7 Proliferation analysis of subATDPCs encapsulated within RAD16-I with 
and without peptide modifications 
MTT assay was used to analyze cell behavior during the first days of culture more accurately. 
Triplicates of 160,000 cell 3D cultures were prepared for RAD16-I with and without RGD and 
heparin modificatons. MTT assess cell viability based on the activity of NAD(P)H-dependent 
cellular oxidoreductases enzymes under defined conditions. These enzymes are capable of 
reducing MTT to its insoluble formazan. It is important to notice that the reduction of MTT 
increase with cellular metabolic activity depending on the NAD(P)H flux and therefore assay 
conditions can alter metabolic activity. Formazan product obtained from the reduction of MTT 
by oxidoreductases was measured from day 1 until day 14 (see Figure 2.5-10). During the first 
days of culture, modified peptides showed higher absorbance that cells growing in unmodified 
peptide, but after four days there were no significant differences. In regard to culture media, no 
significant difference could be appreciated (p > 0.05). 
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Figure 2.5-10: MTT assay of subATDPCs 3D cultures. SubATDPCs viability was also assessed quantitatively 
with MTT assay. Purple lines represent cells growing in control medium, and red lines represent their grown in 
cardiac induction medium. All peptide modifications show a greater absorbance that cells growing in bare RAD16-I 
peptide until day 4. 
It is important to mention that after four days more or less all conditions presented the same 
pattern of absorbance. However, the cells that grew in RAD16-I bare self-assembling peptide in 
cardiac induction medium started to decrease their absorbance after 11 days of culture. Careful 
analysis of subATDPCs growing in RAD16-I peptide in cardiac induction medium after 20 days 
of culture showed that cells started to migrate outwards of the construct. This effect was also 
observed for the other conditions when the 3D cultures were considerably condensed. Figure 
2.5-11 shows a picture that clearly demonstrates the migration of the cells outwards the 
construct. 
 
Figure 2.5-11: Macroscopic view subATDPCs 3D culture in RAD16-I. In the left, it can be observed a 3D 
construct with a blanket covering the whole structure. An amplification in the right part of the picture shows that it is 
a cape of cells migrating outwards of the construct. Yellow arrows indicate the direction of cells migration. 
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2.5.8 Nanomaterial evaluation for their effect gene expression 
Gene and protein expression of subATDPCs encapsulated in 3D constructs of RAD16-I peptide 
with and without the presence of RADRGD  and heparin modifications were analyzed. Firstly 
an overview of gene expression at the second week of culture with control and cardiac induction 
media was assessed by RT-PCR. TBX5, MEF2C and NKX2.5 (early cardiac markers) and MHC, 
ACTN1 and GJA1 (definitive cardiac markers) were analyzed using RPL22 as internal control 
(data not shown). TBX5, MEF2C and GJA1 were expressed equally in constructs growing in 
control and cardiac induction media, but a band of ACTN1 was only observed when the samples 
were induced with cardio medium. No expression of NKX2.5 or MHC, was observed. These 
results encouraged us to quantify TBX5 and MEF2C early cardiac markers, and ACTN1 and 
GJA1 definitive cardiac markers using qRT-PCR. The obtained results were compared with 
cells growing in flat surfaces with control or cardiac induction media respectively (Figure 
2.5-12a). 
The obtained results did not present significant differences in terms of gene expression for 
constructs modified with RADRGD or heparin either in control or cardiac induction media (p > 
0.05). However, a significant overexpression of TBX5, MEF2C, GJA1 and ACTN1 genes was 
found when subATDPCs were cultured in 3D environment with chemical cardiogenic induction 
(*** p < 0.0001, ** p < 0.001, * p < 0.01, ns p > 0.05). The combination of 3D environment 
and chemical induction compared with 2D cultures with chemical induction did not show any 
significant effect due to the 3D environment itself (p > 0.05). On the other hand, as it can be 
seen in Figure 2.5-12c, the combination of 3D environment with chemical induction caused an 
overexpression of TBX5 in all conditions. In the case of MEF2C this significant overexpression 
was only observed in RAD16-I samples (p < 0.01 after 2 weeks of culture and p < 0.0001 after 4 
weeks of culture) and RAD16-I/RADRGD (p < 0.01 after 4 weeks of culture). ACTN1 was 
highly expressed in all conditions as compared with 2D control medium cultures (between 20 
and 60 fold after 2 weeks of culture, and 300 fold in cells cultured on RAD16-I/RADRGD with 
heparin after 4 weeks of culture). Finally an overexpression of GJA1 was detected in cells 
growing in RAD16-I/RADRGD, RAD16-I with heparin and RAD16-I/RADRGD with heparin 
after 2 weeks of culture and after 4 weeks of culture in cells growing in RAD16-I peptide. It 
was observed in Figure 2.5-12c that the combination of 3D environment and cardiac induction 
implied an overexpression of TBX5, MEF2C and GJA1 as compared with the same cells 
growing in 2D cultures with chemical induction. However, ACTN1 was much more expressed in 
these 2D cultures than in the 3D environment. 
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Figure 2.5-12: Early and definitive cardiac markers expression by subATDPCs growing in RAD16-I 0.15 % 
with and without modification depending on culture media. TBX5 and MEF2C early cardiac markers and ACTN1 
and GJA1 were quantified by qRT-PCR. The expression of these genes by subATDPCs cultured in four different 3D 
environment modifications (RAD16-I and RAD16-I/RADRGD with or without heparin) were compared with 
subATDPCs growing on flat surfaces. (a) 3D cultures growing in control medium were referred to 2D cultures 
growing in control medium. (b) 3D cultures growing in cardiac induction medium were referred to 2D cultures 
growing in cardiac induction medium. (c) 3D cultures growing indistinctly in control or cardiac induction medium 
were referred to 2D cultures with control medium observing a significant effect of the cardiac induction medium (*** 
p < 0.0001, ** p < 0.001, * p < 0.01, ns p > 0.05). The orange dotted lines represent the expression of subATDPCs 
growing in cardiac induction medium referred to subATDPCs growing in control medium. 
At protein level, GATA4 transcription factor and GJA1 (connective protein Cx43) expression 
were analyzed. Interestingly, we noticed that cardiac induction medium highly increased both 
GJA1 and GATA4 expression in contrast to control medium. Although, subATDPCs growing in 
flat surfaces with cardiac induction medium showed expression of GATA4 and GJA1, the 
environment provided by 3D systems up-regulated it (Figure 2.5-13). Again, it is remarkable 
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that any either the presence of RGD motif or heparin polysaccharide increased GATA4 or GJA1 
expression in comparison with RAD16-I peptide in cardiac induction. Interestingly, only 
samples containing heparin express GATA4 and only samples without RGD express GJA1 in 
control medium conditions.  
 
Figure 2.5-13: Protein expression of 3D constructs. (a) GATA4 and GJA1 Western Blot from subATDPCs 
growing in 3D scaffolds. (b) Quantification of GATA4 and GJA1 expression from subATDPCs growing in 3D 
scaffolds respect 2D samples in control media and normalization by actin. Red line indicates the normalized protein 
expression of 2D cultures (by actin). (*** p < 0.0001, ** p < 0.001, * p < 0.01). 
2.5.9 Mechanical characterization 
Another important aspect to analyze was the stiffness of the matrix where the cells were 
growing. Viscoelastic properties of 3D constructs were analyzed by dynamic mechanical 
analysis (DMA). Samples were deformed under an oscillating stress within a range of 
frequencies and the resultant sinusoidal strain was evaluated. The stress/strain ratio equals the 
complex viscoelastic modulus (G*) which is defined as 𝐺𝐺 ∗= 𝐺𝐺′ + 𝑖𝑖𝐺𝐺′′; where G’ is the storage 
modulus and  G” the loss modulus. G’ describes the elastic component (measures the stored 
energy and is related to the stiffness of the sample), and G” represents the viscous component 
(measures the energy converted to heat and is related to the capacity of the sample to dissipate 
the energy through molecular motion).  
In this case the storage modulus was determined as a measure of the stiffness of the 3D cultures 
analyzed. It was observed that the proposed modifications did not show differences in storage 
modulus when the cells were cultured in control medium during 2 weeks. However, the 
induction with cardio medium promoted an increase of the storage modulus at the same time of 
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culture (from 4 to 40 KPa). Interestingly, only self-assembling peptides missing heparin and 
cultured in control medium presented similar storage modulus than constructs cultured with 
cardiac induction medium (approximately. 40 KPa) after 4 weeks of culture. 
 
Figure 2.5-14: Dynamic mechanical analysis of subATDPCs encapsulated in RAD16-I with and without 
modifications (RGD and heparin). Storage modulus of the different matrices was measured in triplicate for each 
condition 
It was suggested that the increase of viscoelastic properties could induce a differential protein 
expression. Comparing the results obtained by qRT-PCR and DMA it could be stated that the 
increase of storage modulus lead to an increase of some cardiac genes of subATDPCs. 
However, the increment in storage modulus in RAD16-I and RAD16-I/RADRGD constructs 
after 4 weeks of culture in control medium did not show any differential gene expression. 
Therefore, it could be concluded that in addition to the elasticity of the construct, the signaling 
provided by the cardiac induction medium is of high importance.  It is relevant to remark that in 
this particular case we were considering the increase of the stiffness effect along the time, but 
not the initial conditions. 
Then, we examined the effect of the material stiffness at the time of the encapsulation (initial 
conditions). It was previously reported that the increase in nanofiber concentration implies and 
increase of stiffness (0.15 % RAD16-I corresponds to 120 Pa while 0.2 % RAD16-I to 220 
Pa)85. SubATDPCs were cultured in RAD16-I and RAD16-I/RADRGD at two different initial 
stiffness using cardiac induction medium (see Figure 2.5-15). The expression GATA4 (early 
cardiac marker) and GJA1 (definitive cardiac marker) at protein level were analyzed. As it can 
be seen in Figure 2.5-15, either initial stiffness conditions as well as matrix modification 
(RAD16-I/RADRGD) presented a strong effect by down-regulating protein expression (p < 
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0.00001). This effect could be observed clearly at 2 weeks of culture with less significant 
changes at 4 weeks of culture.  
 
Figure 2.5-15: Protein expression of 3D constructs depending on nanofiber RAD16-I scaffold concentration. 
Either initial stiffness conditions as well as matrix modification (RAD16-I/RADRGD) present a strong effect by 
down-regulating protein expression (*** p < 0.0001, ** p < 0.001, * p < 0.01, ns p > 0.05). SubATDPCs growing in 
flat surfaces with cardiac induction medium are taken as control. 
GATA4 and GJA1 proteins were significantly down-regulated (p < 0.0001) when the initial 
stiffness of the matrix was 220 Pa as compared with an initial stiffness of 120 Pa (p < 0.0001). 
This pattern was observed after 2 and 4 weeks of culture for RAD16-I matrix except for RGD 
samples after 4 weeks of cultures where there were no change on GATA4 expression. The 
addition of RGD motifs in the 3D structure lead to a significant reduction of both proteins 
expression (p < 0.0001) as compared with RAD16-I control matrix. The increase of the stiffness 
did not show, in the presence of RGD motif a significant effect for GJA1 expression. However, 
higher stiffness caused GATA4 down-regulation (p < 0.0001). 
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2.6 CONCLUDING REMARKS 
Heart is a complex tissue whose behavior is affected by multiple factors. The understanding of 
the individual effect of each factor can be of great interest for the development of further 
therapeutic treatments, but the study of all these factors and their combination in vivo is 
extremely difficult14. The deconstruction of heart tissue using in vitro models can help to 
elucidate the effect of these factors on healthy or pathologic tissue86–88. Different studies in 
terms of GFs delivery and effect89–96, gene and protein expression90,97–110, mechanical 
properties111,112, electrical properties113–118, between others, are nowadays under development.  
For the study of all these parameters, different methodologies15,114,119–124 have been used during 
the last years with different kind of cells81,110,125 and materials8,41,96,122,123,126–132. 2D cultures 
allow analyzing cell behavior in a simplistic way and fix some factors before develop a more 
complex 3D system. Although 2D cultures are the simplest in vitro cultures, it is commonly 
difficult to fix the best parameters for each cell type since they have specific dimensions, 
behavior, and requirements. For this reason, the isolation of one cell type implies the 
determination of the best conditions for its culture. In the RECATABI European project, IGTP 
group defined the basic needs of subATDPCs in 2D cultures. The stipulated conditions (T, gas 
mixture, and cell growth medium between others) were transferred to 3D cultures.  
During last decades, TE has become an important tool for the deconstruction of complex 
systems using 3D models14. Interestingly, combining different materials and different cell types, 
it is possible to analyze different parameters. Each of these combinations leads to really distinct 
systems which allow analyzing a wide range of specific parameters8,122,127,133–135.  
In this work, a specific system of subATDPCs entrapped in a 3D matrix of RAD16-I self-
assembling peptide with and without integrin-receptor binding (RGD) and heparin binding 
domains modifications were analyzed. Although the conditions for subATDPCs cultured were 
previously stipulated, the 3D system itself included additional factors to be taken into account. 
This 3D model has been widely used with different cell lines, but slight changes such as 
construct volume, peptide concentration, and cell seeding density must be assessed for each cell 
type51,53,56,84,85. After several analyses, it was concluded that the best working conditions for 
these cells in 3D cultures of RAD16-I with or without chemical induction were: RAD16-I 0.15 
% at cell density of 2,000 cells/µL with α-MEM enriched media from Sigma. The presented 
results show that slightly differences in 3D cultures conditions highly affect cellular behavior. 
In this case, a high difference in cell viability and cell network formation was observed with 
slight changes in culture media. Additionally, cell density, RAD16-I concentration, and 
construct volume affect cell behavior in terms of network formation. Here, particular attention 
was focused in cellular connectivity. This concept is really important in cardiac tissue since the 
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synchronous action of CMs lead to the obtaining of a functional tissue136. Therefore, all the 
commented parameters were switched to obtain a good milieu where the cells could interact 
forming an intricate network. 
Numerous publications are focused on the complete cell differentiation towards a cardiac-like 
phenotype134,137–144. We hypothesize that a complete differentiation for the obtaining of a 
functional CM-like cells and its further introduction in an ischemic tissue would result in lower 
cell integration. The final objective of the RECATABI European project was to repopulate the 
damaged myocardium introducing cells that can differentiate towards CM-like phenotype or 
promote neovascularization. This may restore contractility and blood supply, and generate 
favorable atmosphere for native SCs proliferation and differentiation via release of 
prohomostatic cytokines145. We think that in vitro cell commitment towards a cardiac phenotype 
could improve the connectivity, induce further differentiation in vivo, and may help to obtain a 
better functionality. Here, we demonstrated that the 3D environment provided by RAD16-I self-
assembling peptide is able to maintain the cardiac commitment of subATDPCs and that 
chemical induction can induce the overexpression of cardiac markers such as TBX5, MEF2C, 
ACTN1, and GJA1. We hope that these in vitro studies provide valuable information for further 
in vivo studies. Interestingly, the viability of subATDPCs encapsulated inside the new nanofiber 
(with and without the RGD modification and heparin polysaccharide) was completely assessed 
after 13 and 21 days of culture, which means that a large experiment with mice model could be 
performed. Additionally, the cell alignment presented in the new nanofiber is a good starting 
point to obtain cardiomyogenic cells with a degree of organization which indicates their 
potential spontaneous lineage commitment. Furthermore, cytotoxicity of materials on the stem 
cells was assessed using MTT assay observing no undesirable results.  
Thus it has been demonstrated that RAD16-I nanofiber peptide is a promising material to 
maintain cells in 3D milieu and analyze the effect of specific cues. Additionally, we propose to 
use this model to introduce the cells in an infarcted myocardium with the aim to improve the 
effect of the grafted cells, enhancing their retention and therefore their capability to produce an 
effect. Nevertheless, this system would not be optimal for in vivo implantation since its 
mechanical behavior is weak and the continuous heart beating has been reported to crush it146. 
Possible alternative is exposed in Chapter 4. 
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3.1 BACKGROUND 
3.1.1 Overview 
Cardiac muscle participates actively in the contraction of the heart atria and ventricles. This 
movement causes the rhythmical beating of the heart, which induce the circulation of the blood 
and its contents throughout the circulatory system of the body. The most exceptional property of 
this muscle is its capacity to initiate an electrical potential at a fixed rate that spreads rapidly 
from cell to cell to trigger the contractile mechanism without connection to other parts of the 
body. This electrical stimuli play pivotal roles in muscle cell function, as cell fate and function 
are tightly regulated in response to environmental factors and intercellular signals12. The 
generation and precise time distribution of the electrical impulse is initiated by the Pacemaker 
cells situated in the sinoatrial (SA) node (see Figure 1.1-5). The action potential spreads all over 
the heart causing depolarization of cellular membranes and activation of the contractile 
apparatus in cardiomyocytes (CMs)3. For the synchronous contraction of the heart muscle itself, 
it is imperative the tight connection of CMs to enable the propagation of electrical signals all 
across the heart4.  
After myocardial infarction (MI), adverse remodeling and scar tissue formation due to 
intracellular signaling and neurohormonal activation actively affects heart contraction. The 
newly remodeled tissue shows poor cell-cell coupling which results from cell death and loss of 
gap junctions. Progressively, the wall of the scarred area becomes thinner affecting the systolic 
function and increasing the wall stress. This fact promotes further adverse remodeling with left 
ventricle dilatation, apoptosis and necrosis of myocytes, which increase cell disconnection5. 
This fact affects the spread of electrical excitation wave along the plasma membranes of 
adjoining cardiac muscle cells. In a healthy myocardium, cell connection triggers the release of 
calcium from an intracellular membrane-bound compartment, the sarcoplasmic reticulum, 
which increases cytoplasmic calcium and consequently stimulates contraction of the 
myofibrils4. Individual CM must depolarize and contract in a coordinated fashion in order to 
generate forces for pumping blood. Myocardial ischemia depresses active electrical cell 
membrane properties, and this generates regional potential differences between normal and 
ischemic compartments6. 
The emergence of cell grafting as a novel approach for the treatment of heart diseases leads the 
scientific community to develop diverse methodologies to improve its efficiency. The implanted 
cells must tolerate the action potential of the native myocardium and at the same time coupling 
with it. The arrhythmias associated with selective cell therapies are in part attributed to the lack 
of integration and electrical coupling of the cells with the recipient myocardium. Therefore, in 
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addition to survival and function, the electrical integration of grafts is a significant challenge to 
solve. In other terms, electrical signals are present during normal fetal development, and it is 
thus reasonable to hypothesize that similar stimulus may play a role in the differentiation and 
integration of cells introduced into a cardiac tissue3,7. It is believed that electrical integration can 
be improved by engineering cardiac tissue constructs in vitro before grafting8.  
In this chapter, it will be analyzed the effect of electrical stimulation (ES) in the constructs 
presented in Chapter 2. Specifically, a new system will be developed to allow the use of ES on 
RAD16-I three-dimensional (3D) models with the aim to evaluate its effect on the encapsulated 
cells (subcutaneous adipose tissue derived progenitor cells, subATDPCs). The viability, 
morphology, and proliferation of subATDPCs encapsulated in the self-assembling peptide under 
chemical and electrical stimuli will be analyzed. 
3.1.2 Myocardial fibers and impulse propagation 
As commented in Chapter 1, cardiac muscle is an involuntary striated muscle formed by 
cylindrically shaped cells called CM with sizes ranging between 80-150 μm in length and 10-20 
μm in diameter9. CMs are markedly elongated and form layers of tissue with sharply 
demarcated fiber orientation (see Figure 3.1-1), leading to anisotropic architecture (directionally 
dependent)10,11. 
 
Figure 3.1-1: Myocardial tissue is characterized for an anisotropic architecture. In 1954, it was demonstrated 
that cardiac tissue is comprised of individual CMs completely bounded by membrane. Subsequently, gap junctions 
and their distribution as mediators of intercellular communication were described12.  
Tissue anisotropy is a valuable property for normal impulse propagation, because such fiber 
orientation impacts on directional variations of certain properties, most commonly, conduction 
velocity12. The principal determinant of anisotropic conduction in ventricular muscle is the 
elongated shape of the cells rather than the junctions distribution. Cell geometry (elongation) 
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determines the number of junctions per unit space that propagation has to go through in 
different directions. For example, numerous sites for intercellular current transfer exist in both 
directions, but because of the elongated shape of the cells, a wave front moving in the transverse 
direction must cross more intercellular junctions. Thus, the wave fronts would encounter greater 
resistance and propagate more slowly than wave fronts traveling an equal distance in the 
longitudinal direction13. 
3.1.3 Electrical synchronism of cardiomyocytes 
The CMs are the most physically energetic cell in the body, contracting continuously, without 
tiring, 3 billion times or more in an average human lifespan4. In a CM cytoplasm, known as 
sarcoplasm, there are numerous mitochondria (40 % of the cytoplasmic volume), which reflects 
the large energy demands of the heart14. An important structure within the CM is the sarcomere, 
which represents its basic contractile unit. It is formed by myofibrils that run parallel to the long 
axis of the fiber and are composed of long proteins such as actin and myosin and other proteins 
that hold them together. These proteins are organized into thin (actin), and thick (myosin) 
filaments repeated all along the length of the myofibril. CMs are surrounded by a cell membrane 
called sarcolemma and typically contain one or two nucleus. Additionally, they are surrounded 
by a delicate connective tissue framework that contains an extensive capillary network that 
ensures their high metabolic demands of cardiac cells (Figure 3.1-2a). 
To produce a heartbeat, the contractile capabilities of the billions of CM that make up the heart 
have to be mustered in a highly synchronous fashion. This specific assembly requires both an 
orderly spread of the electrical activation wave and an efficient transmission of contractile force 
from one cell to another. This issue is faced creating a 3D syncytium with intimate joins of 
neighboring cells through the membranes. CMs are arranged end-to-end so that a cardiac muscle 
fiber is composed of individual muscle cells. At their ends, these cells often divide themselves 
longitudinally before joining to adjacent fibers. This type of division allows cells to form 
connections with several of its neighbors forming a network of branching fibers. The 
specialized end-to-end arrangements between adjacent CMs are thickened plasma membranes 
called intercalated discs that help to hold adjacent cells together and transmit the force of 
contraction from cell to cell. Intercalated disks integrate the activities of individual cells and 
provide continuity between adjacent CMs, serving as electrical synapses to allow impulses to 
pass from cell to cell (Figure 3.1-2b)15. 
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Figure 3.1-2: Structure of cardiac muscle. (a) Photomicrograph of CMs that shows their nuclei and intercalated 
discs. (b) Schematic view of cardiac muscle fibers and their parts (c) Intercalated disc connects CMs and consists of 
desmosomes, fascia adherens and gap junctions. Cardiac muscle fibers are formed by myofibrils, which are 
composed of myofilaments arranged in sarcomeres (c). T tubules are responsible for transmitting the impulse from 
the sarcolemma (plasma membrane, b) using the energy supplied by mitochondria (b). 
Intercalated discs consist of gap junctions, fascia adherens, and desmosomes (Figure 3.1-2c). 
These junctions serve to hold cells together, to allow ions to pass, and to transmit electrical 
impulses. Specifically, fascia adherens junctions anchor sites for the actin filaments. Secondly, 
desmosomes function as strong adhesive binding sites between cardiac cells preventing them 
from splitting during contractions. Finally, gap junctions are clusters of channels that span the 
closely opposed plasma membranes, forming cell to cell pathways for rapid conduction of 
action potential and direct transmission of chemical signals13. 
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3.1.4 Electrical stimulation  
The use of ES is well established in today’s medicine. It is used as bone growth stimulators 
(implantable and external), for chronic cutaneous wound-healing systems, for functional 
electrical stimulation devices, and for stimulators for pain relief. Therefore, due to the wide 
variety of bioelectrical presence and its significant influence within in vivo tissues, it has been 
subject of study for the past years5,7,16–21. In this context, several in vitro studies have already 
shown the ability of the electrical field to influence the behavior of a variety of cell types22. 
ES can be defined as a safe physical method to induce different changes in cell behavior. Here, 
we will apply ES to induce physical changes in the cells, but further studies can be directed to 
trigger biochemical changes moving towards cardiac phenotype. Several potential advantages of 
this type of stimulus have been described21,23:  
1. Absence of toxic chemicals. This type of stimulation represents a safe alternative to 
drugs such as 5-azacytidine (5-aza) and chemical cytokines24. 
2. Absence of the immunogenic response in the host tissue. 
3. Less expensive than growth factors (GFs) and chemicals. It offers a cheap, simple, and 
flexible way to deliver GFs by inducing the cells themselves to produce these materials 
through natural pathways22. 
4. Use of simple equipment designed with basic theoretical understanding of 
electromagnetism. 
5. Requirement of little cell handling and processing of tissue engineered constructs. 
6. It can be used synergistically with other techniques22. 
Endogenous electric fields play an essential role in the functioning of all living organisms. It is 
well-known their effect in the action potentials of nerves and muscles, but it has also been said 
to control cellular functions, such as morphology, elongation, gene expression, proliferation, 
and migration22. ES aims to mimic the electrical environment of electroactive muscle cells and 
help to regulate cell-cell and cell-ECM interaction21. It has been shown that ES alters several 
properties of engineered tissues, including cell differentiation, proliferation, morphology, 
adhesion, migration, and function23. It has been also demonstrated that different stimulation 
parameters affect different sets of tissue characteristics. Direct current (DC) field stimulation 
typically directs cell orientation, alters cell morphology, and directs cell migration, while 
alternating current (AC) fields enhance cell differentiation and increase tissue function23. 
Despite its great potential, its role in tissue regeneration and its ability to influence cell 
behavior, ES has rarely been considered in tissue engineering (TE)22. The utilization of external 
electrical stimuli holds promise to gain greater control over cellular growth, maturation, 
adhesion, and orientation. Its early use in TE has been reported to improve contractile and 
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conductive properties of cardiac constructs, enhance proliferation and differentiation of stem 
cells (SCs), and increase cell alignment and length of neurite outgrowth22. 
In other terms, electrical propagation through cardiac tissue is primordial for proper heart 
function. Therefore, electromechanical coupling between the engineered constructs and host 
myocardium for simultaneous beating is required. So, the engineered cardiac patch should 
connect to the electrical syncytium of the existing myocardium, rather than having spontaneous 
contractile activity. Cells distribution at the nanometer scale in an engineered cardiac tissue 
must be coupled by functional gap junctions and be capable of propagating electrical impulses 
to prevent arrhythmia upon implantation. At the millimeter scale, the tissue should consist of 
elongated myofibers aligned to facilitate the synchronous contractions. In this context, the main 
challenge is to provide the appropriate electromechanical stimulation during in vitro cell culture. 
The difficulty is to establish a functional excitation–contraction machinery of individual CM 
and to find regimes of electrical or mechanical stimulation, (or both) that result in cell 
coupling25. Therefore, the use of electrical field stimulation as a pre-training method for 
inducing synchronous construct contractions is currently under development within different 
platforms23,26. 
Radisic and co-workers reported, using a 3D model of neonatal rat ventricular myocytes, that 
the effects of ES depend strongly on the time of its initiation16. They found that after cell 
disaggregation by enzyme digestion, cells were transiently incapable of transmitting electrical 
signals and contract in response to pacing (Figure 3.1-3; Phase 1). After cell isolation, all the 
connections between cells were disrupted. They hypothesize that during Phase 1 cells began to 
recover from the adverse treatment synthesizing and assembling the lost proteins. At the same 
time, they recovered surface channels and receptors. At this point, ES had an inhibitory role, 
and it was convenient to delay it until the cells were fully recovered. When cells started to 
connect one to each other, cultivation with an electrical field could be performed (Figure 3.1-3; 
Phase 2). It was described that the application of ES to 3D constructs induces hyperpolarization 
at the anode end of the cell and depolarization at the cathode end of the cell. The cells aligned 
with the electrical field lines were subjected to the largest voltage difference and were likely the 
first ones to generate action potentials and contract. Processes formed at the cells’ ends 
promoted the establishment of gap junctions, propagation of pacing signals, and generation of 
action potentials that induced synchronous macroscopic contractions. As the contractions began, 
they could drive the organization of sarcomeres and thereby increased the contractile force in 
response to electrical stimuli. Therefore, ES could enhance the development of ultrastructural 
and contractile properties of the individual cells and increase the number of functionally 
coupled cells engaged in synchronous contractions of the constructs16. 
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Figure 3.1-3: Progressive development of conductive and contractile properties of cardiac constructs cultured 
in vitro. Phase 1 pre-culture without ES. Phase 2: cultivation with ES. The cells oriented in the direction of the 
electrical field will be the first ones to elongate and establish gap junctions with neighboring cells. Reproduced from 
Radisic et. al. 200416 
Methods of electrical stimulation 
Electrical stimuli can be applied in the form of monophasic or biphasic signals, such as 
sinusoidal, saw tooth or square wave signals, in the form of pulses, pulse bursts, or 
continuously. These signals can be generated easily by low-cost integrated chips, signals 
generators, or dedicated therapeutic systems22. 
Different methodologies to deliver an electrical stimulus have been developed (see Figure 
3.1-4). With direct stimulation (Figure 3.1-4a), the electrodes are in direct contact with the cell 
culture media or implanted into the patient or laboratory animal. Indirect stimulation is a 
contactless approach used in many therapeutic devices and in vitro experimental setups. Three 
indirect techniques are used: capacitive, inductive, and combined (Figure 3.1-4b-d). 
Specifically, capacitive stimulation is generated between the two plates that serve as electrodes, 
following the same principle as in a capacitor. Inductive coupling uses controlled 
electromagnetic fields produced by coils placed around the cell culture to induce an electrical 
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field. Finally, combined coupling method is a combination of a magnetic field and an 
alternating current generated by a transient electromagnetic field22. 
 
Figure 3.1-4: Methods to deliver an electrical stimulus in vitro22. These methods can be divided into direct (direct 
contact with the cell culture) and indirect (there is not direct contact). Indirect methods can be divided into capacitive 
(b), inductive (c) and combined (d) methods. Image adapted from Balint et. al. 2013.  
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3.2 PREVIOUS RESULTS 
In the work performed by Llucià-Valldeperas et. al.27, the effect of ES on the cardiac 
differentiation potential of two different types of ATDPCs obtained from patients undergoing 
cardiac surgery was studied. Cardiac adipose tissue biopsy samples were obtained from fat pads 
surrounding the cardiac groove, near the base of the heart and around the aortic root28. 
Subcutaneous samples were taken from fat pads between skin and sternum from the same 
patients29. 
The protocol reported consisted of 2 ms monophasic square-wave pulses of 50 mV/cm at 1 Hz, 
which is similar to the native heart, over 14 days as it is presented in Figure 3.4-1B.  
 
Figure 3.2-1: Effect of electro-stimulation on subATDPCs growing in 2D cultures. (A) Scheme and picture of the 
system used to electro-stimulate subATDPCs in 2D culturesi  (B) ES program used in 2D cultures (C) Real-time PCR 
for the analysis of cardiomyogenic genes in cardiac and subcutaneous ATDPCs. Relative fold expressions of 
cardiomyogenic markers in electro-stimulated vs. non-treated controls are shown in both cardiac and subcutaneous 
ATDPCs. Cardiac Troponin I (cTnI) transcripts were not detected in either cell type. Values were normalized to 
GAPDH expression and are shown as mean ± SEM for six independent experiments, performed in duplicate; *p ≤ 
0.05 vs. subcutaneous ATDPCs group. (D) Protein expression subATDPCs detected by immunofluorescence on a 
vertical patterned surface: (a) Phalloidin staining (red) and GJA1 expression (green); (b), sarcomeric α-actinin (red) 
and GATA-4 (green) expression; and (c) SERCA2 (red) and MEF2 (green) expression. Nuclei were counterstained 
with Hoechst 33342. Scale bars=50mm. Reproduced from Llucià-Valldeperas et. al. 201327 
Cells were cultured on biocompatible patterned surfaces. Cardiomyogenic differentiation was 
examined by qRT-PCR (for cardio and subcutaneous ATDPCs) and by 
immunocytofluorescence (for subcutaneous ATDPCS) as it can be observed in Figure 3.4-1C 
i System custom made by Electronic and Biomedical Instrumentation Group, Departament Enginyeria Electrònica, Universitat 
Politècnica de Catalunya (UPC). 
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and D. qRT-PCR results (Figure 3.4-1C) showed a significant up-regulation of MEF2C (p = 
0.05) and GATA4 (p = 0.03) at day 14 for cardiac ATDPC after stimulation. On the other hand, 
subcutaneous ATDPCs only exhibited an increase of GJA1 expression (2-fold). 
Imunocytofluorescence also showed that, in response to ES, subATDPCs became aligned 
following the linear surface pattern of the construct (Figure 3.4-1D)27.  
These results lead our group to inquire how this type of stimulus can affect cells growing in 3D 
systems.
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3.3 SPECIFIC AIMS 
Tissue engineering (TE) as a new discipline open the window for a wide variety of studies. 
These studies are predicted to be more relevant than traditional 2D cultures in the context that 
3D systems can mimic the in vivo environment in a more realistic way. However, these novel 
systems are technically tricky. The protocols already stipulated for general 2D cultures are 
needed to be redefined for their use in these models and, usually, each system needs a specific 
protocol. For this reason, although during the last decades much research has been focused in 
this area; nowadays a lot of work is still needed.  
In the previous chapter, subATDPCs behavior in the 3D milieu provided by self-assembling 
peptide RAD16-I was tested. The effect of chemical induction was also analyzed. In this 
chapter, ES will be applied in the 3D system developed in Chapter 2 with the aim to analyze the 
behavior of the encapsulated cells in terms of viability, morphology and proliferation. The 
general aim is to imitate, as well as possible, the conditions that the cells would find in vivo and 
analyze their response to the stimulus. 
Therefore, the specific objectives of this chapter are: 
− To set the protocol for the electrical induction of cells cultured in 3D scaffolds based on 
RAD16-I and test the hypotheses that subATDPCs in RAD16-I self-assembling peptide 
scaffolds are able survive under electrical conditions similar to the native heart (section 
3.5.1 and 3.5.2). 
 
− To assess the potential of subATDPCs to undergo proliferation in 3D cultures, under 
electrical or chemical induction (section 3.5.3). 
 
− To study subATDPCs behavior under the combination of the 3D environment provided 
by RAD16-I with electrical and chemical stimuli (section 3.5.4).  
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3.4 MATERIALS AND METHODS 
3.4.1 Cells used in this chapter 
Human normal dermal fibroblasts (hNDF) adherent cells, isolated from the skin of anonymous 
adult patients, were kindly provided by Dr. Jesús Otero Hernández from “Hospital Universitario 
Central de Asturias”. They were seeded in T75 flasks using Dulbecco’s Modified Eagle 
Medium (DMEM - Labclinics, E15-099) supplemented with 10 % (v/v) fetal bovine serum 
(FBS - Lonza, DE14-801F), 1 % (v/v) penicillin/ streptomycin (P/S - Labclinics, 011-010), and 
2 mM Glutamine  (Labclinics, M11-004) at 37 ºC in 5 % CO2 humidified atmosphere. Initially, 
5·105 cells were seeded in T75 flask. When cells density was about 3,000 cells/cm2, they were 
detached using Trypsin-EDTA 0.05 % - 0.02 % (Invitrogen, 25300-062) and expanded until 
there were enough cells to start 3D cultures (encapsulations). 
Subcutaneous adipose tissue derived progenitor cells, obtained from cardiac surgery, were 
provided by IGTP group from ICREC Research Program, “Hospital Universitari Germans Trias 
i Pujol”, and treated as explained in Chapter 2. Shortly, pools of 5 patients were prepared and 
adhered cells were grown in control medium under standard conditions (37 °C in 5 % CO2 
humidified atmosphere). Control medium consisted on: Minimum Essential Medium, alpha (α-
MEM - Sigma; M4526) supplemented with 10 %  FBS (Lonza; DE14-801F; Lot 1SB003), 1 % 
(v/v) P/S (Labclinics; P11-010), 1 % L-glutamine (Labclinics; M11-004), and 5 µg/mL 
plasmocin (InvivoGen; ANT-MPT)  
3.4.2 Control three-dimensional cultures 
Assembly: SubATDPCs pools were thawed at passage 5 and expanded until passage 7. At 
passage 7, cells were trypsinized, washed with sucrose 10 %, and resuspended in sucrose 10 % 
to render 1.6·105 cells in 40 µL. All 3D cultures started at passage 8. The constructs were 
prepared mixing equal volume of the cell suspension and RAD16-I self-assembling peptide 
(PURAMATRIXTM – Corning, 354250) obtaining a final cell suspension which contained 2·106 
cells/mL. The mixture was carefully mixed by pipetting, and 80 µL were loaded into each 9-
mm-diameter cell culture insert (PICM01250, Millipore, Billerica, MA) previous wet with 
medium. Medium was added carefully in sequential steps on the top of the hydrogel and 
allowed to infiltrate, to wash out the remaining sucrose. Finally, 500 µL were loaded inside the 
insert and 2.5 mL in the well. On alternate days, 500 µL of medium was discarded from the well 
and 500 µL of fresh medium were added carefully on the wall of the insert until the end of the 
experiment. Incubation was performed, in the same way, as in flat surfaces (37 ºC, 5 % CO2). A 
scheme of the defined protocol is presented in Figure 2.4-1. 
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Assembly of 3D cultures attached to the membrane: The preparation of the 3D constructs was 
conducted in the same way as explained, obtaining a final cell suspension of RAD16-I self-
assembling peptide containing 2·106 cells/mL. The cell-peptide mixture was carefully mixed by 
pipetting, and 80 µL were loaded into on a dry 9-mm-diameter cell culture insert membrane 
(PICM01250, Millipore, Billerica, MA). Using this procedure, the peptide solution penetrates 
into the porous of the membrane and the subsequent self-assembling, by media loading, stacks 
the gel on the surface of the membrane. Two different final peptide concentrations were used: 
0.15 % and 0.2 %. 
3D cultures maintaining: All 3D cultures were maintained during four days in control medium. 
After this interval of time, the medium of all samples was entirely replaced. The constructs were 
covered with cardiac induction medium or control medium again (see Figure 2.4-2). The cardiac 
induction medium was prepared using Iscove’s Modified Dulbecco’s Medium (IMDM - Gibco; 
2198032), and HAMF12 Nutrient Mix, GlutaMAXTM supplement (Gibco; 31765027). The 
combination of these media was supplemented with insulin-transferrin-selenium (ITS - Gibco, 
41400-045), α-MEM (100x, Lonza, BE13-114E), horse serum (HS - Sigma, H1138-100mL), 
Ascorbic acid 2-phosphate (Aa 2P- Sigma, A4403), and Transforming growth factor beta 1 
(TGF-β1 - Millipore, GF111). 1 % (v/v) P/S (Labclinics; P11-010), and 5 µg/mL plasmocin 
(InvivoGen; ANT-MPT) (see Figure 2.4-2) were also added. 
3.4.3 Electrical stimulation studies  
Electrical stimulator set-up: The stimulation unit set-up used was custom made by “Electronic 
and Biomedical Instrumentation Group, Departament Enginyeria Electrònica, Universitat 
Politècnica de Catalunya (UPC)” by Dr. Benjamin Sanchez (see Figure 3.4-1).  
The set-up consists of a combination of a monophasic programmable electrical device, a printed 
circuit board (PCB) (FR-4 plastic laminate designed with Ultiboard Circuit Design, National 
Instruments) that enabled electrical stimulation of up to six petri dishes (10x35 mm), and two 
Platinum-Iridium wire electrodes (0.5 mm diameter) per culture plate and insert (0.4 m pore, 12 
mm external diameter, 9 mm internal diameter Millipore, cat PICM01250) (Figure 3.4-1)18. 
After the customization of the inserts with the electrodes, both were sterilized by ethylene oxide. 
Before starting a culture in the proposed system, the whole system was treated with ethanol and 
ultraviolet light overnight.  
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Figure 3.4-1: The electrical stimulation set-up inside the cell culture incubator. The Printed Circuit Board (PCB) 
(in green), cultures plates with media and detail of an insert with the stimulation electrodes (left top). 
Electro-stimulation conditions: For a given electric field amplitude applied to the cells using 
two stimulation electrodes, a fraction of the electric field is lost near the electrodes due to the 
electrode impedance. This effect results from the medium-electrode interface and as a 
consequence, the effectiveness of the applied electric field is variable from the point of view of 
the cells. The variability of the field depends on the electrode material, the electrodes, the 
effective stimulation area and the medium volume. To mitigate this effect and increase the 
electrodes’ surface, the electrodes were twisted at the end (Figure 3.4-1, top and Figure 3.4-2a 
and b). Furthermore, the experimental protocol conditions were modified according to the 
measured effective electric field applied to the cells. The conditions were verified within a set of 
experimental validation measurements.  
 
Figure 3.4-2: Electro-stimulation protocol. (a) Top-view of one insert prepared for ES. (b) Cross-section of one 
insert prepared for ES. The electric field always follows the same direction. (c) Conditions stipulated for the ES set-
up. (d) Trains of electrical pulses (rectangular, monophasic, 2 ms time duration, amplitude 50 mV/cm, frequency 1 
Hz). 
At the other end, each of the electrodes was connected to the connector provided by the PCB 
and to the electrical stimulator through an isolator stage to prevent DC stimulation (outside 
incubator). As for the electrical connection between corresponding culture plates, three of the 
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culture plates were in parallel and in series with the other three. With this connection, a sample 
could be removed without the need to stop the experiment18. 
Electrical stimulation protocol: With the aim to electro-stimulate cells growing in a 3D milieu, 
the assembly of the constructs was performed in inserts previously start ES. Each insert was 
custom made with two platinum electrodes which free ends were connected to the stimulator. 
Two custom made electrodes were placed in a Petri dish, and one construct was prepared in 
each insert. Cell encapsulation was performed as control 3D cultures (see section 3.4.2) but in 
this case petri dishes were filled with 3 ml of culture medium instead of 2.5 ml. Constructs were 
pre-cultured without ES during 2 or 7 days depending on the experiment. Trains of electrical 
pulses (rectangular, monophasic, 2 ms time duration, at 50 mV/cm and 1 Hz) were applied 
continuously for an additional 14 days (Figure 3.4-2c and d). Constructs cultured without 
electrical stimulation under identical conditions were used as controls. 
3.4.4 Macroscopic and microscopic analysis of 3D cultures 
With the aim to analyze the macroscopic behavior of 3D constructs, all samples were analyzed 
under Stereoscopic microscope Nikon digital Slight DS-2MV, while network formation was 
followed using Nikon Eclipse TE2000-1 microscope. 
3.4.5 Live and dead staining (L&D) 
The viability of the cells cultured in 3D cultures was assessed using two-colour fluorescence 
cell viability assay based on intracellular esterase activity and plasma membrane integrity 
(LIVE/DEAD® Cell Viability Assays, Invitrogen; L-3224) as it has been explained in Chapter 
2, section 2.4.7. Images were taken with Zeiss AxioVert 200M / ApoTome Microscope. 
3.4.6 Dapi and phalloidin staining (D&P) 
Cells were double stained using DAPI [4’,6-Diamidino-2-phenylindole] (Sigma; D9542) and 
Phalloidin–tetramethylrhodamine B isothiocyanate (Sigma; 7418) as it has been explained in 
Chapter 2, section 2.4.8. The samples were examined under Zeiss AxioVert 200M / ApoTome 
Microscope.  
3.4.7 MTT viability assay 
MTT was used to analyze cell viability as it has been explained in Chapter 2, section 2.4-9. 
Briefly, each analyzed day, the culture media were aspirated, and MTT reagent (Sigma; M5655-
1G) was added to a final concentration of 0.5 mg/mL in culture media covering the samples. 
The samples were incubated for 3 hours at 37 ºC. At the end of the incubation period, the 
solution was removed, and the constructs were lysed using dimethylsulfoxide (DMSO – Sigma, 
D8418) to lyse the cells and resuspend the formazan crystals. All samples were analyzed in 
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triplicate. The absorbance was read at 550 nm with a BIOTECH ELX 800 spectrometer using 
DMSO as a blank. 
3.4.8 Study of gene expression by RT-PCR  
Reverse transcription polymerase chain reaction (RT-PCR) was performed to analyze gene 
expression. The samples were lysed and RNA was extracted with PeqGold Total RNA kit 
(Peqlab; 12-6834-02), followed by cDNA synthesis using Quantitect Reverse Transcription Kit 
(Qiagen; 205311) according to manufacturer protocol (detailed information about these steps is 
reported in Chapter 2, sections 2.4-10 and 2.4-11). RT-PCR reaction was carried out using 30 
ng of cDNA in a final volume of 50 μL containing: 1X ThermoPol Reaction Buffer (stock 10X), 
0.4 units of Deep Vent DNA polymerase (New England Biolabs; M0258S), 200 μM of dNTPs 
and 0.3 μM primers. The RT-PCR took place under the following conditions: 3 min at 95 ºC 
(activation) followed by 35 cycles of 20s at 94 ºC, 30 s of annealing (Tm dependent on primer 
pair, see Table 3.4-1) and 30 s at 72 ºC. Final extension step was performed at 72 ºC during 15 
min. Commercial primers were used for GATA4 gene (Qiagen; QT00031997), cardiac 
troponinI (Qiagen; QT00084917), and GJA1 also known as Connexin43 (Qiagen; QT00012684) 
(see Table 3.4-1). Synthetic primers were used for human 18S housekeeping gene amplifying a 
fragment of 245 bp: h18S forward 5’-GCTACCACATCCAAGGAAGGCAG-3’ and h18S 
reverse 5’-CGCTCCCAAGATCCAACTACGAG-3’. RT-PCR products were size fractionated 
by 2 or 4 % agarose gel electrophoresis, depending on the expected fragment size. 
Table 3.4-1: Primer information provided by Qiagen. 
 
3.4.9 Statistical analysis 
The means and standard deviations were calculated for the recorded data. 
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3.5 RESULTS AND DISCUSSION 
3.5.1 Set-up electro-stimulation system  
The first efforts within this chapter were focused on the preparation of an ES system. It must be 
able to induce ES to the cells growing in the 3D constructs developed in the previous chapter, as 
it has been done with 2D cultures27 (see previous results). It consisted of the components 
presented in Figure 3.5-1: the monophasic programmable electrical device and the isolator stage 
(Figure 3.5-1a), the Printed Circuit Board (PCB - Figure 3.5-1b), two inserts with Platinum-
Iridium wire electrodes per petri dish and six petri dishes per PCB (Figure 3.5-1c). The 
maximum capacity per PCB was twelve inserts.  
 
Figure 3.5-1: Components of the electrical stimulation system. (a) Electrical stimulator and isolator stage. (b) 
Printed circuit board (PCB). (c) PCB with the six petri dishes containing two inserts per petri dish. Detail of the 
inserts in the petri dish. (d) Modified insert with the electrodes at the bottom. (e) Modified insert with the electrodes 
at the top.  
Cell culture inserts to electrically stimulate 3D systems were adapted to allow the passage of 
current introducing Platinum-Iridium wire electrodes. The electrodes were included in the 
inserts in two different ways: 
Insert with the holes at the bottom part (Figure 3.5-1d)  
The constructs could not be directly prepared in this insert since the peptide-cells mixture could 
spread out through the holes. Consequently, constructs were performed into regular inserts and 
pre-cultured without ES during 7 days. Generally, at day 7, the structures had condensed and 
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had enough consistency to enable their transference into the adapted inserts. Then, ES was 
initiated.  
Inserts with the holes at the top part (Figure 3.5-1e) 
In this case, encapsulation and ES were performed in the same insert without the need of 
transferring the 3D construct. It was important to assure to twist down the electrodes as shown 
in the picture. In this way, they were medium-coated during the experiment and the circuit was 
closed enabling the pass of the current. 
The PCB with the petri dishes containing the modified inserts was located inside the incubator 
in order to provide the right conditions to the cell culture (temperature of 37 ºC and 5 % CO2 in 
humidified atmosphere). The monophasic programmable electrical device and the isolator stage 
were placed outside the incubator. The electrical pulses were generated by the electrical 
stimulator, and the electric field passes through the PCB thanks to the connectors that allow the 
connection of the inserts electrodes. 
3.5.2 Preliminary studies 
Setting of electro-stimulation protocol using hNDFs  
hNDF were used to set the ES protocol. This cellular type were easy available and gave us the 
opportunity to adjust the parameters, become familiar with the system, and understand the 
equipment function. Additionally, hNDFs grew faster and were more studied in our laboratory 
than subATDPCs. 
As mentioned, for modified inserts with the electrodes at the bottom, the encapsulation 
assembly was carried out in normal inserts. After 7 days of culture, the constructs were 
transferred into modified inserts in order to start the electrical stimuls. hNDFs constructs were 
quite condensed at this time point (see Figure 3.5-2a) and a good cellular network was formed at 
day 5 compared to the rounded shape of the cells one day after encapsulation (see Figure 
3.5-2c). This macroscopic morphology allowed the simple transference from the standard insert 
to the modified one. Two weeks after starting electrical stimuli, all the constructs (both electro-
stimulated and non-electro-stimulated) reached at a similar construct diameter reduction: 0.27 
cm the electro-stimulated construct and 0.24 cm the no electro-stimulated (total time of culture 
21 days). The high condensation of the 3D culture, at the final point of the experiment, did not 
allow visualizing the cellular network properly. Interestingly, L&D assay at days 15 and 21 
(Figure 3.5-2b), confirmed that most of the cells remained alive under this electrical conditions, 
which are similar to the native heart ones. After 8 days of being subjected to electrical pulses 
(day 15) and at the end of the culture, after 14 days of electrical stimulation (day 21) most part 
of the cells were alive (green) and only some of them died (red). 
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Figure 3.5-2: Effect of electro-stimulation on 3D constructs of hNDF in RAD16-I 0.15 %. Cells were 
encapsulated in 0.15 % RAD16-I and cultured with control medium with and without ES. ES started at day 7. (a) 
Condensation graphic for 3D constructs with and without ES. (b) Cell viability of electro-stimulated hNDF within the 
self-assembling peptide hydrogel at days 15 and 21 (live cells stain green and dead cells, red). 3D reconstruction 
images were obtained from several optical sections taken with Zeiss ApoTome system. (c) Pictures of cell 
morphology after 1 and 5 days of culture with a 10x objective under the contrast phase microscope.  
Analysis of electro-stimulation of subATDPCs  
SubATDPCS are pretended to be implanted in an infarcted tissue to assist myocardial 
regeneration. For this reason, it is of high interest to analyze their behavior under electrical 
conditions similar to the ones of the native heart. The developed system allowed analyzing this 
issue. SubATDPCs in the 3D environment provided by 0.15 % RAD16-I presented good 
viability and construct diameter reduction (see Chapter 2), both in control and cardiac induction 
media. For this reason, the analysis of the effect of ES was carried out in both conditions.  
First of all, the effect that ES could cause on subATDPCs behavior growing in control media 
was evaluated, considering as controls samples not treated with ES and cultured with the same 
medium. The first important observation was that subATDPCs had slower response in terms of 
cellular network formation and construct diameter reduction when compared with hNDF. No 
significant construct diameter reduction was observed after 7 days of culture (Figure 3.5-3a). 
Thus, the constructs were not stiffer enough, and some samples broke during the process of 
transference to the modified inserts. Broken samples were discarded (2 of a total of 8).  
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After starting ES protocol, the construct diameter reduction was similar in both electro-
stimulated and non-electro-stimulated samples. No notable differences were observed and after 
4 days of ES, the diameter size of electro-stimulated and non-electro-stimulated samples was 
approximately 0.4 cm (Figure 3.5-3a). 
The formation of the network started before the ES as it can be visualized in Figure 3.5-3b. 
Importantly, L&D assay (Figure 3.5-3c) showed high cell viability of the electro-stimulated 
constructs after 14 and 20 days. Thus, it can be concluded that ES did not affect negatively 
subATDPCs maintenance in RAD16-I self-assembling peptide in terms of construct diameter 
reduction, network generation, and viability. These results are of high interest for further in vivo 
implantation since we can conclude that the cells would tolerate the electrical conditions found 
in vivo. 
 
Figure 3.5-3: Effect of electro-stimulation on 3D constructs of subATDPCs in RAD16-I 0.15 %. Cells were 
encapsulated in 0.15 % RAD16-I and cultured with control medium with and without ES. ES started at day 7. (a) 
Condensation graphic for 3D constructs with and without ES. (b) Contrast phase pictures of cell morphology at days 
1, 5, 7 and 9 of culture. (c) Cell viability of electro-stimulated subATDPCs within the self-assembling peptide 
hydrogel at days 14 and 20 (live cells stain green and dead cells, red). 3D reconstruction images were obtained from 
several optical sections taken with Zeiss ApoTome system.  
Additionally, some samples from electro-stimulated and non-electro-stimulated 3D constructs at 
different days were analyzed by RT-PCR. As it can be observed in the corresponding agarose 
gel electrophoresis (Figure 3.5-4), at day 20, the electro-stimulated sample showed the 
expression of cTnI and also GATA4 and GJA1 although fainted. GJA1 was highly expressed 
after 7 days of ES but its expression decrease one week later. These preliminary results, with a 
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slight expression of early and late cardiac markers, were promising, but further analyses are 
required to make a definitive statement.  
 
Figure 3.5-4: RT-PCR of subATDPCs growing in control media under electrical induction as compared with 
samples without this stimuli. Expression analyses of subATDPCs growing in 0.15 % RAD16-I in control medium, 
electro-stimulated (ES) and non-electro-stimulated (no ES). Samples were taken at day 14 (d14) and day 20 (d20). 
The analyzed genes were h18S (245 bp), gap junction protein, alpha 1 (92bp), cardiac troponinI (113bp), and GATA4 
(81bp). Agarose gel 4 %. 
With the aim to improve the technical issues of the protocol previously discussed, a new 
strategy was addressed in order to avoid the transference of the constructs from standard inserts 
to modified inserts during the culture. For this purpose, modified inserts with the electrodes at 
the top were used (Figure 3.5-1e). Thereby, the encapsulation was performed in the same insert 
where it was electro-stimulated, avoiding the transference. This new approach allowed us to 
start ES at the second day of encapsulation, when the network started to be formed but before it 
was completely structured. This procedure was conceived with the aim to force the cells to form 
a network with anisotropic architecture. As Milica et. al. reported, it is important to allow cells 
to recover from trypsinization, but it is also indispensable to obtain a degree of organization to 
assure the better conditions for electric impulse propagation16. 
For this reason, we thought it could be interesting to force the electrical field to always affect 
the constructs in the same direction, to induce some order within the cellular growth. With this 
objective, the encapsulations were fixed at the bottom of the culture insert. In order to achieve 
this goal, the cell-peptide mixture was loaded on a dry insert membrane. In this way, the peptide 
solution wet the membrane penetrating into the porous. The subsequent self-assembling, by 
medium loading, stacks the gel on the surface of the membrane. Therefore, construct attached 
onto the membrane could not float when medium was added. Also, with the aim to maintain the 
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constructs attached on the insert membrane, the peptide concentration was increased to 0.2 % 
RAD16-I to slow down the condensation process (see Figure 2.5-5b). 
 
Figure 3.5-5: Effect of electro-stimulation on 3D constructs of subATDPCs in RAD16-I immobilized on the 
insert membrane. Cells were encapsulated in 0.15 % and 0.2 % RAD16-I and cultured with control medium with 
and without electro-stimulation (ES and no ES respectively). ES starts at day 2. (a) Contrast phase constructs pictures 
at days 5, 10, 15 and 18 under the magnifier. (b) Condensation graphic for 3D constructs. The diameter of three 
samples for each condition was measured to obtain a standard deviation. 
Accordingly, subATDPCs were encapsulated in 0.15 % and 0.2 % RAD16-I and cultured in 
control medium during 18 and 15 days respectively, starting the ES at the second day of culture. 
The macroscopic images and the condensation process tendency for both peptide concentrations 
are shown in Figure 3.4-5a and b. Although 0.2 % RAD16-I constructs were initially stuck onto 
the membrane, from day 10 on, most encapsulations detached from the bottom of the insert and 
started to condense. For this reason, and regarding the directionality of the electric field, as this 
protocol did not ensure the immobilization of the construct, it was not possible to achieve any 
conclusion. The condensation obtained with the ES protocol was similar to that the one obtained 
without it in both peptide concentration conditions.  
A preliminary gene analysis was performed by RT-PCR as it is presented in Figure 3.5-6. The 
early cardiac marker GATA-4 and definitive cardiac marker GJA1 were analyzed. GJA1 was 
detected in all conditions while GATA4 was not amplified in any of the samples. It was 
hypothesized that subATDPCs in this conditions are not dedifferentiating into an early cardiac 
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precursor but evolving into a CM-like phenotype with good interconnection between them. 
Nevertheless, it was only a preliminary data that needs to be further explored.  
 
Figure 3.5-6: RT-PCR of subATDPCs growing in control media under electrical stimulation at two different 
RAD16-I self-assembling peptide concentrations. The analyzed genes were h18S (245 bp),gap junction protein, 
alpha-1 (92 bp) and GATA4 (81 bp). Analysis of subATDPCs expression growing in 0.15 % and 0.2 % RAD16-I 
using electro-stimulation (ES) and control medium. The samples were analyzed at days 5 (d5), 10 (d10), 15 (d15) and 
18 (d18) of culture. Agarose gel 4 %. 
The impossibility to fix the construct using the previously described protocol leads us to change 
the strategy. Agarose bed was selected to be added on the top of the 3D constructs to keep them 
fixed on the bottom of the culture inserts. At day 7, the entire medium of the culture inserts was 
removed, and 80 µL of cell culture agarose was loaded on the construct. Agarose adhered the 
construct in the insert assuring that it would not change the position, and the electrical field 
would always affect it in the same direction18. Once the agarose was gelled (20 minutes at room 
temperature) inserts and petri dishes were refilled with the appropriate media. A preliminary 
study using different concentrations and volumes of agarose was performed (data not shown). 
The best condition to enable the diffusion of the medium and to maintain the position of the 
construct was 80 μl of 0.75 % agarose. This protocol will be used in the next experiments. 
3.5.3 Proliferation studies of subATDPCs in a 3D environment with chemical and 
electrical stimulation  
Numerous methods can monitor cell health. Plasma membrane integrity, DNA synthesis, DNA 
content, enzyme activity, presence of ATP, and cellular reducing conditions are known 
indicators of cell viability or cell death. Assays that measure metabolic activity are suitable for 
analyzing proliferation, viability, and cytotoxicity. The reduction of tetrazolium salts such as 
MTT, MTS and XTT between others or the reduction of resazurin only occurs in metabolically 
active cells. Actively proliferating cells increase their metabolic activity while cells exposed to 
toxins, typically decrease their activity.  
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The effect of both inductive stimuli (chemical and electrical) in terms of cell proliferation and 
construct macroscopic behavior was analyzed. MTT proliferation assay was performed with 
samples under chemical and electrical induction separately. In each case the results were 
compared with cells growing in 3D environment without stimulation. SubATDPCs were 
cultured into the soft nanofiber scaffold RAD16-I in presence of control and cardiac induction 
media (Figure 3.5-7). As observed in Figure 3.5-7a, the evolution of constructs diameter 
reduction was dependent on the culturing medium. After 14 days of culture the diameter of 
constructs cultured in cardiac induction medium measured  0.19 cm while in control medium 
measured 0.52 cm (see Figure 3.5-7a and e). 
At the same time, the cellular metabolic activity (related to mitochondrial oxidoreductase 
activity) was measured (Figure 3.5-7f). After induction with cardiac induction medium, at days 
7 and 9, the metabolic activity of cells cultured of both conditions were similar. However, from 
day 11 to 14 each condition showed a different profile. Control cultures profile showed a slight 
increase of oxidoreductase activity, while chemically induced cultures presented a decreasing 
tendency. Initially, we thought that this effect was due to cell dead associated to the high 
condensation of chemically induced cultures. Nevertheless, by looking at the constructs in detail 
we observed a consistent mass of cells leaving out the scaffolds (see Figure 3.5-7c). As MTT 
assay was performed only for the cells growing inside the constructs, but not for the remaining 
cells in the tissue culture insert, we sub-estimated the total number of cells in the chemically 
induced samples.  
We hypothesize that cells do not have enough space in such condensed environment to fulfill 
the nutrient and oxygen requirements and start to migrate outwards the construct. This 
movement could be an advantage for future therapeutic applications of cell delivery into an 
infarcted heart. However, this should be further studied in order to understand the underlying 
causes entirely.  
Moreover, to assess whether the cells were alive, L&D assay was performed at day 10 of culture 
with cardiac induction medium (Figure 3.5-7b). Although some dead cells were observed (in 
red) the majority remained alive (green). Surprisingly, the cells growing inside the 3D cultures 
induced with cardiac induction medium presented a highly aligned pattern. This alignment was 
again confirmed at day 14 of culture with the pictures of D&P staining (Figure 3.5-7d). The 
whole construct was captured (Figure 3.5-7d left) and magnification (Figure 3.5-7d right) 
showed the aligned pattern of the cells. This alignment could be due to an efficient spatial 
disposition since cell density increases in a highly condensed construct.  
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Figure 3.5-7: Behavior, growth and survival of subATDPCs into RAD16-I cultured in control vs cardiac 
induction medium. Cells were encapsulated in 0.15 % RAD16-I and cultured with cardio and control media during 
14 days. The induction with cardiac induction medium starts at day 4. (a) Constructs pictures at different days under 
the magnifier. (b) L&D assay of a 3D construct cultured with cardiac induction medium at day 10 (live cells stain 
green and dead cells, red). (c) Contrast phase picture (left) and DAPI staining picture (right) of cells leaving from a 
3D construct cultured with cardiac induction medium at day 14. The white line marks the 3D construct. (d) D&P 
staining of the 3D construct cultured with cardiac induction medium at day 14. 3D reconstruction images were 
obtained from several optical sections taken with Zeiss ApoTome system. (e) Condensation graphic of samples 
cultured with control and cardiac induction media. The diameter of three samples for each condition was measured to 
obtain a standard deviation. (f) Proliferation graphic of samples cultured with control and cardiac induction media. 
The cell number was measured with MTT assay. The samples were measured in triplicate to obtain a standard 
deviation.  
This analysis was also performed for electrically induced cells. The results obtained are shown 
in Figure 3.5-8. Using ES the condensation process was not observed as compared with 
chemical induction (Figure 3.5-8a and c), and no major differences existed between the 
diameter of electro-stimulated and non-electro-stimulated constructs.  
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Figure 3.5-8: Behavior and survival of subATDPCs into RAD16-I under electrical stimulation. Cells were 
encapsulated in 0.15 % RAD16-I, cultured with control medium and electro-stimulated up to day 14. (a) Constructs 
pictures at different days under the magnifier. (b) Fluorescence pictures of electro-stimulated 3D constructs at 
different days. Days 9 and 14 D&P staining (nuclei stain in blue and cytoskeletal filaments in pink) and day 11 L&D 
assay (live cells stain green and dead cells, red) were performed. 3D reconstruction images were obtained from 
several optical sections taken with Zeiss ApoTome system. (c) Condensation graphic of electro-stimulated (ES) and 
non-electro-stimulated (no ES) samples. The diameter of three samples for each condition was measured to obtain a 
standard deviation. (d) Proliferation graphic of ES and no ES samples. The cell number was measured with MTT 
assay. The samples were measured in triplicate to obtain a standard deviation.  
The cell morphology was analyzed by contrast phase microscopy (data not shown) and by 
fluorescence staining (Figure 3.5-8b), and no cellular network could be noticed. This fact 
confirmed one of our hypotheses that only when cells form network and inter-connect one to 
each other, stretch all together allowing the construct condensation process to occur. 
The proliferation assay (Figure 3.5-8d) showed a decrease in the metabolic activity of the 
electro-stimulated 3D constructs, similarly to what was observed in chemically induced samples 
(see Figure 3.5-7). L&D assay was performed 4 days after starting the ES, and the majority of 
the cells were alive. Unfortunately, in this case we could not elucidate if this effect was due to 
cell death, end of proliferation in combination of cell death, or migration outwards of the 
construct (as observed before for cardiac induced samples). We speculate that maybe the cells 
were also leaving out the scaffold due to the influence of the electro-stimulation, but since the 
constructs did not condense we could not reach any conclusion. 
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3.5.4 SubATDPCs growing in a 3D culture based in RAD16-I peptide combining 
chemical and electrical stimuli 
Next step of these proof of concept studies consisted in combining the chemical and electrical 
induction in order to analyze subATDPCs behavior. Thus, cardiac induction medium was added 
at day 4 of culture, and as the stimulus was pretended to be increased gradually, ES started at 
day 7. Agarose beds were used to fix the 0.15 % RAD16-I construct, and all the encapsulations 
were electro-stimulated until day 18, but using different media.  
The construct morphology and construct diameter reduction can be observed in Figure 3.5-9a 
and b, respectively. Just before started ES, the chemically induced constructs showed a diameter 
of 0.52 cm while the constructs maintained in control media gave a diameter of 0.77 cm. In fact, 
at the end of the culture there was a difference of 0.49 cm in the diameter of the constructs. As it 
has been suggested in Chapter 2, induction with cardiac induction medium enhances the cell 
interactions and consequently, the condensation. Cell morphology was analyzed at the end of 
the culture under the fluorescence microscope.  
Again, D&P staining of an electro-stimulated construct with control medium revealed no 
network formation at day 18, (rounded shape cells, Figure 3.5-9c). This absence of connection 
correlates with the fact that the constructs were not able to condensate (Figure 3.5-9a). On the 
contrary, electro-stimulated constructs cultured with cardiac induction medium condensate and 
the cells interacted one to each other forming an intricate network. In Figure 3.5-9d it can be 
observed the whole construct after L&D assay (left) and by D&P staining (center). A close up 
of the construct (right) showed the elongation of the cells and their intricate network.   
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Figure 3.5-9: Effect of chemical and electrical stimulation combination on 3D constructs of subATDPCs in 
RAD16-I. Cells were encapsulated in 0.15 % RAD16-I, half of them cultured with control and the other half with 
cardio media and all electro-stimulated. At day, 4 cardio medium was added to the corresponding samples and at day 
7 the electro-stimulation started. (a) Constructs pictures at different days under the magnifier. (b) Condensation 
graphic of 3D constructs electro-stimulated growing in control or cardio medium. (c) D&P staining of electro-
stimulated sample growing with control medium at day 18. (d) Live and dead assay (left) (live cells stain green and 
dead cells, red) and D&P staining (center and right) of samples electro-stimulated with cardio medium at day 18. 3D 
reconstruction images were obtained from several optical sections taken with Zeiss ApoTome system.  
At the end of these studies it is important to compare the results obtained in this chapter and the 
ones obtained in Chapter 2. It was observed a differential network formation and therefore 
construct diameter reduction when subATDPCs were cultured in control medium without 
stimuli. Figure 2.5-2, Figure 2.5-5, Figure 2.5-6 and Figure 3.5-3 show the formation of an 
intricate network with the subsequent construct diameter reduction. On the other hand, Figure 
3.5-7, Figure 3.5-8 and Figure 3.5-9 do not present the formation of this network. This fact was 
attributed to the cell pool used. Although the aim of combining cells of different patients is to 
avoid at the maximum extent experimental variability we observed that at least 5 patients were 
not enough to homogenize the results.  
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3.6 CONCLUDING REMARKS 
Heart is a complex integrated system that leverages mechanoelectrical signals to synchronize 
CM contraction and push blood through the body30. In vivo, the correct magnitude, timing, and 
distribution of these signals are critical for proper functioning. Indeed, aberrant signals can lead 
to acute incidents, long term pathologies, and even death30. For the thorough investigation of the 
specific factors that deeply affect cardiac function in vitro models are emerging as engaging 
tools. Nonetheless, the complex and intricate set of signals that trigger heart function are hard 
complicated to replicate accurately and fully in an in vitro model30.  
Progenitor cells have the ability to differentiate into various cell types, which can be achieved 
by extrinsic physical stimuli (mechanical31–34 or electrical2,19,27,35,36), chemical stimuli (cytokines 
and effector molecules)37–41, biological/genetic stimuli (cell co-cultures42,43, genetic 
manipulations41), and even environmental effect34,44–46. It has been reported that endogenous 
electric fields play an essential role in the functioning of all living mechanisms. It is thought that 
the use of external electrical stimuli may lead to gain greater control over cellular growth 
maturation, adhesion, and orientation22. Additionally, ES is a safe method to induce changes in 
progenitor cells towards cardiac phenotype, avoiding more harmful agents such as 
demethylation agents47 or viral vectors48. In this chapter, we have studied the effect of an 
applied electrical field on subATDPCs using the in vitro model developed in Chapter 2, and 
combining it with the chemical induction previously described. At this point, we have obtained 
an evidence of the viability of the presented system. However, further studies could lead us to 
replicate in vivo environment in a more feasible way and analyze specific cell responses before 
in vivo implantation. 
A direct stimulation methodology was chosen to electrically stimulate the in vitro models 
developed in Chapter 2. Methodologically, direct stimulation is the simplest electrical 
stimulation method. However, it may carry some disadvantages such as insufficient 
biocompatibility of electrodes, changes in pH, reduced levels of molecular oxygen, and the 
generation of dangerous Faradaic byproducts (reactive oxygen species in the culture medium)22. 
All these factors were demonstrated not to be harmful in this type of cultures as it has been 
observed in viability assays of hNDF and subATDPCs, after 2 weeks of ES. 
In our study, the approach was to evaluate the effect that ES has on subATDPCs seeded in 
RAD16-I scaffold combined or not with chemical induction. In this framework, macroscopic 
morphology, viability, and proliferation of subATDPCs growing in the 3D structures were 
analyzed. Interestingly, the cells remained alive and were able to proliferate in the stipulated 
conditions, which were similar to those found in the native heart. 
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ES was suggested as a promising tool for solving various cardiovascular related problems22. Its 
galvanotactic property (movement of an organism or any of its parts in a particular direction in 
response to an electric current) could be crucial in better controlling angiogenesis. This effect 
can improve cell viability inside 3D structures that would be implanted in an ischemic heart. 
Additionally, from the point of view of Cardiac Tissue Engineering, electricity could help to 
overcome the challenge of insufficient alignment and differentiation or even better coupling 
between cells that can lead to improved contractile and conductive properties16. With this 
preliminary study, we wanted to lay the foundations for further ES studies using this 3D in vitro 
model (RAD16-I). More systematic analysis (more times and samples) would be needed to 
better assess the platform. 
The lack of gap junctions due to the absence of electrophysiological connection between donor 
and host cells has been reported to lead to failed cell integration into the myocardium24. What is 
interesting is that although subATDPCs do not present the desired alignment, do express GJA1 
with and without ES in control medium. This fact implies good cell-cell connection and leads us 
to think that this property would benefits cell integration after their implantation within the 
appropriate environment. In further steps with longer ES times, it would be interesting to 
control field direction using the agarose bed to help cell alignment and improve cell 
connectivity. In this way that could lead to better conductive properties5,16,49. 
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3.7 FURTHER STEPS 
This Chapter gives an overview of the possibilities of the developed 3D in vitro model to 
analyze specific factors that could have a significant effect on cellular behavior. Specifically, 
here we deal with the effect that the electrical stimulus would have on subATDPCs that are 
planned to be used for clinical purposes. In this Ph.D. Thesis only a preliminary studies that 
helped us to set the ES protocol and to analyze subATDPCs behavior was assessed. Further 
studies are needed before concluding the effect of ES in subATDPCs growing in 3D 
environment: 
- Analyze different ES conditions. 
- Determine when it is better to start the electrical stimulus. As it was described by Milica 
et. al.16 the effect of ES would change if it is introduced before the cells synthesize and 
assemble the lost proteins while recover surface channels and receptors. 
- Analyze the effect of ES alone at short times at gene and protein level. 
- Analyze the effect of ES alone after long culture times at gene and protein level (data 
previously reported that MSCs take at least 1 to 4 weeks to complete their 
differentiation into CM within heart). 
- Determine the better combination in terms of time for the joining of chemical and 
electrical stimulus. 
- Analyze the effect of ES in combination with chemical induction at short times at gene 
and protein level. 
- Analyze the effect of ES in combination with chemical induction after long culture 
times at gene and protein level. 
The analysis of this parameters and their combination may help to understand better the 
behavior that these cells could have in vivo after their implantation in an ischemic heart with the 
hope to improve its function. Additionally, it may help to improve the methodology to obtain 
better results. 
In other terms, the developed system might also be useful for cell training before their in vivo 
implantation. After the complete characterization of the cells, it could be interesting to culture 
the cells at different times of ES and implant the construct in an in vivo model to study their 
coupling capacity. 
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4.1 BACKGROUND 
4.1.1 Overview 
As commented in the previous chapters, although the treatments for myocardial infarction (MI) 
have been improved during the last decades, the death of cardiac muscle remains an issue. Due 
to the benefits reported for cardiomyoplasty, cells-based therapies give new hope in 
regenerative medicine and are undergoing experimental and clinical trials. Unfortunately, until 
now, cell transplantation has not achieved clear hemodynamic benefits for myocardial 
diseases1,2. It has been estimated that a cell number on the order of one billion would need to be 
replaced in patients with heart failure3. Moreover, they are needed to survive, differentiate, and 
have mechanical and electrical cell-cell contacts between them and the host4. The main obstacle 
for the grafted cells is that the ischemic event is followed by inflammatory reaction, and 
cytokines and growth factors (GF) secretion. Therefore, the transplantation of unprotected cells 
into this environment results in a significant cell death. Additionally, the constant beating 
(human heart beats normally over 2 billion times and pumps over 150 million liters of blood in a 
life span which stimulate cell wash out5) leads to low bioretention and engraftment. In this 
context, it seems suitable to provide a safe environment (niche) to maintain the cells in the 
affected zone and aid their proliferation and differentiation2. 
After MI, the changes not only affect the contractile elements of the myocardium, but also the 
extracellular matrix (ECM), that gives structural strength, is pathologically modified (collagen 
type I decrease from 80 % to 40 %). Therefore, both cardiomyocyte (CM) death and scar 
formation modulate cardiac remodeling, which refers to the changes in size, shape, structure, 
and physiology of the heart. The regional structural changes lead to global left ventricular (LV) 
geometric change (dilated cardiomyopathy), altering fiber direction and diminishing function. 
All these events lead to an increase in LV wall stress and mitral valve regurgitation. This 
process may progress inducing heart dilatation, a negative symptom in the evolution of heart 
failure patients, related with morbidity and mortality2,6. Kelley et. al. first demonstrated that 
restraining infarct expansion preserved LV geometry and prevents a decline in cardiac function. 
As, clinical studies have confirmed the effectiveness of LV restrain in humans, it is possible that 
biomaterials could be used in situ to increase the wall thickness, restore the geometry, and 
provide structural support of an injured LV7. 
In this context RECATABI consortium proposed an approach to address both, the death of CM, 
and the remodeling of the heart muscle, with the final aim to avoid heart failure. Basically, the 
strategy consisted in the development of a bioactive implant containing three components: (1) 
an elastomeric microporous membrane, to provide biomechanical support, (2) a self-assembling 
peptide (SAP) nanofiber gel, to provide an adequate microenvironment within the membrane’s 
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pores, and (3) subcutaneous adipose tissue derived progenitor cells (subATDPCs)8 as a cell 
component. Figure 4.1-1 presents the initial scheme of the bioactive implant proposed by 
RECATABI consortium, which included inside the elastomeric porous membrane a mixture of 
RAD16-I SAP with subATDPCs. With this approach the cells would remain adhered to the 
implanted zone preventing cell loss and providing more directed repair mechanism3. 
4.1.2 Materials used for cardiac tissue engineering during the last years9 
During the last years, the study of many scientists has been and still is focused in the design of 
scaffolds. The issue remains in obtaining a scaffold with the appropriate characteristics to 
provide to the cells a suitable milieu where they can grow in three-dimensional (3D) 
configuration that closely mimic heart native architecture10,11. In addition, the scaffold may 
work as a vehicle for cell delivery. The main purpose is to replicate the biological and 
mechanical function of the native ECM allowing cells to grow and migrate out of the synthetic 
niche in order to colonize the affected zone. Parameters such as topography, charge, roughness, 
hydrophilicity, and hydrophobicity are known to be essential to enhance cell attachment, 
differentiation, and viability.  
One of the first materials used for Cardiac Tissue Engineering (CTE) was based on 
hydrolytically degradable biocompatible polymers composed of polylactic acid (PLA), 
polyglycolic acid (PGA), or their copolymer poly(lactic-co-glycolic) acid (PLGA). 
Subsequently, researchers realized that the mechanical properties of the material used needed to 
be adapted to the elastic properties of the heart tissue12. Several studies have been performed in 
this specific field working with various natural or synthetic biomaterials. Between natural 
biomaterials collagen, fibrin, gelatin, and alginate have been extensively investigated for CTE13. 
Additionally, chitosan has been widely used due to their intrinsic characteristics as a soft 
material for myocardial repair and their anti-oxidative properties14,15. Interestingly, the poor 
mechanical properties of this material were improved reinforcing the hydrogel with chitosan 
fibers10. Other natural materials like elastin, fibroin, fibronectin, laminin, and vitronectin with 
diverse structural and biological features are suitable for CTE approaches15–26. Moreover, cross-
linked matrices of low and high molecular weight maltodextrins obtained an adequate stiffness 
grade material27. In parallel, lots of efforts have been focused in the use of artificial materials. 
Different kinds of polymers have been used for these purposes. Due to their elastic properties, 
elastomers such as poly(glycerol sebacate) (PGS), poly(ester urethane urea) (PEUU), poly(L-
lactic acid)-co-poly-(3-caprolactone) (PLCL), and poly(1,8-octanediol-co-citrate) (POC), 
resulted to be interesting materials. For instance, blending POC and PLCL produced an 
elastomeric nanofibrous scaffold with mechanical properties (tensile strength and Young’s 
Modulus) comparable to the native cardiac tissue28. Other materials that have recently attracted 
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attention due to their excellent mechanical properties (especially fatigue resistance) are 
poly(aliphatic/aromatic-ester)s (PED). PEDs are thermoplastic elastomers that can be tailor 
made to have stress-strain curves typical of elastomers or to have a higher toughness typical of 
thermoplastics29. On the other hand, spherical beads of PLGA have also been used as a platform 
for delivery, improving the post-infarcted cardiac function30.  
Besides cell repopulation and ventricle dilatation, it is clear that there are other issues in the 
necrotic heart tissue that need to be solved. One of these properties is electrical conductivity 
which presents decreased performance. Dvir et. al. proposed to incorporate gold nanowires 
(NWs) within alginate scaffolds which can improve electrical communication between adjacent 
cardiac cells 31. Moreover, materials especially resistant to the formation of fibrous capsule, 
such as polyethylene glycol (PEG), are suitable candidates for CTE32–37. 
In terms of clinical applicability, an important criterion for the choice of one biomaterial is its 
methodology of application. Trying to maximize cell retention and survival in the ischemic area 
during cell delivery; injectable extracellular matrices have been widely studied as vehicles for 
cell injection. Due to their properties, hydrogels seem to be ideal materials for injectable 
scaffolds. They are highly hydrated and possess ECM-like viscoelastic and diffusive transport 
characteristics. Although injectable cell therapies are desirable to avoid invasive chirurgic 
procedures, they present two main challenges: (1) the material needs to be liquid until the 
moment of injection and then solidify quickly after delivery in vivo, and (2) the continuous 
contraction-relaxation cycles of heart tissue, makes difficult the integration of the material 
within the host muscular, vascular, and connective tissue compartments. Therefore, although 
different studies have demonstrated that the use of injectable matrices enhances the beneficial 
effect of intramyocardial cell injection, their poor mechanical properties remain a handicap and 
previously assembled patches appeared as an alternative21. 
4.1.3 RECATABI concept 
The primary goal of European Consortium RECATABI (Regeneration of Cardiac Tissue 
Assisted by Bioactive Implants)38,39 was to develop a bioengineered platform to support cell 
survival after implantation. Additionally, this platform should allow cell mobilization into the 
ischemic tissue to promote slow progressive tissue remodeling and tissue replacement with 
minimal ventricle dilatation. These objectives were faced by the fabrication of nanoscale-
engineered biomaterials and scaffolds to match the biological, biomechanical, and biophysical 
requirements of the implanted tissue.  
The chemical and biophysical cues of ECM in vivo are essential elements for the regulation of 
cell fate and function40. Synthetic and natural hydrogels possess many properties to those of the 
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ECM, which makes them suitable candidates for engineered cellular niches (see Chapter 2). 
RECATABI platform proposed the use of RAD16-I, which was proved to have biomimetic 
characteristics, with the purpose to display structural and functional properties (after the 
addition of specific motifs) similar to ECM. As commented, from the clinical point of view 
these types of materials are appropriate candidates for non-invasive techniques, but 
unfortunately they cannot meet the demanding mechanical requirements of heart tissue, which 
greatly limits their use. RECATABI consortia propose to include RAD16-I inside of a porous 
scaffold with microscopic pores. The microporous scaffold would be able to act as a vehicle and 
protect mechanically the cells into the soft nanofiber scaffold, creating cell niches2. 
Additionally, the proposed scaffolds would be able to provide mechanical strength and 
geometrical definiteness to the heart. Therefore, the microporous scaffolds were designed to 
function as carriers to implant the cells into the infarcted myocardium and to be able to sustain 
the cyclic mechanical deformation of heart beating. Elastomeric membranes were introduced as 
principal candidates since they are capable of recovering from deformation and represent a 
feasible substrate from the mechanical perspective. The developed implant presented in Figure 
4.1-1 combines self-assembling peptide41, newly designed elastomeric membranes, and 
subcutaneous adipose tissue derived progenitor cells (subATDPCs)8,9,40,42. 
 
Figure 4.1-1: RECATABI therapeutic concept: Regeneration of cardiac tissue assisted by a bioactive implant. 
Elastomeric microporous membrane scaffolds (with mechanical properties similar to cardiac tissue) were filled with a 
self-assembling peptide nanofiber (a synthetic ECM analog) containing stem cells (1) in order to obtain a bioactive 
implant (2). The membrane acts as a carrier but most importantly, protects mechanically the cells growing into the 
soft nanofiber scaffold. Additionally it was designed to act as a LV restrainer. 
The scaffolds designed and synthesized by the Center of Biomaterials and Tissue Engineering 
group of UPV for the RECATABI project were: a non-degradable polymeric porous membrane 
of ethyl acrylate (EA) and a partially degradable polymer of caprolactone methacryloxyl ethyl 
ester (CLMA) membranes. Mechanical support properties of biodegradable materials would be 
lost along the time which could derivate in LV dilation, complicating to avoid tissue loss 
function. Both materials, which are described in section 4.2 (Previous Results), were filled with 
RAD16-I to obtain two different bioactive implants. The combination of RAD16-I with 
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elastomeric membrane would be referred as composite henceforth. Cell addition into the 
composite will be referred as a bioactive implant. 
In terms of ventricle remodeling, one of the principal mechanisms by which cellular therapy 
could bring functional benefits would be that the implant should provide a supporting 
scaffolding effect. This result would limit the spread of the infarcted area, preventing the 
excessive remodeling and dilatation of the ventricle which may reduce the risk of heart failure 
progression and the indication for heart transplantation. This approach takes advantage of the 
ability of an elastomeric material to serve as flexible patch. Here the consortium proposes that, a 
permanent scaffold would contribute to the regeneration but also act as a permanent mechanical 
restraint to limit ventricular dilatation3,43. Additionally, it was expected that within this approach 
the cells would remain in the implanted site preventing cell loss. 
4.1.4 Clinical Translation, a gap to bridge 
Advanced-therapy medicinal products (ATMPs) are medicines based on gene therapy, somatic-
cell therapy or tissue engineering that wants to offer new insights for the treatments of diseases 
that right now have not available solution. During the last decade, the biology of stem cells has 
been presented together with expressions such as “promise”, “rapid progress” and “future 
therapies”. This lead to a growing concern about its possible future clinical use. The lack of an 
EU-wide regulatory framework in the past led to divergent national approaches which hindered 
the access to these products44. The regulatory framework for ATMPs was established by 
Regulation (EC) No 1394/2007 on advanced therapy medicinal products and the European 
directives 2003/63/EC and 2009/120/EC45. The aim of this regulation is to ensure the free 
movement of these medicines within the European Union (EU) and to facilitate their access to 
the EU market. Moreover, it could foster the competitiveness of European pharmaceutical 
companies in the field while guaranteeing the highest level of health protection for patients.  
Typical regulatory concerns surrounding the use of cellular components are product safety, cell 
characterization and control, and characterization of their manufacturing process. With regard to 
safety, cell donors must be carefully screened. Additionally, once the cellular product is 
expanded in Good Manufacturing Practices (GMP) production facilities, it must be checked by 
several standardized tests such as viability, sterility, adventitious agents, genetic 
stability/tumorigenicity, pyrogenicity, mycoplasma infection, etc. Additionally, it is required to 
test biological activity and toxicity in a relevant animal model according to Good Laboratory 
Practice (GLP). Finally, in order to guarantee respect for human subject rights, ensure data 
quality, and steer clear of avoidable errors is mandatory. European Directives 2001/20/EC and 
2005/28/EC on Good Clinical Practice (GCP), and associated guidelines must be followed. 
Likewise, and specifically for the clinical translation of stem cells (SCs), the International 
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Society for Stem Cell Research Guidelines (ISSCR Guidelines) offer an adequate starting point. 
In conclusion, a medicinal product development, from discovery to marketing authorizations, is 
thus a costly, lengthy, highly regulated, and high-risk process46.  
Although still today, a clear statement on cell therapy efficacy cannot be made, and the 
experimental basis of myocardial cell therapy is incomplete, several clinical trials have already 
been initiated5,47. Significant findings for cellular cardiomyoplasty, show an enhanced 
contractile and systolic function, improvement in LV remodeling parameters and a decrease of 
LV end-systolic volume11,34,48,49. Despite many cell types have been analyzed, most clinical 
trials have worked with autologous bone marrow mononucleated cells (BM-MNC) delivered 
using different methodologies such as intracoronary injection, stop-flow balloon catheter, and 
angioplasty balloon catheter among others 50. Interestingly, several experimental studies showed 
the benefits of engineered materials charged with SCs for ischemic models. The first clinical 
trial for the use of CTE was the MAGNUM Clinical Trial (Myocardial Assistance by Grafting a 
New bioartificial Upgraded Myocardium)51. In this approach, a collagen type I matrix was 
seeded with autologous BM-MNC and grafted onto the LV wall. The cell-seeded collagen 
matrix increased the thickness of the infarct scar with viable tissue and helped to normalize 
cardiac wall stress in injured regions, thus limiting ventricular remodeling and improving 
diastolic function. The main limitations of collagen scaffolds for heart repair are their low 
mechanical properties and its complete bio resorption and degradation at mid-term. Clinical 
studies are also under way to investigate the safety and feasibility of cell implantation in 
patients32. 
Moreover, some of the remaining questions before cell transplantation could be safely translated 
to clinic are optimal timing for cell transplantation, ideal cell type and number, long-term 
survival, application route, and terminal differentiation post-implantation52. The identification of 
the migration, differentiation, and regeneration mechanisms is also of great interest. In addition, 
even though cell component is the main analyzed factor, it is also important to analyze patient 
selection, concomitant procedures, cell transplantation, cell survival, cell tracking, dose, age, 
regulatory issues, and funding34,53. In conclusion, despite significant technical advancements, 
there is still a definite need for further refinements before CTE concepts could be translated into 
clinical practice.  
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4.2 PREVIOUS RESULTS 
This Chapter is focused in the in vitro work developed by the European RECATABI project in 
Dr. Semino’s laboratory. The five groups mentioned in the introduction worked during 3 years 
side by side to direct the investigation. At the beginning of the project, the cells and the 
biomaterials to be used along the project were defined. To make this decision all the efforts 
were focused on the stipulation of the most favorable source of cells and materials to be applied 
in future therapeutic protocols54–56. In one side, Dr. Bayés-Genís group isolated, and 
characterized the cell candidate (subcutaneous Adipose Tissue Derived Progenitor Cells 
(subATDPCs), as it is explained in Chapter 2). On the other hand, Dr. Monleón Pradas group 
designed, synthesized, and characterized the biomaterials to be tested during the project. The 
basic properties that the biomaterial must to accomplish were: (1) high porosity with 
controllable porous size and interconnectivity; (2) elastomeric at body temperature; (3) low 
swelling to avoid dimensional changes while maintaining mechanical properties; and (4) low 
degradation to content ventricle dilatation.  
4.2.1 Microporous scaffolds used as cell vehicle and ventricle dilatation 
contention in RECATABI project 
Biomaterials-based artificial matrices are designed to provide structural and functional support 
to cells for organizing into effective tissues. Synthetic polymers can alleviate the complexities 
of processing, purification, immunogenicity, and pathogen transmissions usually associated 
with natural polymers. A scaffold for Tissue Engineering (TE) should have mechanical 
properties matching the host tissue at the site of implant57. In the context of CTE, the intrinsic 
dynamic mechanical environment requires biomaterials designed to match the tissue modulus 
and to recover from the mechanical strains58. In this project, elastomeric materials were 
proposed as principal candidates for heart regenerative applications, since they allow better 
flexibility for cell-scaffold integration57. The biostable elastomer poly(ethyl acrylate) - PEA - 
and the semidegradable one poly(caprolactone methacryloyloxyethyl ester) - PCLMA - were 
found to be suitable candidates for the intended application due to their physical and mechanical  
properties and their reported capacity to maintain different type of cells59–68. The advantage of 
using elastomeric materials has not been definitely shown, but there is a strong reason to believe 
that mechanical properties of the match material matter6. Previous studies showed an 
improvement in LV function due to an augmented elastin network; therefore elasticity and 
distensibility in the infarcted LV appeared as an advantage6. 
Cell adhesion to synthetic materials is a complex phenomenon critical for biomedical and 
biotechnical applications. It can be controlled by guiding the wettability, charge, chemistry, 
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roughness, and stiffness of such scaffolds. Additionally, it has been reported that biomaterial 
surface chemistry modulates cell responses (both in vitro and in vivo) such as cell survival, 
cycle progression, and phenotype expression69. The molecular mechanisms of all these cues 
remain poorly understood, but the effect of the biomaterials in cell responses is generally 
attributed to the material-dependent capacity to absorb different type of protein species, at a 
specific concentration, and with or without biologically activity70,71. Also morphological 
interactions (biomaterial topography) affect this interaction. On the other hand, in the absence of 
specific cell adhesion domains, positive surface charges play an important role in cell 
attachment72. The density of charges is highly important for cell attachment. Moderate densities 
of positive charges, which support a slight increase of hydrophilicity, can improve cell 
adhesion. However, high densities of charges render the surface very hydrophilic, which then 
diminishes cell adhesion. In other terms, microporous scaffolds have the same order of 
magnitude that cells size and therefore, they are not capable to reproduce properly the 3D 
environment found in vivo. 
Previous studies showed that PEA and PCLMA (both hydrophobic and with null charge) 
elastomeric membranes are good candidates for cell adhesion. They were chosen as main 
candidates for RECATABI European project. 
Material samples of copolymer composition determined as suitable candidates to match 
mechanical and degradation requirements 
Polymer films based on the combination of ethyl acrylate (EA) and caprolactone 
methacryloyloxyethyl ester (CLMA) were synthesized in different mass proportions, intended to 
serve as basic chemistries for the elastomer scaffold membranes (monomeric structures are 
presented in Figure 4.2-1). The EA monomer yields PEA, biostable and elastomeric at body 
temperature. It was chosen because  of the wide expertise of UPV group using it with different 
architectures and several cell types: keratocytes, chondrocytes, neural cells, endothelial cells or 
dental pulp stem cells59,60,62,63.On the other hand, the CLMA monomer yields PCLMA, also 
elastomeric with a biostable skeleton and a biodegradable lateral chain of caprolactone. It was 
previously proved to have outstanding biological behavior, and was also tested with different 
architectures and several cell types: chondrocytes, bone marrow stem cells, and osteoblasts66–68. 
 
Figure 4.2-1: Monomers used for the synthesis of the elastomeric membranes employed in RECATABI 
Project. (a) Ethyl acrylate (EA), and (b) Caprolactone methacryloyloxyethyl ester. 
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PEA scaffolds were designed with interconnected cylindrical orthogonal or spherical 
interconnected pores and PCLMA scaffolds with spherical interconnected pores. PEA and 
PCLMA scaffolds were 0.8 mm-thick and were cut into samples having 5 mm in diameter. 
Porous size of both elastomeric membranes was about 120 microns. The architecture of 
developed scaffolds was analyzed by scanning electron microscopy (SEM) in a frontal view and 
cross section (Figure 4.2-2). Cylindrical interconnected orthogonal pores of PEA scaffold were 
clearly observed in a cross section image (Figure 4.2-2a). Different layers of cylindrical crossed 
pores in parallel and perpendicular planes could be also visualized (Figure 4.2-2b). On the other 
hand, interconnected spherical pores of PCLMA scaffold were readily appreciated leaving a 
trabecular regular aspect to the scaffolds (Figure 4.2-2c and d). 
 
Figure 4.2-2: Scanning electron microscopy images of the designed microporous membranes. (a, b) PEA 
scaffolds with cylindrical orthogonal pores and (c, d) PCLMA scaffolds with spherical pores: (a, c) cross-section, (b, 
d) surface. PEA with spherical pores is not shown.  
Mechanical properties of poly(ethyl acrylate-co- caprolactone methacryloyloxyethyl ester), 
P(EA-co-CLMA), copolymers in different proportions of EA and CLMA were tested (Figure 
4.2-3). Both homopolymers and their copolymers were hydrophobic as it can be concluded from 
their equilibrium water content (EWC) (Figure 4.2-3c). Additionally, both were elastomeric at 
body temperature as it could be deduced from the results of Young Modulus, Breaking Strength, 
and Strain at Break (Figure 4.2-3a and b). The degradation of PEA and PCLMA homopolymers 
was followed by immersion in phosphate buffer saline (PBS), and in an aqueous medium at pH 
3.5. At different times up to 60 days the weight loss of both biomaterials was determined. The 
biostable PEA did not degrade, whereas PCLMA lost 15 % of its mass by hydrolysis in the acid 
medium (Figure 4.2-3d and e). 
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Figure 4.2-3: Mechanical and degradation features of the designed elastomeric membranes. (a) Young moduli 
obtained as the slope of the stress-strain curves and breaking strength performed on P(EA-co-CLMA) copolymers 
with different proportions of their homopolymers. (b) Strain at break obtained from the tensile measurements 
performed on P(EA-co-CLMA) copolymers with different proportions of their homopolymers. (c) Equilibrium water 
content, defined as the ratio of the mass of absorbed water at equilibrium to the mass of the dry material. The mass of 
absorbed water was measured after immersion of P(EA-co-CLMA) copolymers with different proportions of their 
homopolymers in PBS at 37 ºC until equilibrium. (d) Weight loss versus degradation time in acid medium and PBS 
for PEA elastomeric membrane. (e) Mass loss versus degradation time in acid medium and PBS for PCLMA 
elastomeric membrane.  
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4.3 SPECIFIC AIMS 
Tissue death after blood supply restriction is only the beginning of a host of deleterious events 
that lead to an impasse that could conclude with heart failure. Nowadays, the recovery of heart 
function after MI to avoid this no exit way is a notable concern. While immediately intervention 
is focused on the cause to avoid damage at the maximum extend, new efforts are focused on the 
consequence.  
In vitro analysis is of great interest for the deconstruction of complex organ systems such as the 
heart with the final aim to analyze specific factors. All the knowledge obtained from this kind of 
models is useful for its application in the obtaining of tissue substitutes that could repair a 
damaged tissue. The final aim of RECATABI European project was to obtain a patch capable of 
restoring ventricular function after MI. This thesis is mainly focused in the in vitro work of 
RECATABI project. In Chapter 2 and Chapter 3, in vitro models to analyze specific cues were 
developed; in this Chapter the preparation of bioactive implants and its in vitro analysis are 
presented. The main objectives of this chapter are: 
- To define a methodology to assemble the bioactive implant consisting of elastomeric 
membranes filled with RAD16-I self-assembling peptide and subATDPCs (section 
4.5.1 and 4.5-2). 
 
- To establish and verify a proof of concept for the maintenance of implanted cells at the 
myocardial infarcted site using a bioactive implant based on PEA or PCLMA 
elastomeric membranes (section 4.5.3). 
 
- To study the properties of the bioactive implant prepared with PEA elastomeric 
membrane in terms of cell viability, growth, distribution, and protein and gene 
expression (section 4.5.4). 
 
- To study the properties of the bioactive implant prepared with PCLMA elastomeric 
membrane in terms of cell viability, growth, distribution, and protein and gene 
expression (section 4.5.5). 
Additionally, and only as an overview, a summary of the most relevant results of the in vivo 
analysis developed by IGTP and CardioMonde groups are presented. 
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4.4 MATERIALS AND METHODS 
4.4.1 Culture of cells used to establish RECATABI concept protocol. 
Two different cell types were used to establish the RECATABI concept protocol: human normal 
dermal fibroblasts (hNDF) and mouse fibroblasts cell line (L929). Once established, the cells 
used were subcutaneous adipose tissue derived progenitor cells (subATDPCs) 
Human normal dermal fibroblasts (hNDF) adherent cells, isolated from the skin of anonymous 
adult patients, were kindly provided by Dr. Jesús Otero Hernández from “Hospital Universitario 
Central de Asturias”. hNDF were seeded in T75 cm2 flasks using Dulbecco’s Modified Eagle 
Medium (DMEM - Labclinics, E15-099) supplemented with 10 % (v/v) fetal bovine serum 
(FBS - Lonza, DE14-801F), 1 % (v/v) penicillin/ streptomycin (P/S - Labclinics, 011-010), and 
2 mM Glutamine (Labclinics, M11-004) at 37 ºC in 5 % CO2 humidified atmosphere. 
Mouse fibroblast cell line L929 from subcutaneous connective tissue, areolar and adipose 
(Sigma Aldrich, 04102001-1VL) at passage 10 were seeded and expanded with DMEM - high 
glucose (Sigma, D-6546). The media was supplemented with 10 % FBS ( Lonza, DE14-801F), 
1 % P/S (Labclinics, 011-010), and 2 mM L-glutamine (Sigma, G7513). Cultures were 
maintained at 37 ºC in 5 % CO2 humidified atmosphere. 
Subcutaneous adipose tissue-derived progenitor celli: SubATDPCs, obtained from cardiac 
surgery as explained in Chapter 2, were provided by IGTP group from ICREC Research 
Program, “Hospital Universitari Germans Trias I Pujol”73,74. Informed consent was obtained 
from all subjects, and the study protocol conformed to the principles outlined in the Declaration 
of Helsinki75. SubATDPCs were treated as explained in Chapter 2 (See 2.4.1. Cell culture). 
Adhered cells were grown under standard conditions (37 °C in 5 % CO2 humidified atmosphere) 
in Minimum Essential Medium, Alpha (α-MEM - Sigma; M4526) supplemented with 10 % FBS 
(Lonza; DE14-801F; Lot 1SB003), 1 % (v/v) P/S (Labclinics; P11-010), 1 % L-glutamine 
(Labclinics; M11-004) and 5 µg/mL plasmocin (InvivoGen; ANT-MPT).  
4.4.2 RECATABI concept 
SubATDPCs pools were thawed at passage 5 and expanded until passage 7. Parallel, 1 % 
RAD16-I (PuraMatrix 1% (w/v) – Corning, 354250) was diluted, in two steps, with 20 % 
sucrose and 10 % sucrose to obtain a solution of 0.3 % RAD16-I. Then, cells at passage 7 were 
trypsinized, washed with sucrose 10 % and resuspended in sucrose 10 % to render the double of 
the desired final concentration. Equal volume of the cell suspension and RAD16-I 0.3 % was 
mixed to render the final cell suspension in 0.15 % RAD16-I. When the mixture was prepared 
i Kindly provided by Dr. Carolina Soler-Botija, Hospital Germans Trias i Pujol, Badalona 
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and mixed correctly by pipetting, different methodologies were tested to introduce it inside the 
porous elastomeric membranes as it will be explained in results and discussion section. 
4.4.3 Plasma treatment 
The elastomeric membranes were placed in a cylindrical Pyrex reactor equipped with a copper 
coil that generates plasma under vacuum conditions (0.02 mbar). A mixture of argon with 
different oxygen percentages (0 – 40 %) was fed into the chamber increasing the final pressure 
up to 0.06 mbar. The samples were then submitted to plasma at 50-100 W for 10 min. This work 
was performed by Dra. Núria Marí-Buyé. 
4.4.4 Preparation of the elastomeric membrane pre-filled with RAD16-I self-
assembling peptide nanofiber scaffolds (composite) 
The self-assembling peptide RAD16-I was loaded inside the elastomeric membranes scaffolds’ 
pores before the addition of the cells. Prior to its use, RAD16-I was placed in a bath sonicator 
(Bandelin) for 30 min at 25 ºC applying 30 W to decrease its viscosity and diluted to 0.15 % 
(w/v)42. The mixture was vortexed (Elmi SkyLine) to ensure homogenization. Each elastomeric 
membrane was submerged in a RAD16-I nanofiber peptide 0.15 % solution and with the help of 
the vacuum the solution was forced to penetrate in the microporous structure of the hydrophobic 
scaffolds. Next, an increase of the ionic strength with PBS or culture medium was used to 
induce the self-assembly42. The efficient filling and gelling was assessed by SEM and Congo 
Red Staining after 30 min gelling. Materials to be used for cell culture were previously 
sterilized with gamma radiation.  
4.4.5 Structural, mechanical and electrical characterization of the elastomeric 
membranes and its composite 
Morphology: The porosity of the bare scaffolds, π (pore volume fraction), was obtained through 
the specific volume of PEA (reciprocal of 1.13 g·cm-3)76 or PCLMA, respectively, v, the weight, 
m, and apparent (geometric) volume, V, of the scaffolds as: π=Vpores/V=1-mv/V. The specific 
volume of PCLMA was previously obtained as follows: dry pieces of PCLMA films were 
weighed in air, m, and immersed in n-octane (95 %, Fluka, ρn-octane = 0.703 g cm-3), m’, at room 
temperature. Specific volume was calculated as the volume of n-octane displaced, obtained as 
Vdispl=(m-m’)/ρn-octane, divided by the mass of the sample: v=Vdispl/m. Mettler AX 205 balance 
(Mettler-Toledo Inc., Columbus, OH, USA) with a sensitivity of 0.01 mg, equipped with a 
Mettler ME 33360 density accessory kit, was used. This work was performed by Maria Arnal in 
“Universitat Politècnica de València” (UPV). 
Surface wettability: The wettability of the elastomeric membranes was measured using a Drop 
Shape Analysis System DSA100 (KRÜSS, Deutschland). Briefly, water drops were deposited 
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on the membranes and the contact angle between each drop, and the surface of the membrane 
was measured.  
Swelling and tensile properties: To quantify the swelling of the scaffolds, 5 mm-diameter pieces 
of PEA and PCLMA films were dry weighed and after different times of immersion in PBS at 
37 ºC until equilibrium was confirmed42. The EWC was obtained as the ratio of the mass of 
water absorbed at equilibrium to the mass of dry polymer: EWC=(mwet-m)/m. Pieces of PEA and 
PCLMA scaffolds and their films were cut into 0.5 x 3 cm2 pieces. Then, tensile tests were 
performed in a Microtest SCM3000 95 (Microtest SA, Madrid, Spain) device at a deformation 
rate of 0.2 mm/min until fracture. The tensile modulus was obtained in each case as the average 
of the slope in the strain-stress plots. This work was performed by Maria Arnal in UPV. 
Study of the impedance: The electrical impedance of the membranes filled with hydrogel and 
submerged in α-MEM medium was measured at 10 kHz using a commercial impedance meter 
(Autolab, PGSTAT128N). Membranes filled with physiologic serum (ρ =0.625 Ωm) were also 
measured to normalize the membranes filled with hydrogel impedance values (Ω) to resistivity 
units (Ω·m). Platinum electrodes (0.5 mm diameter) were used for measurements performed at 
room temperature (25 ºC). The electrodes were introduced in parallel to the membrane plane 
and separated by a distance of 5 mm. This work was performed in collaboration with Dr. 
Benjamin Sanchez from “Universitat Politècnica de Catalunya” (UPC).  
4.4.6 Cell seeding in elastomeric membrane/self-assembling peptide composites 
SubATDPCs pools were thawed at passage 5 and expanded until passage 7. Before cell seeding, 
RAD16-I 0.15 %  was introduced inside the bare elastomers pores as described in section 4.4.4. 
Once filled with the solution, elastomers of 8 mm diameter were placed in 48-well plates and 5 
mm diameter ones in 96-well plates. Then, subATDPCs passage 7 were trypsinized and divided 
into two solutions at a final concentration of 10,000 cells/µL and 5,000 cells/µL in sucrose 10 
%. The first suspension was injected (using a Hammilton syringe) inside 8 mm diameter 
scaffolds for gene and protein profile analysis and inside 5 mm diameter scaffolds for image 
analysis. The second suspension was injected in 5 mm scaffolds for viability studies. After 
injection, the samples were incubated with soft shake during 30 min allowing the cells to 
migrate slightly into the construct. Finally 800 µL and 350 µL of fresh media were added in 48- 
and 96- well plates respectively allowing the peptide to gel. Samples were cultured under 
standard conditions (37 ºC and 5 % CO2 in humidified atmosphere) during 1 and 7 days, and 
half of the media was changed daily. The same procedure was performed with bare elastomers 
prefilled with PBS (see Figure 4.4-1). 
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Figure 4.4-1: Bioactive patch preparation: methodology scheme. Elastomeric membranes were 
polymerized leaving interconnected pores. Here a section of a scaffold with spherical pores is taken as an 
example. The scaffolds were filled with RAD16-I (composites) or PBS (bare PEA) using vacuum. 
Finally, subATDPCs were injected inside the scaffolds. Scaffold size and cell number were dependent on 
the analysis but cell density was maintained (625 cells/µL). 
4.4.7 Congo Red staining 
Congo Red staining was performed to stain the β-sheet structure characteristic of the self-
assembling peptide RAD16-I inside the pores of elastomeric membranes. Samples were 
incubated with 0.1 % (w/v) Congo Red in water for 5 minutes and washed several times with 
PBS. Finally, the samples were analyzed under Stereoscopic microscope Nikon digital Slight 
DS-2MV. 
4.4.8 Live and dead staining (L&D) 
The viability of the cells cultured in 3D cultures was assessed using two-color fluorescence cell 
viability assay based on intracellular esterase activity and plasma membrane integrity 
(LIVE/DEAD® Cell Viability Assays, Invitrogen; L-3224) as it has been explained in Chapter 
2, section 2.4.6. Images were taken with Zeiss AxioVert 200M / ApoTome Microscope. 
4.4.9 Dapi and phalloidin staining (D&P) 
Cells were double stained using DAPI [4’,6-Diamidino-2-phenylindole] (Sigma; D9542) and 
Phalloidin–tetramethylrhodamine B isothiocyanate (Sigma; 7418) as it has been explained in 
Chapter 2, section 2.4.7. The samples were examined under Zeiss AxioVert 200M / ApoTome 
Microscope.  
4.4.10 MTT viability assay  
Cell viability was analyzed in 5 mm diameter scaffolds using MTT assay. Shortly, 250,000 cells 
were seeded in each scaffold. After 1 and 10 days, the culture media was aspirated and MTT 
reagent (Sigma, M5655) was added to a final concentration of 0.5 mg/mL in culture medium. 
The samples were incubated for 3 hours at 37 ºC and formanzan crystals were dissolved by 
soaking the samples about 10 min in 300 μl of dimethylsulfoxide (DMSO – Sigma; D8418) 
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with shaking. All samples were analyzed in triplicate and controls of the scaffolds without cells 
were also analyzed. The absorbance was read at 550 nm with a BIOTECH ELX 800 
spectrometer. 
4.4.11 Study of gene expression by RT-PCR  
Reverse transcription polymerase chain reaction (RT-PCR) was performed to analyze gene 
expression in two-dimensional (2D) cultures and bioimplant cultures. The samples were lysed, 
and RNA was extracted with PeqGold Total RNA kit (Peqlab; 12-6634-02). Before lysis the 
samples were cut in small pieces to better extract the material filing the elastomeric membrane 
porous. Following, cDNA synthesis was performed using Quantitect Reverse Transcription Kit 
(Qiagen; 205311) according to manufacturer protocol and as it has been explained in Chapter 2, 
sections 2.4.10 and 2.4.11. RT-PCR reaction was carried out using 30 ng of cDNA in a final 
volume of 25 μL containing 1X ThermoPol Reaction Buffer (stock 10X), 0.42 units of TAQ 
DNA polymerase (Sigma; D1806), 200 μM of dNTPs (Sigma; DNTP100), and 0.3 μM primers 
(synthesized by Sigma). The RT-PCR took place under the following conditions: 3 min at 95 ºC 
(activation) followed by 35 cycles of 20 s at 94 ºC, 30 s of annealing (Tm dependent on primer 
pair, see Table 4.4-1) and 30 s at 72 ºC. Final extension step was performed at 72 ºC during 15 
min. RT-PCR products were size fractionated by 2 or 4 % agarose gel electrophoresis, 
depending on the expected fragment size. 
4.4.12 Study of gene expression by qRT-PCR 
Real Time reactions were performed with LightCycler® 480 Real-Time PCR System (Roche), 
using the iQ™  SYBR® Green Supermix (Bio-RAD; 170-8882) as explained in Chapter 2, 
section  2.4.14. Briefly, the samples were lysed, and RNA was extracted with PeqGold Total 
RNA kit (Peqlab; 12-6634-02), followed by cDNA synthesis using Quantitect Reverse 
Transcription Kit (Qiagen; 205311) according to manufacturer protocol (detailed information 
about these steps is reported in Chapter 2, sections 2.4.10 and 2.4.11). Before lysis the samples 
were cut in small pieces to better extract the material filing the elastomeric membrane porous. 
Relative gene fold variations were all determined by the comparative CT method (2-ΔΔCt) and 
expression of the target genes (TBX5 as early cardiac marker and GJA1as definitive cardiac 
marker) was normalized to the housekeeping gene (ribosomal protein 22L, RPL22). Primers 
used are defined in Table 4.4-1. 
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Table 4.4-1: Primers for RT-PCR and qRT-PCR. Early and definitive cardiac markers were analyzed. 
Additionally, E-cadherin (CDH1) and its natural repressor SNAI1 were studied. 
 
4.4.13 Western Blotting for protein analysis 
Bioimplants of 8 mm diameter were cut in small pieces and lysed with the help of pestles to 
crush the samples using RIPA buffer (Sigma; R0278) containing proteinase inhibitor cocktail 
(Roche; 11836153001). 2D samples growing on PEA or PCLMA films were taken as control. 
Protein content of the supernatant was determined using Micro BCATM Protein assay kit (Pierce-
Thermo Scientific; 23225). Equal amounts of total protein (10 µg) were denatured using SDS 
(Sigma; L5750-500G) and β-mercaptoethanol at 95 ºC during 10 min. The whole lysate was 
separated by electrophoresis on 10 % SDS-PAGE gels at 150 V during 1 h 30 min and 
transferred using wet transference on PVDF membrane (Invitrogen; LC2002) during 2 h at 40 
V. The membranes were blocked with 5 % milk buffer during 2 h at room temperature. Then, 
they were incubated with rabbit polyclonal anti-GATA4 1 µg/mL ( Santa Cruz; sc-9053), rabbit 
polyclonal anti-GJA1 1 µg/mL (Santa Cruz; sc-9059) or rabbit polyclonal anti-TBX5 1 µg/mL 
(Santa Cruz, sc-48782) at room temperature for 1 h. After 3 short washes with Phosphate 
Buffered Saline (PBS - Gibco; 18912-014) complemented with Tween-20 (Sigma; P-1379) 
(PBST) and an overnight PBST wash, the blots were incubated with peroxidase-conjugated to 
rabbit IgG goat polyclonal secondary antibody 1µg/mL (Abcam; ab97051). The protein bands 
were detected after incubation with SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo Scientific; 34080) using ImageQuant LAS 4000 mini equipment. Goat polyclonal anti-
Actin antibody (Santa Cruz; sc-1615) was used to normalize using peroxidase-conjugated to 
goat IgG rabbit polyclonal as secondary antibody (Abcam; ab97100).  
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4.4.14 Immunocytochemistry 
After seven days of in vitro culture, composites were fixed for 20 min with paraformaldehyde 4 
% (PFA – Sigma, 158127) and the expression of ACTN1 and F-actin (for PEA samples) and 
Vimentin and F-actin (for PCLMA samples) was examined. Briefly, composites were washed 
with PBS (Sigma, P4417) and permeablized during 60 min with PBS-1 % bovine serum 
albumin (BSA – Sigma; A2153) (PBSA). Afterwards, PEA were incubated overnight at 4 ºC 
with Monoclonal Anti-sarcomeric α-actinin Clone EA-53 (Sigma, A7782) diluted in PBSA at a 
dilution rate of 1:100 and PCLMA samples in Monoclonal Anti-Vimentin Clone V9 (Sigma, 
V6630) diluted in PBSA at a dilution rate of 1:40. Subsequently, samples were exposed to the 
secondary antibody goat anti-mouse 488 (DakoCytomation; Z0420). Additionally, it was used a 
marker for selective F-actin staining (Alexa Fluor Phalloidin 647 – Invitrogen, A22287) at a 
dilution of 1:200 in 0.1 % PBSA for 2 h at room temperature. Nuclei were counterstained with 
DAPI (Sigma; D9542) at a final concentration of 1µg/mL. Finally, samples were cryoprotected 
by immersion in phosphate buffer (PB) 0.1 M containing 30 % sucrose for 1 day and included 
in optimal cutting temperature (OCT) embedding compound. Sections of 100 µm were obtained 
by using a cryostat (Leica, CM 1900) and evaluated by confocal microscopy (Olympus 
FV1000). This work was performed in collaboration with Dr. Cristina Martínez-Ramos in UPV.  
4.4.15 Scanning electron microscopy  
Composites and bioactive implants were treated using standard procedures in order to evaluate 
the morphology by SEM. Samples were fixed with 2.5 % Glutaraldehyde in PB 0.1 M for 60 
minutes at 37 ºC. After that, samples were treated with 1 % osmium tetraoxide for 2 h, followed 
by dehydration using increasing concentrations of ethanol for 10 min each wash (30º, 50º, 70º, 
96º, 100º). Finally, samples were air dried and sputtered with gold before study in a Hitachi (S-
4800) microscope. Imaging of samples was performed using 15 kV of voltage. This work was 
performed in collaboration with Dr. Cristina Martínez-Ramos in UPV. In parallel, some samples 
also dehydrated in subsequent steps and coated with gold were examined using NovaNano SEM 
230 model (FEI, The Netherlands). 
CryoSEM images of the composites were also obtained using a JSM5410 (JEOL Ltd., Tokyo, 
Japan) device equipped with a cryounit (Oxford CT 1500) to confirm the uniform filling of the 
scaffolds with the peptide gel. Cross sections were previously obtained by immersion of the 
samples in liquid nitrogen. Water within the peptide gel was sublimated at -70 ºC in the 
cryogenic unit for 15 min in vacuum. Samples were gold-sputtered and observed at 15 kV and 
15 mm of working distance in a Hitachi (S-4800) microscope. 
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4.4.16 Genetic labelling of subATDPCs  
Cells were transduced using CMVp-RLuc-mRFP1 lentiviral vector (2 x 106 transducing 
units/mL, MOI = 21, 48 h) to express the Renilla luciferase (Rluc) control reporter labelled with 
red fluorescent protein (RLuc-RFP) under the control of the cytomegalovirus (CMV) promoter, 
a reporter of cell number. Additionally, to monitor cardiomyogenic lineage differentiation, 
positively transduced cells expressing RLuc-RFP were selected by fluorescence-activated cell 
sorting and transduced with lentiviral vector hcTnIp-PLuc-eGFP to express the promoter-less 
Luciferase (PLuc) reporter construct labelled with enhanced green fluorescen protein (PLuc-
eGFP) under the regulation of human cardiac Troponin I promoter (hcTnIp)75,77. Dr. Juli Bagó 
kindly performed this transduction. Doubly transduced cells were loaded into the bioactive 
implant which was delivered onto the infarcted area of a MI model75. 
4.4.17 Myocardial infarction modelii  
The study was performed on 8 female severe combined immunodeficiency (SCID) mice (20 to 
25 g; Charles River Laboratories, inc.). Myocardial infarction was created as previously 
described78 occluding the left anterior descending (LAD) coronary artery which provoke and 
acute infarct. The animals were randomly assigned to one of the following groups: (1) PEA-
bioimplant implantation and no MI induction (the PEA sham group, n=2), (2) MI induction and 
PEA-bioimplant implantation (n=2), (3) PCLMA-bioimplant implantation and no MI induction 
(the PCLMA sham group, n=2), and (4) MI induction and PEA-bioimplant implantation (n=2). 
The bioimplants were implanted immediately after occlusion75. 
4.4.18 Assembly and transplantation of the bioimplant 
The bioimplants were cultured in standard conditions for 24 h before implantation onto the 
healthy or the infarcted myocardium of mice. The fixation of the implant was made making use 
of synthetic surgical glue (Glubran2) to fix their edges to the tissue and avoid sliding. Three 
days post-implantation hearts were arrested in diastole with arrest solution (68.4 mM NaCl, 59 
mM KCl, 11.1 mM Glucose, 1.9 mM NaHCO3, 29.7 mM BDM (2,3-butanedione monoxime), 
1000U Heparin). Then the samples were excised, fixed, cryopreserved in 30 % sucrose in PBS, 
embedded in OCT (Sakura; 4583), and snap-frozen in liquid nitrogen-cooled isopentane. Tissue 
blocks were stored at -80°C until sectioning75. 
ii All in vivo bioactive implant implantation in small animal models and subsequent analysis were 
performed by Dr. Carolina Soler-Botija of IGTP group. 
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4.4.19 Non-invasive bioluminescence imaging of luciferase activity from 
bioimplant  
Anesthetized mice, bearing a bioimplant seeded with PLuc expressing cells, were 
intraperitoneally injected with 150 μl of luciferin for in vivo BLI (16.7 mg/mL in physiological 
serum) (Caliper, Hopkinton, MA). Mice were monitored right after implantation and before 
sacrifice. Quantification and analysis of photons recorded in images was performed using the 
Caliper image analysis software (Caliper, Hopkinton, MA). 
4.4.20 Histology and immunohistochemistry 
Mouse heart cryosections were stained with Masson’s trichrome (collagen: blue, myocardium: 
red) and photographed using a TL RCITM stereoscope (Leica) for morphology evaluation. 
Additionally, sections were incubated with the primary antibodies against cTnI (2 µg/mL) 
(Abcam) and RFP (2 µg/mL) (Abcam) to enhance cells detection. Actin fibres were stained with 
Phalloidin Alexa568 (1:40, Invitrogen). Nuclei were counterstained with Hoechst 33342 and 
results analysed with Leica TCS SP2 mycrosystem. 
4.4.21 Statistical analysis 
GraphPad Prism version 5.00 Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com was used for statistical analyses. The results are given as mean ± SD as 
obtained of three independent experiments per group. Two-way analysis of variance performed 
comparison of means in proliferation and qRT-PCR assays with Bonferroni’s posttest. 
Comparison of assays was made by correlation and linear regression analysis. Differences were 
considered significant if p-value < 0.05. 
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4.5 RESULTS AND DISCUSSION 
4.5.1 Set the protocol 
The first approach of RECATABI concept was to introduce a mixture of cells and RAD16-I 
self-assembling peptide inside the porous of elastomeric microporous membranes. The final aim 
was to obtain a patch with mechanical properties similar to heart tissue (provided by the 
elastomeric membrane) and, at the same time, provide a 3D milieu where the cells could grow 
and migrate (provided by RAD16-I). The idea was to mix the cells with RAD16-I peptide (as it 
has been presented in Chapter 2, section 2.4.3) and load the mixture inside the pores of the 
elastomeric membranes designed by Dr. Monleón group at UPV (Figure 4.5-1). 
 
Figure 4.5-1: RECATABI methodology concept. The first approximation for the assembly of bioactive implant 
consisted in the introduction of a mixture of RAD16-I with subATDPCs inside the porous structure of the 
microporous elastomeric membranes provided by Dr. Monleón Pradas group. 
During the progression of the project various elastomeric membranes with different chemical 
and structural characteristics were designed and fabricated. The first membrane to be tested was 
the one composed by ethylene acrylate (EA), which has been widely used by Dr. Monleon 
Pradas group in various applications59,60,62,63. Here, the possibility of using it for the 
development of the proposed bioactive implant was tested. PEA is a hydrophobic polymer, 
therefore its copolymerization with more hydrophilic monomers has been used to improve 
wettability79. As commented above, the protocol suggested pretends to introduce an aqueous 
solution inside the porous membrane, but the high hydrophobicity of the developed membrane 
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makes it difficult. For this reason, it was proposed to slightly increase the hydrophilicity of PEA 
elastomeric membrane including hydroxyl groups in the molecular structure. As it was 
previously reported that high hydrophobicity of this material improves cell adhesion59, only a 
slight increase of the hydrophilicity, trying to introduce the aqueous solution easily inside the 
pores, was tested. A copolymer of poly(ethyl acrylate) and poly (hydroxyl ethyl acrylate) 
(PEA/PHEA) in a blending ratio of 90:10 was prepared. PEA elastomeric membrane and 
PEA/PHEA (90:10) were tested for the delivery of the aqueous solution inside their pores. As it 
can be observed in Figure 4.5-3a, although the addition of hydrophilic residues, both PEA and 
PEA/PHEA (90:10) membranes were highly hydrophobic.  
An alternative proposal was to set up the elastomeric membranes with the aim to eliminate the 
air inside the pores. This approach was hoped to facilitate the diffusion of the aqueous solution 
composed of RAD16-I and cells. The first step was to force a sucrose 10 % solution to penetrate 
inside the elastomeric membrane porous with the help of the vacuum. Subsequently, the 
membranes were dried to moist and then the aqueous solution was loaded on the top (see Figure 
4.5-2). 
 
Figure 4.5-2: Microporous elastomeric membranes pre-conditioning protocol. The proposed elastomeric 
membranes were highly hydrophobic as it can be observed in (Figure 4.5-3a). The first attempt to facilitate the 
penetration of the aqueous mixture inside the elastomeric membranes pores was to fill the pores with PBS with the 
aim that this facilitates the difusion of the mixture. Firstly the membranes were sterilized with EtOH 70 %  and 
carefully dried. PBS was forced to penetrate into the pores of the elastomeric membrane pores using vacuum, and 
then it was substituted by sucrose 10 % to avoid RAD16-I peptide gel. Once the sucrose 10 % were filling the pores 
the elastomeric membrane was dried to moist. At this step, the membranes were prepared for the loading of cells + 
peptide mixture. 
After the pre-conditioning protocol, RAD16-I was loaded on the membrane and the gel process 
was immediately induced. The samples were stained with Congo Red to assure the formation of 
β-sheet structures. Figure 4.5-3a (C and D) show that the pre-conditioning protocol allowed the 
aqueous solution to get inside the porous and that the gel process was conducted successfully. 
PEA/PHEA (90:10) presented lower Congo Red staining what may mean that a lowest 
quantity of mixture was retained inside the elastomeric membrane pores. 
It is well known that each cell type would have different behavior inside each biomaterial. 
However, the mechanistic of the cell introduction at short times will depend mostly on porosity, 
interconnectivity and wettability of the material, and the cell size. Here, first seeding tests were 
performed with hNDF cells with the aim to set the protocol. L&D staining (Figure 4.5-3b) 
showed a high concentration of live cells on the top of both elastomeric membranes, but not 
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inside. Some of the cells seeded on PEA membrane were able to diffuse inside the porous but 
PEA/PHEA (90:10) showed no cells inside its structure (Figure 4.5-3b). Additionally, the 
loading of only hNDF without the self-assembling peptide was compared with the loading of 
the mixture. DAPI staining results in Figure 4.5-3C showed that PEA/PHEA (90:10) presented 
no cells inside his structure regardless on the SAP presence. On the other hand, PEA contained 
higher number of cells when they were introduced in combination with RAD16-I. These results 
suggested PEA as a better membrane to be used for the preparation of the bioactive implant 
proposed. However, it would be harder needed to increase the seeding efficiency. 
 
Figure 4.5-3: Mixture of cells and RAD16-I loading on PEA and PEA/PHEA (90:10) membrane after pre-
conditioning protocol. (a) Macroscopic view of the hydrophobic behavior of PEA and PEA/PHEA (90:10) 
elastomeric membranes (A, B). RAD16-I introduction and subsequent self-assembling by increasing salt charge (C, 
D). The correct formation of β-sheet was assessed by Congo Red Staining. (b) L&D assay of PEA and PEA/PHEA 
bioactive implants after RAD16-I + hNDFs mixture loading and subsequent self-assembly of RAD16-I. Live cells are 
stained in green and dead cells in red. Inside and outside sections are presented. (c) Contrast phase (A-D) pictures and 
DAPI staining (E-H) imaging of hNDF cells loaded with or without RAD16-I on PEA and PEA/PHEA membranes. 
It was proposed that the low seeding efficiency inside the structure could be caused by: (1) the 
hydrophobic nature of the biomaterial which avoids the solution to infiltrate inside the pores or 
(2) the pores size. It is crucial to design an optimized scaffold that would improve nutrient and 
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cell transfer to the center of the scaffold, both in vitro and in vivo. Scaffold porosityiii in 
particular controls the key processes of nutrient supply to cells, metabolite dispersal, local pH 
stability, and cell signaling69. The size of the pores can affect how close the cells are at the 
initial stages of cultivation (cell-cell communication), but also influences the amount of space 
the cells have for 3D organization in the later stages of tissue growth. In this work all the 
elastomeric membranes tested had a pore size of approximately 120 µm where cells would be 
able to contact intimately one to each other and have enough space for achieve a 3D 
organization.  
With the aim to overcome the hydrophobic issue, both membranes were treated with physical 
plasma, modifying the surface properties to allow the aqueous solution to diffuse, but without 
modifying the bulk properties (see Figure 4.5-4). 
 
Figure 4.5-4: Mixture of cells and RAD16-I loading on PEA and PEA/PHEA modified with plasma treatment. 
(a-d) Contrast microscopy images of hNDF cells cultured in PEA and PEA/PHEA (90:10) elastomeric membranes 
without RAD16-I using plasma treatment (c, d) and without it (a, b). (e-h) DAPI staining images of hNDF cells 
cultured in PEA and PEA/PHEA (90:10) elastomeric membranes without RAD16-I using plasma treatment (g, h) and 
without it (e, f). (i-l) Contrast microscopy images of hNDF cells cultured in PEA and PEA/PHEA (90:10) elastomeric 
membranes with RAD16-I using plasma treatment (k, l) and without it (i, j). (m-p) DAPI staining images of hNDF 
cells cultured in PEA and PEA/PHEA (90:10) elastomeric membranes with RAD16-I with plasma treatment (o, p) 
and without it (m, n). 
iii In vivo tissues have a hierarchical structure that varies over length scales of 0.1-1mm. The subcellular structures (1-
10µm) control cell-cell inter-relationships and supracellular scale structures (100-1000µm) build the essential 
functional units of the tissue69. 
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Different plasma conditions were tested (data not shown), and elastomeric membranes 
presenting high hydrophilicity were obtained, but in cell seeding efficiency terms, no significant 
improvement were observed. This outcome was mainly caused because most part of the 
aqueous solution run through the porous and no cells could remain neither on the top nor inside 
the elastomeric membrane. Additionally, it is possible that plasma treatment produced an 
extreme surface hydrophilicity that avoids cell adhesion through previous protein adhesion. 
Moreover, after subsequent tests it was observed that plasma modification (at least with the 
specific conditions applied) was time dependent, which would make it difficult to transfer the 
procedure to the clinic. Consequently, plasma treatment was discarded. On the other hand, the 
results presented in Figure 4.5-3 and Figure 4.5-4 for PEA/PHEA (90:10) elastomeric 
membrane showed the formation of clusters and in general less cell number as compared to 
PEA elastomeric membrane. Therefore, it was concluded to discard PEA/PHEA (90:10) 
elastomeric membrane, which do not present a special improvement for the proposed protocol.  
Continuing with the aim to increase cell number inside the elastomeric membrane pores, PEA 
elastomeric membrane pre-conditioned with the protocol given in Figure 4.5-2 was loaded with 
different cellular densities. Two different mixtures of RAD16-I self-assembling 0.15 % peptide 
containing 160,000 cells or 500,000 cells were prepared for the loading. L&D and D&P assays 
were used for the analysis. 
 
Figure 4.5-5: Analysis of cell density effect for the preparation of the bioactive implant. Two different cell 
densities combined with RAD16-I were loaded on PEA elastomeric membrane. L&D assay (green for live cells and 
red for dead cells) and D&P staining (blue for nuclei and pink for actin filaments) were used to analyze cell viability 
and morphology, respectively. Pictures of the top and bottom of the bioactive implant were taken to assure if the cells 
were able to diffuse through the pores. 
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In this case, little pressure applied with the tip in the moment of the loading was used. As it can 
be observed in Figure 4.5-5, when 500,000 cells were loaded they remained on the top of the 
membrane. Instead, when 160,000 cells were loaded some cells where found inside the pores. 
We hypothesize that, presumably due to an increase of solution density; higher cell density 
would not be able to diffuse inside the pores. Interestingly, in both cases cells were alive and 
formed a good network.  
At this point it was noticed that natural diffusion was not enough to fill the scaffolds with the 
aqueous solution (peptide + cells) due to their hydrophobic nature. Therefore, an alternative 
loading procedures such as the application of pressure or even centrifugation to force the 
solution to penetrate into the pores were tested42. These procedures yielded heterogeneous 
filling of the elastomeric membranes pores, therefore, these methods were not further 
considered and the idea to introduce the RAD16-I peptide and cells in one step was substituted 
by two subsequent steps procedure.  
4.5.2 Combination of self-assembling peptide gel with 3D elastomeric scaffolds 
and cell seeding methodologyiv 
The technical impossibility to obtain a homogeneous distribution of RAD16-I peptide and cells 
inside the pores of PEA elastomeric membrane in one step method, lead the consortium to 
redefine the parameters and a new protocol of two steps was assessed.  
The first action of this two steps procedure was to fill the elastomeric pores with the self-
assembling peptide using pressure and obtaining the composite. As it was not desired to subject 
the cells to a process that can negatively affect their viability and performance, they were seeded 
afterwards. The procedure described in Materials and Methods Section (4.4.4 Preparation of the 
elastomeric membrane pre-filled with RAD16-I self-assembling peptide nanofiber scaffolds 
(composite)) allowed the homogeneously filling of the scaffold pores with the RAD16-I 
solution as it can be observed in Figure 4.5-6. Again, Congo Red staining assure the correct gel 
of the hydrogel within the pores. 
 
iv This work has been performed in close collaboration with UPV and published in Acta Biomaterialia 
Journal: Vallés-Lluch A, Arnal-Pastor M, Martínez-Ramos C, Vilariño-Feltrer G, Vikingsson L, Castells-
Sala C, Semino C E and Monleón Pradas M 2013 Combining self-assembling peptide gels with three-
dimensional elastomer scaffolds Acta Biomater. 9 9451–60. 
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Figure 4.5-6: Congo red staining of PEA-composite. The introduction of RAD16-I peptide by pressure inside the 
elastomeric membranes was assessed by the staining of β-sheet structure formed by the SAP after gel. PEA 
elastomeric membrane filled with PBS (left) and with RAD16-I (right). 
After confirm the correct introduction of RAD16-I inside the pores, cell seeding on the 
composite was tested. Four conditions were analyzed using PEA elastomeric membranes: PEA 
was filled with PBS or RAD16-I and static or dynamic seeding was used. L929 fibroblasts (105 
cells) in sucrose 10 % were loaded in a droplet on bare scaffolds filled with PBS or RAD16-I 
solution. The cells were allowed to diffuse inside the composite with or without smoothly 
shaken and after 30 min medium was added to induce RAD16-I to gel. As it can be observed in 
Figure 4.5-7 and Figure 4.5-8, cells colonized the scaffolds filled with RAD16-I easily, and 
consequently after 7 days they were able to proliferate and occupy all the pores. Comparison of 
the images obtained from scaffolds seeded statically and dynamically clearly indicates that the 
dynamic seeding favors the migration of the cells inside the pores42. 
 
Figure 4.5-7: Seeding of L929 cells on PEA elastomeric membranes using different cell-seeding methodologies. 
Fluorescence microscopy images of the PEA elastomeric membranes surfaces (with and without RAD16-I self-
assembling peptide within their pores) seeded with L929 fibroblasts (statically and dynamically). Samples were fixed 
after 1 day (scale bar 200 μm) and 7 days (scale bar 100 μm) of culture and stained with DAPI (nuclei in blue). 
One day after cell loading, dynamic cell seeding for scaffolds containing RAD16-I gel led to a 
uniform distribution of the cells throughout the scaffold (Figure 4.5-7). The cells seemed to be 
leaning on the polymeric trabeculae at this culture time, and after 7 days they appeared invading 
completely the lumen of the pores (the area occupied by the scaffold is clearly seen in dark)42  
(see Figure 4.5-8).  
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Figure 4.5-8: Cross-section of L929 cells seeded statically and dynamically in PEA elastomeric membranes 
with and without RAD16-I peptide in their pores. DAPI stain for nuclei (blue), phalloidin stain for actin (green) 
and vimentin stain for cytoskeleton (red). Images correspond to 100 μm thick internal slices after 7 days of culture. 
Scale bar 100 µm. 
From the point of view of the cells, the presence of RAD16-I within the pores improved 
fibroblasts colonization in terms of cell number and distribution (Figure 4.5-7). Interestingly, 
after 7 days of culture, the cells proliferated much more when the pores were filled with the self-
assembling peptide gel. The dynamic seeding conditions achieved the best results in terms of 
cell density and uniformity within the pores. We hypothesize that RAD16-I increase the 
diffusion speed of the cells. PEA is a hydrophobic polymer onto which most cells are willing to 
adhere and spread, thus delaying their progress through the structure. Swimming through the 
peptide solution seems a faster way of colonization than creeping on the scaffold’s pores 
surfaces. In these experiments, the cells were seeded with the minimum amount of medium, and 
cultured as a droplet onto the composite; this procedure avoids their spilling out of the scaffold 
and optimizes cell seeding. RAD16-I was gelled later, consequently entrapping the cells inside 
the pores. 
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The same protocol was tested using PCLMA elastomeric membranes (Figure 4.5-9). After 
filling the pores by pressure with RAD16-I, L929 cells were seeded as a droplet on the top of 
the membrane and dynamic seeding was used. As it can be observed, most part of the cells 
remains on the surface of the porous of the elastomeric membrane, but do not inside the 
trabeculae. 
 
Figure 4.5-9: Cross-section of L929 cells seeded dynamically in PCLMA elastomeric membranes with RAD16-
I peptide in their pores. DAPI stain for nuclei (blue), phalloidin stain for actin (green). Images correspond to 100 
μm thick internal slices after 7 days of culture. Scale bars: 100 μm (a) and 50 μm (b). 
These results showed that it was feasible to combine elastomeric hydrophobic scaffolds with 
RAD16-I to prepare a composite. The obtained composite have some of the distinctive 
advantages of both materials. It can act as a vehicle for cell seeding and cell supply with unique 
properties: a cell-friendly and ECM-like microenvironment that facilitates efficient and uniform 
cell colonization of the scaffolds. At the same time shape stability, mechanical consistency and 
strength was provided. In terms of mechanical properties, the composite represents an 
improvement respect the 3D system provided by the nanofibers. RAD16-I has the rheological 
properties of soft gels, and thus negligible resistance to shearing and tensile stresses and to 
manipulation in general. Its combination with elastomeric membranes represents an 
improvement of several orders of magnitude: from module values typical of soft hydrogels (10 
to 80 Pa) to values typical of an elastomer (order of 1 MPa). Therefore, a manageable construct, 
able to withstand tractions, compressions and shears to the extent that a typical elastomer 
scaffold does, were obtained42.  
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4.5.3 Proof of concept of the bioactive implant development for maintenance of 
implanted cells at the myocardial infarcted site using PEA and PCLMA 
elastomeric membranesv 
The first step of the project was to provide a proof of concept of the viability of the proposed 
bioimplants using both suggested elastomeric membranes. Since the architecture and 
composition are different it was not pretended to select a definitive elastomeric membrane, but 
analyze the strengths and weaknesses of each one. 
Composite development (elastomeric membrane + RAD16-I self-assembling peptide) 
The architecture of developed scaffolds was analysed by SEM in a frontal view and cross 
section (Figure 4.5-10). Cylindrical interconnected orthogonal pores of PEA scaffold can be 
clearly observed in a cross section image (Figure 4.5-10b). Additionally, different layers of 
cylindrical crossed pores in parallel and perpendicular planes can be visualized (Figure 4.5-10a). 
On the other hand, interconnected spherical pores of PCLMA scaffolds can be readily 
appreciated providing a trabecular regular aspect (Figure 4.5-10c and d). Again the correct 
filling and gel of RAD16-I self-assembling peptide inside the pores of elastomeric membranes 
was assessed using Congo Red staining and SEM imaging. The positive Congo red staining 
(Figure 4.5-10c and g) indicated that the formation of the gel leads to a β-sheet structure. In 
parallel, the cryoSEM images (Figure 4.5-10d and h) confirmed that the scaffolds’ pores were 
uniformly filled with the peptide gel. The hydrogel was shown as a honeycomb-like structure 
after sublimation of water. Although the quantity of RAD16-I cannot be quantified the complete 
filling of the porous was assessed. 
 
Figure 4.5-10: Characterization of PEA and PCLMA bare membranes and composites. Microscopic images of 
the (a-d) PEA scaffolds with cylindrical orthogonal pores and (e-h) PCLMA scaffolds with spherical pores. (a, e) 
SEM images, cross section, (b, f) SEM images, surface. (c, g) Congo Red staining and (d, h) cryoSEM images of the 
scaffolds loaded with 0.15% RAD16-I and gelled with PBS, surface. White arrows point out the elastomeric 
membrane while the black ones point out the self-assembling peptide structure after gel. 
v This work was performed in close collaboration with UPV and IGTP groups from Valencia and 
Badalona respectively. 
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For the obtaining of the elastomeric membranes with the desired architecture a porogenic 
template was used. Due to the characteristics of each monomer used (stable PEA and 
semidegradable PCLMA), different types of porogenic template were employed depending on 
the stability of the monomers: a nylon mesh for PEA with subsequent wash with HNO3 and 
sinterized microspheres of poly(methyl methacrylate) for PCLMA with a more softly wash with 
acetone. Therefore, although each elastomeric membrane has its specific architecture, both 
present high porosity and interconnectivity where the cells can achieve a good interconnection. 
The measured porosities of both types of scaffolds, swelling in PBS and their apparent tensile 
moduli (together with the tensile moduli of the bulk respective samples) are listed in Table 
4.5-1.  
Table 4.5-1: Structural and mechanical parameters of the elastomeric membrane. Morphological parameters 
(porosity, π, equilibrium water content in PBS, EWC, and Young modulus, E) of PEA scaffolds with cylindrical 
orthogonal pores and PCLMA scaffolds with spherical pores. Young modulus between brackets corresponds to the 
bulk PEA and PCLMA polymers. 
 
In general, the values obtained for PCLMA scaffolds are slightly higher than those for PEA, but 
it can be stated that both structures are highly porous, have a hydrophobic character and 
elasticity typical of elastomeric polymers. Since they differ in their chemical composition and 
architecture (sizes and shape of pores and interconnectivity), their biological performances will 
likely be different. Nonetheless, it can be safely stated that the stiffness of both proposed cardiac 
bioactive implants would closely match the values reported for the heart muscle of mice after 
dissection (0.06 MPa) and the ones of rat or human (0.14 or 0.2-0.5 MPa, respectively at the end 
of diastole)13,32,80. The hydrophobic nature is again demonstrated in Table 4.5-1 (none of them 
swells more than 10 % in PBS) and Figure 4.5-11. 
 
Figure 4.5-11: Wettability of PEA and PCLMA elastomeric membranes. Contact angle images of PEA and 
PCLMA scaffolds. Both elastomeric membranes showed an acute angle corresponding to a high hydrophobic 
material. 
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Electrical resistivity of the composites 
The electrical resistivity (ρ) of the composites was also analyzed, and data were normalized. 
Electrical resistivity of 53.0 ± 8.5 Ωm was obtained for PEA membrane while 52.8 ± 5.5 Ωm 
was obtained for PCLMA (Table 4.5-2). By comparing PEA and PCLMA membranes, it can be 
observed that both membranes studied present similar electrical resistivity and both of them 
below the resistivity of transmural and non-transmural infarcted myocardium. 
Table 4.5-2: Electrical parameters of PEA and PCLMA composites. Electric impedance values at 10 KHz for 
PEA and PCLMA scaffold previous filled with RAD16-I 0.15 % self-assembling peptide and healed transmural and 
non-transmural myocardium. 
 
a In work / b Cinca et. al. 1998 and Salazar et. al. 200481,82 / cSalazar et. al. 200482 
From an electrical standpoint, it is well-known that the electrical resistivity is lower and less 
frequency dependent in necrotic than in healthy myocardium83,84. According to the values 
reported in Table 4.5-2 it can be observed that the resistivity values for the composites are 
below to infarcted non-transmural and transmural myocardium resistivity, but the resistivity 
value of normal myocardium is larger compared to infarcted myocardium (250 Ω·cm at 10 kHz) 
81. We think that the resultant equivalent resistance coming from the parallel combination of the 
infarcted tissue and the scaffold will actually benefit the electrical coupling with native 
myocardium tissue. Based on the simple circuit theory principle, which confirm that the 
equivalent resistance of two resistances in parallel is equal or lower than the lowest resistance, 
the scaffold will provide a low-resistance pathway that should contribute to facilitate the 
electrical signal propagation from the native heart tissue into the scaffold. Thus, we speculate 
that both composites, which have similar electrical resistivity, will equally facilitate the 
propagation of electrical pulses throughout the contact area between the composites and the 
infarcted zone. 
Bioimplant preparation (elastomeric membrane + RAD16-I self-assembling peptide + 
subATDPCs) 
Once assessed the correct introduction of RAD16-I nanofiber peptide inside both elastomeric 
membrane, subATDPCs suspended in the medium were loaded on the constructs. While 
shaking, the cells were allowed to diffuse while the high ionic strength of the media induced the 
self-assembly of RAD16-I. After 1 and 4 days of in vitro culture, the bioimplants were removed 
from the well plate, and gene expression was analyzed. The morphology of the cells after 7 days 
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of in vitro culture can be observed in Figure 4.5-12. Cells were growing mostly at the surface of 
the construct for both types of elastomeric membranes, which indicated that they were unable to 
invade the scaffolds completely, in vitro. The surfaces were, though, entirely covered by cells 
after this culture time. D&P staining in Figure 4.5-12g to h shows how some cells have been 
able to migrate inside the construct during the first days of culture, but most part remain on the 
surface.  
 
Figure 4.5-12: PEA and PCLMA bioactive implants characterization. Microscopic images of subATDPCs 
growing in the developed composite after 7 seeding days. (a) Surface of PEA bioactive implant; (b) surface of 
PCLMA bioactive implant; (c, d) close up of top PEA, and PCLMA scaffold respectively; (e) PEA scaffold cross 
section; (f) PCLMA scaffold cross section; and (g, h) D&P staining of subATDPCs in PEA and PCLMA bioactive 
implant. In images a o f white arrows show the cells growing in the bioactive implant, black arrows note the 
nanofibers of self-assembling peptide RAD16-I, and red arrows signalize the structure of porous elastomeric 
membrane. White arrows in image g and h indicate scaffolds surface while yellow arrows indicate cells migrating 
inside the composite. Scale bars: a 30µm; b, e-h 100µm; c 3 µm; and d 5 µm. 
Study of gene expression by RT-PCR 
RT-PCR analysis was performed to assess the possible cardiac gene expression of the cells after 
1 and 4 days (Figure 4.5-13) of culture. Day 1 samples showed gene expression before 
implantation of the bioactive implant in mice, and day 4 presents gene expression of the 
bioactive implant cultured in vitro for 4 days, which coincides with the length of the in vivo 
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experiments (1 day of pre-culture and 3 days of follow-up after implantation). Interestingly, 
expression of early cardiac markers such as TBX5 (T-box transcription factor 5), MEF2C 
(Myocyte Enhancer Factor 2C) and some definitive cardiac markers such as ACTN1 (Actinin, 
alpha1), cTnT (Troponin T2) and GJA1 (Gap Junction, alpha 1) could be observed. 
Additionally, expression of CDH1 (E-Cadherin) and SNAI1 (Snail Family Zinc Finger 1, a 
natural repressor of CDH1) were analyzed.  
 
Figure 4.5-13: Expression of cellular markers in the developed bioactive implants by RT-PCR. Cardiac and 
general markers expressed by subATDPCs cultured in the developed implant of PEA and PCLMA after 1 (d1) and 4 
(d4) days of culture in vitro compared to 2D cultures. NC: Negative control (PCR without template). 
No significant differences were detected between day 1 and day 4 on gene expression except for 
cTnT, which was down-regulated in the composite but was up-regulated again in PCLMA at 4 
days of culture. In addition, the expression of CDH1 in both composite-systems was down-
regulated, but SNAI1 repression factor was maintained. CDH1 and GJA1 genes encode for cell 
connection proteins. CDH185 is an anchoring junction involved in mechanisms regulating cell-
cell adhesions, mobility and proliferation while GJA1 is a communicating junction that provides 
a route for the diffusion of low molecular weight materials from cell to cell having a crucial role 
in the synchronized contraction of the heart. CDH1 down-regulation could be translated as a 
decrease of subATDPCs interconnection, which could mean that they were able to migrate as 
the results in Figure 4.5-14 suggest. In vivo results showed a migration either inside the 
membrane or to the infarcted area after implantation. GJA1 expression was maintained which 
could facilitate the assembly of the low molecular route once cells contact one to each other. In 
conclusion, it seemed that subATDPCs were maintaining their gene profile, which indicates that 
they tend to preserve their cardiogenic potential lineage, at least in vitro.  
In vivo implantation 
The in vitro model gives an overview of the bioactive implant potential, but in any case these 
results could be extrapolated to the in vivo scenario. Here, a proof of concept of short time 
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points was developed to analyze the bioactive implant feasibility in terms of integration and cell 
viability. Both bioactive implants were implanted as a proof of concept in small animal models 
(mice) and analyzed 3 days after implantation. With the intention of monitoring cell survival 
and distribution of the implanted cells after the bioactive implant in vivo implantation, a non-
invasive bioluminescence imaging (BLI) system was used. Cells within the bioimplant were 
previously labelled with CMVp-Rluc-mRFP1 reporters for BLI and fluorescence detection.  
 
Figure 4.5-14: General view of the PEA and PCLMA bioactive implants on mice heart after 3 days of 
implantation. A) Whole heart excision and macroscopic examination. (a and b) Macroscopic view of mouse heart 
and bioactive implant (outlined) at 3 days post-implantation, and (c and d) Masson’s trichrome staining of heart cross 
with bioactive implant. The dotted zone in black corresponds to the bioactive implant and the dotted red area to the 
infarcted zone. B) Microscopic view of the bioactive implant. (a and d) Detail of elongated subATDPCs (red) inside 
the PEA (a) and PCLMA (d) bioactive implants; (b and e) views of the PEA (b) and PCLMA (e) bioactive implants 
attached to the myocardium (implant and myocardium are limited by dotted lines (Phalloidin staining in red); and (c 
and f) migration of the subATDPCs (white arrows) to the myocardium (cTnI staining in white) in PEA (c) and 
PCLMA (f) groups. Constitutive expression of RFP (red) in subATDPCs. Nuclei were counterstained with Hoescht 
33342 (blue). Scale bars 1 mm (A, a to d), 50 µm (a-d and f), and 100 µm (e). 
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Photon counts quantification showed human subATDPCs survival and thoracic location three 
days post-implantation of PEA and PCLMA bioimplants (data not shown). Interestingly, it was 
noticed that both bioactive implants intimately attach to the myocardium. Moreover, the whole 
heart excision and histology examination demonstrated that both remained in the position at the 
infarction area where they were placed suggesting some resilience to the heart mechanical 
forces (Figure 4.5-14A a to d). 
Although both bioactive implants were attached to the myocardium, the PCLMA bioimplants 
showed greater cell immobilization and better integration in the infarcted area than the PEA 
ones. Three days after implantation, subATDPCs within the PEA bioimplant were 
homogeneously distributed acquiring some of them an elongated shape (Figure 4.5-14B, a). On 
the other hand, PCLMA bioimplant cells were mainly distributed in the borders of the 
myocardium (My) or inner membrane (im). Only few cells were found in the outer membrane 
(om) (Figure 4.5-14B, e). Few cells already started migration to the damaged myocardium 
Figure 4.5-14B, c and f). 
We did not expect to observe profusely cell migration at such short time assay, but we speculate 
that the cells might start to contribute to a paracrine effect by secreting specific factors; 
phenomena previously reported using mesenchymal stem cells (MSC) and CM in rat and mice 
models, respectively 20,86,87. Importantly, in previous studies an increase of vascularization and a 
reduction of infarct size after ATDPCs injection was reported73. Therefore, their better retention 
onto the infracted tissue using this platform might lead to positive benefits by the stimulation of 
vessel formation.  
After assessing the viability of the proposed bioactive implant through the presented proof of 
concept, the preparation of the bioactive implant was tried to be improved. We decided to focus 
our attention to obtain bioactive implants completely filled with cells, increasing cell number.  
Cell loading on the composite, was substituted by cell injection with a syringe as described in 
section 4.4.7:“Cell seeding in elastomeric membrane/self-assembling peptide composites” (see 
Figure 4.4-1). In vitro studies of the obtained composites with PEA and PCLMA membranes 
are presented in the next sections. 
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4.5.4 Analysis of subATDPCs injected in PEA elastomeric membrane and the 
designed composite 
Characterization of bare PEA scaffolds and composites 
The RAD16-I peptide solution was successfully loaded and gelled inside the PEA scaffolds’ 
pores using the protocol described previously42. The obtaining of the desired composites was 
confirmed by SEM imaging (Figure 4.5-15). Figure 4.5-15a presents an overview of the bare 
PEA and in Figure 4.5-15b it can be appreciated the walls of the microporous completely 
empty. The loading of self-assembling peptide solution gives rise to a nanofiber network 
distributed all along the PEA scaffold pore (Figure 4.5-15c and d). This nanofiber structure does 
not appear when scaffolds were loaded with PBS. 
 
Figure 4.5-15: Assessment of PEA-composite formation. SEM images of surface (a) and sections of bare (b) and 
RAD16-I filled PEA scaffolds (c). (d) Detail of RAD16-I nanofibers. Scale bare: 1 mm (a), 20 µm (b), 10 µm (c), and 
5 µm (d). 
SubATDPCs layout in bare scaffolds or composites  
For the examination of cell distribution in scaffolds, general cell staining with D&P was 
assessed after 7 days of culture. Composites showed much more uniform cell distribution than 
bare PEA scaffolds (Figure 4.5-16). SubATDPCs displayed a more elongated morphology 
around the pores of bare scaffolds; covering the PEA trabeculae as compared to composites 
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where cells showed a compact cell network (they were close one to each other and exhibited a 
spread out morphology). 
 
 
Figure 4.5-16: Surface confocal laser scanner microscopy images of cultured composites and bare PEA 
scaffolds. Phalloidin (red) staining of subATDPCs growing in the pores of composites (a and b) and bare PEA 
scaffolds (c and d). DAPI staining for nuclei (blue). Scale bar: 100 µm (a and c) and 50 µm (b and d).  
Samples were also labeled with ACTN1 marker, which recognizes α-skeletal muscle actinin and 
α-cardiac muscle actinin (Figure 4.5-17). ACTN1 seemed to be expressed more homogeneously 
across the composite than in bare PEA scaffolds (Figure 4.5-17). Within the composite, 
subATDPCs presented ACTN1 in an elongated layout (Figure 4.5-17a and b), but the absence 
of RAD16-I this protein appeared surrounding the nuclei but did not elongate. 
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Figure 4.5-17: Surface confocal laser microscopy images of cultured composites and bare PEA scaffolds. 
ACTN1 (green) staining of subATDPCs growing in pores of composites (a and b) and bare PEA scaffolds (c and d). 
DAPI staining for nuclei (blue). Scale bar: 100 µm (a and c) and 50 µm (b and d).  
In both cases, a significant fraction of cells resided on the top of the scaffolds. SEM imaging 
proved that subATDPCs were able to cover bare PEA and composites’ surfaces (Figure 4.5-18). 
Significantly, subATDPCs growing in composites were uniformly distributed covering the 
surface after 7 days of culture entirely, whereas, on bare PEA scaffolds, a heterogeneous layout 
was observed. Moreover, subATDPCs cultured on composites’ surfaces were organized in a 
well-ordered pattern, which would facilitate cell-cell contact (Figure 4.5-18b). In contrast, 
subATDPCs growing on bare PEA scaffolds exhibited a disorganized distribution adhered to 
PEA trabeculae and maintaining pores empty (Figure 4.5-18e). 
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Figure 4.5-18: Cell morphology analysis on bare PEA or composite by SEM after 7 days of culture. Overview 
of composite (a) and bare PEA (d) seeded with subATDPCs. Close up of the surface of PEA-composite (b and c) and 
the surface of bare PEA seeded with subATDPCs (e and f). Scale bar represents 1 mm (a and d), 100 µm (b and e), 
10 µm (c) and 5 µm (f). 
Viability, growth and distribution of subATDPCs inside PEA bare scaffolds or composites 
SubATDPCs’ viability inside bare and gel-filled scaffolds was monitored after 1 and 10 days of 
culture by MTT colorimetric assay (Figure 4.5-19). The MTT test revealed that there were no 
significant differences in terms of viability between cells growing in bare PEA membranes and 
those cultured in the composites containing the self-assembling peptide RAD16-I (Figure 
4.5-19a). In both structures, cell growth was observed at the same extent. 
 
Figure 4.5-19: MTT viability assay of subATDPCs growing inside bare PEA scaffolds and composites. (a) 
SubATDPCs proliferation from day 1 to day 10 within both structures. (b) Cell distribution inside the structures and 
on the culture plate at day 10 of culture. (c) Coloration of both structures owing to the formation of formazan crystals 
(** p < 0.01 and *** p < 0.001). 
Interestingly, it was noticed that after 10 days of culture a significant fraction of the cells did not 
remain in the inner pores of the PEA scaffolds migrating outwards to end adhered on the surface 
of the well (data not shown). This effect was found to be enhanced in the case of the composite 
with 53 % of the total cells detected on the surface of the well (Figure 4.5-19b). Instead, 36 % 
 
182 
 
Chapter 4 – RESULTS AND DISCUSSION: Analysis of subATDPCs injected in PEA elastomeric membrane 
and the designed composite 
 
 
of seeded cells in bare PEA membranes were detected outside the scaffold. It can also be 
appreciated in Figure 4.5-19c that the purplish intensity from formazan crystals ws stronger in 
bare scaffolds than in the composites. These results indicate that cell mobilization is enhanced 
in the case of composites, which suggest that it is a good platform to assure cell delivery to the 
affected tissue.  
Protein and gene expression of cells cultured in PEA bare scaffolds and composites 
With the aim of characterizing subATDPCs growing in the scaffolds protein and gene 
expression of early and definitive cardiac markers were analyzed, using cells growing on 2D 
PEA surfaces as controls. Here, the expression of early cardiac markers such as GATA4 (GATA 
binding protein 4), TBX5 (T-box transcription factor 5), NKX2.5 (NK2 homeobox 5), and 
MEF2C (Myocyte Enhancer Factor 2C); as well as some definitive cardiac markers such as 
ACTN1 (α-actinin), cTnT (Troponin T2, Tropomyosin-binding subunit in troponin complex), 
GJA1 (Gap Junction protein, alpha-1), and MHC (myosin, heavy chain) were examined.  
 
Figure 4.5-20: Protein and gene expression of cells cultured in bare PEA scaffolds and composites. a) Western 
blotting. Protein expression of cells cultured on 2D PEA compared to cells cultured in bare PEA scaffolds (RAD16-I 
-) and composites (RAD16-I +). C+ stands for the positive control for each protein. b) RT-PCR. Gene expression of 
cells cultured on 2D PEA compared to cells cultured in bare PEA scaffolds and composites. C- stands for the 
negative control used. c) qRT-PCR. The expression of TBX5 and GJA1 were assessed by Real Time RT-PCR 
experiments, establishing the base line through conventional monolayer cultures on PEA surfaces. No significant 
differences were observed between bare PEA and composites (p > 0.05) 
The expression of TBX5 early cardiac marker was found both at protein and gene levels (Figure 
4.5-20a and c, respectively). Real time RT-PCR showed no significant (p > 0.05) difference 
between subATDPCs cultured in bare PEA or in composites. This early cardiac marker has been 
reported to be critical in heart development, and has been shown to interact with NKX2.5, 
GATA4 and MEF2C to synergistically activate target genes expression in CM88. A light band of 
MEF2C was detected by RT-PCR (Figure 4.5-20b). This gene has been reported to play a key 
role in myogenesis89 and has long been associated with the regulation of myocardial-expressed 
genes90. The expression of GATA4 and NKX2.5, also early cardiac markers, was not detected, 
which was not surprising at this early time point considering that at least 1 to 4 weeks have been 
 
183 
 
Chapter 4 – RESULTS AND DISCUSSION: Analysis of subATDPCs injected in PEA elastomeric membrane 
and the designed composite 
 
 
reported to be needed for implanted MSC to reach differentiation into CM within heart91. In 
addition, definitive cardiac markers were evaluated. GJA1, which is the major gap junction 
protein in the heart and therefore has a crucial role in the synchronized contraction, was 
analyzed at protein and gene levels (Figure 4.5-20a and c). No significant (p > 0.05) increase in 
gene expression (respect to 2D cultures) was detected by qRT-PCR (Figure 4.5-20c). 
Additionally, at protein level, GJA1 was not detected in any tested condition (Figure 4.5-20a). 
Moreover, MHC, ACTN1, and cTnT, at gene level were studied. MHC gene expression was not 
detected, but ACTN1 and cTnT were identified (Figure 4.5-20b). Finally, ACTN1 expression 
was detected at gene and protein levels and cTnT at gene level in all conditions (Figure 4.5-20b 
and Figure 4.5-17). 
4.5.5 Analysis of subATDPCs growing in PCLMA elastomeric membrane and 
the designed composite 
Characterization of bare PCLMA and composite 
RAD16-I self-assembling peptide was introduced by pressure inside the porous of PCLMA 
elastomeric membrane and after gel their fiber appeared covering all the trabecular structure as 
it can be seen by the SEM imaging (Figure 4.5-22).  
 
Figure 4.5-21: Assessment of PCLMA-composite formation. SEM images of bare (a, b) and RAD16-I filled 
PCLMA scaffolds (c, d). (c’) Detail of RAD16-I nanofibers. Scale bare: (a, c), 50 µm and (b, d), 30 µm. 
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Figure 4.5-22a and b show the bare PCLMA porous and Figure 4.5-22c and d the elastomeric 
membrane filled with RAD16-I. The nanofiber of self-assembling peptide did not fill the 
microporous but remain on the surface of the trabeculae. Figure 4.5-22c’ shows an amplification 
of the nanofiber structure. In this case, it seemed that RAD16-I self-assembling peptide 
nanofibers remained on the surface of the porous but did not fill them completely. To better 
analyze the deposition of RAD16-I self-assembling peptide, images from 30 µm to 500 nm were 
analyzed. In Figure 4.5-22a, it cannot be clearly observed the presence of self-assembling 
peptide, but Figure 4.5-22b shows a coarse surface. Subsequent amplifications (Figure 4.5-22c 
to d) demonstrated the presence of nanofibers deposited on the top of the wall pores. Herein, it 
could be concluded that RAD16-I peptide introduced inside the microporous of PCLMA 
scaffold do not provide a 3D environment filling completely the elastomeric membrane pores, 
but appeared to be deposited on the porous surface. 
 
Figure 4.5-22: Analysis of RAD16-I self-assembling peptide deposition of PCLMA wall pores. The subsequent 
amplification of PCLMA filled with RAD16-I show the deposition of the self-assembling peptide on the elastomeric 
membrane surface (a) 2000X (b) 8000X (c) 15000X (d) 100000X 
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SubATDPCs layout in bare scaffolds or composites  
For the examination of cell distribution in scaffolds, general cell staining with D&P was 
assessed after 7 days of culture. An uniform distribution of subATDPCs was observed for 
PCLMA-composite (Figure 4.5-23a and b). Additionally, the PCLMA-composite was also 
stained with Vimentin, a type III intermediate filament found in various non-epithelial cells, 
especially in MSC (Figure 4.5-23c and d). Vimentin is attached to the nucleus, endoplasmatic 
reticulum and mithocondria. 
 
Figure 4.5-23: Surface confocal laser scanning microscopy images of PCLMA composites. (a, b) Phalloidin 
staining of subATDPCs growing inside PCLMA composite at different magnifications. (c, d) Phalloidin and 
Vimentin staining of subATDPCs growing in PCLMA composite at different magnifications. Scale bar (a, c) 100 µm 
and (b, d) 20 µm. Nuclei are counterstained with DAPI (blue). 
Additionally, bare and composite PCLMA elastomeric scaffolds were analyzed by SEM 
imaging (Figure 4.5-24). As it occurred for PEA elastomeric membrane, a significant fraction of 
cells resided on the top of the scaffolds covering the surface. Again cell distribution depended 
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on the presence of RAD16-I self-assembling peptide. SubATDPCs growing in composites were 
uniformly distributed covering the surface after 7 days of culture entirely, whereas, on bare 
PCLMA scaffolds, a heterogeneous layout was observed. Therefore, although RAD16-I was not 
providing a 3D environment within PCLMA pores, it aids subATDPCs to grown in an ordered 
arrangement. 
 
Figure 4.5-24: Cell morphology analysis on bare PCLMA or composite by SEM after 7 days of culture. 
Overview of composite (a) and bare PCLMA (d) seeded with subATDPCs. Close up of the surface of PCLMA 
composite (b and c) and the surface of PCLMA-composite seeded with subATDPCs (e and f). Scale bar represents 1 
mm (a and d), 100 µm (b and e), 30 µm (c and f). 
Viability, growth and distribution of subATDPCs inside PCLMA bare scaffolds or composites 
SubATDPCs viability inside the PCLMA bare elastomer and the composite was monitored after 
1 and 10 days of culture by MTT colorimetric assay (Figure 4.5-25). As revealed by the MTT 
test, there was no significant differences (p > 0.05) in cell viability between cells growing in 
bare PCLMA membrane and cells cultured in the composite containing the self-assembling 
peptide RAD16-I (Figure 4.5-25a). In addition, after 10 days of culture no significant increase 
on cell number could be observed. In this case, most part of subATDPCs remained inside the 
scaffolds instead of migrating outwards (Figure 4.5-25c). In contrast with PEA elastomeric 
membranes, the migration of subATDPCs in PCLMA membranes was much lower (about 22 % 
for PCLMA and more that 50 % for PEA elastomeric membrane). No significant difference 
could be observed after the addition of RAD16-I inside the elastomeric membrane pores. We 
hypothesize that this could be caused by the lack of a 3D nanofiber network filling the 
microporous of the PCLMA elastomeric membrane. At day 1 the cells adhered on the surface 
covering the trabeculae, but the lack of the diffusion media provided by the 3D nanofiber 
environment avoided their mobility outwards. We hypothesize that this lack of mobilization 
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caused an early fill of the elastomeric membrane surface which did not leave space for cell 
proliferation. 
 
Figure 4.5-25: MTT viability assay of subATDPCs growing inside bare PCLMA scaffold and composite. (a) 
SubATDPCs proliferation from day 1 to day 10 inside the composite and bare PCLMA (b) Cell distribution inside the 
structures and on the culture plate at day 10 of culture. (c) Coloration of both structures owing to the formation of 
formazan crystals (*** p < 0.001). 
Protein and gene expression of cells cultured in PCLMA bare scaffolds and composites 
The characterization of subATDPCs growing in the scaffolds was conducted by protein and 
gene expression of early and definitive cardiac markers, using cells growing on 2D PCLMA 
surfaces as controls. The expression of early cardiac markers such as GATA4, TBX5, NKX2.5, 
and MEF2C; as well as some definitive cardiac markers such as ACTN1, cTnT and GJA1 were 
examined.  
 
Figure 4.5-26: Protein and gene profile of cells cultured in bare PCLMA scaffolds and composites. a) Western 
blotting. Protein expression of cells cultured on 2D PCLMA compared to cells cultured in bare PCLMA scaffolds 
(RAD16-I -) and composites (RAD16-I +). C+ stands for the positive control for each protein. b) RT-PCR. Gene 
expression of cells cultured on 2D PCLMA compared to cells cultured in bare PCLMA scaffolds and composites. C- 
stands for the negative control used. c) qRT-PCR. The expression of TBX5 and GJA1 were assessed by Real Time 
RT-PCR experiments, establishing the base line through conventional monolayer cultures on PEA surfaces. No 
significant differences were observed between bare PEA and composites (p > 0.05). 
The expression of early cardiac markers TBX5 and MEF2C were detected at gene level (Figure 
4.5-26b) in both bare PCLMA and composite structures. However NKX2.5 was not detected in 
any condition. Real time qRT-PCR showed no significant (p > 0.05) difference on TBX5 
expression between subATDPCs cultured in bare PCLMA or in composites, but presented a 10-
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fold up-regulation respect to 2D cultures (Figure 4.5-26c). Additionally, GATA4 was not 
detected at protein level (Figure 4.5-26a). The expression of TBX5 and MEF2C has been 
reported to synergistically activate target genes expression in CMs and specifically MEF2C 
expression has been related with the expression of genes such as ACTN1 and MHC88–90. In 
parallel, the evaluation of definitive cardiac markers showed expression of ACTN1 and GJA1 at 
gene level, but cTnT was not detected in this case (Figure 4.5-26b). Real time RT-PCR showed 
no significant (p > 0.05) difference on GJA1 expression between subATDPCs cultured in bare 
PCLMA or in composites (Figure 4.5-26c). However, at protein level GJA1 was detected in 
composites but not in bare PCLMA (Figure 4.5-26a). This lead us to hypothesize that the 
presence of RAD16-I inside the pores of PCLMA elastomeric membranes improve cell 
interconnection, in agreement to what it was observed by cell distribution into the scaffolds (see 
Figure 4.5-25).  
It is important to notice that experiments conducted with PEA and PCLMA elastomeric 
membranes used different subATDPCs pools (each pool was obtained from 5 different patients). 
This leads to different gene expression at 2D level, which means that only internal comparisons 
could be stated. However, in both cases it can be concluded that the combination of RAD16-I 
with this elastomeric membranes leads to the obtaining of a non-cardio-conductive biomaterial 
which is able to maintain the phenotype of the seeded cells. 
4.5.6 In vivo studies 
RECATABI European project combines the work of interdisciplinary groups of scientists as it 
has been stated. After in vitro work, more intensive in vivo studies were performed using small 
animal models (work developed by IGTP group in Badalona) and large animal models (work 
developed by Cardio-Monde group in Hôpital Européen Georges-Pompidou, Paris). Here some 
of the obtained results are reported. 
Small animal models (mice)vi 
In terms of performance, it was noticed that PEA elastomeric membrane was too rigid to be 
implanted in the small mice hearts, and long term studies were only performed using PCLMA 
elastomeric membranes with this animal model. In these experiments, it was sought to monitor 
cardiomyogenic lineage differentiation and the survival of subATDPCs. 
vi Experiments performed by IGTP group and published in: Soler-botija C, et. al. 2014 Engineered 3D bioimplants 
using elastomeric scaffold, self-assembling peptide hydrogel, and adipose tissue-derived progenitor cells for cardiac 
regeneration Am. J. Transl. Res. 6 291–301 
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The cells obtained from fat pads undergoing cardiac surgery were isolated (as explained in 
Materials and Methods) and double transduced to report the cell number (CVM-RLuc-RFP 
reporter) and to monitor cardiomyogenic lineage differentiation (hcTnIp-PLuc-eGFP reporter). 
These cells were used for the preparation of the bioactive implant with PCLMA elastomeric 
membrane as described in section 4.4.7. “Cell seeding in elastomeric membrane/self-
assembling peptide composites” (see Figure 4.4-1). The bioimplant was placed onto the healthy 
or the infarcted myocardium of mice and non-invasive BLI imaging was used to monitor 
luciferase activity. A scheme of the whole procedure is presented in Figure 4.5-27. 
 
Figure 4.5-27: In vivo studies procedure used for small animal models. (a) Cells transduction with CMVp-RLuc-
mRFP1 and hcTnIp-PLuc-eGFP lentiviral vector. Transduced cells (b) were introduced in PCLMA elastomeric 
membrane (c). (d) MI was induced using coronary artery ligation as previously described78 and subsequently 
bioactive implants were implanted using surgical glue (Glubran®2). (f) Mice were monitored immediately after 
implantation and at 1, 2, and 3 weeks post-implantation by BLI. Fluorescence was also detected from the excised 
hearts immediately after sacrifice. Quantification and analysis of photons recorded and fluorescence in images were 
performed using non-invasive BLI imaging system. All animals were analysed for (g) cTnI specific firely luciferase 
and (g) constitutive Renilla luciferase expression (modified from Soler-Botija et.al.)75. 
A total of 25 female SCID mice (20-25 g; Charles River Laboratories, Inc.) were used for this 
study. The animals were randomly assigned to one of the following four groups: (1) bioimplant 
implantation (PCLMA+RAD16-I+subATDPCs) and no MI induction (the sham group, n=6), (2) 
MI induction and no bioimplant (the control- MI group, n=5), (3) MI induction and scaffold 
(PCLMA) implantation (the MI-scaffold group, n=5), and (4) MI induction and bioimplant 
implantation (the MI-bioimplant group, n=9)75. 
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Figure 4.5-28: BLI and fluorescent evaluation of cTnI expression and survival of PCLMA bioactive implant 
placed over the mouse infarcted myocardium. A) Representative BLI of labeled subATDPCs within the bioactive 
implant displays the luciferase signal from the cell differentiation reporter (PLuc-eGFP) that is regulated by the hcTnI 
promoter. Images of the hcTnI-specific reporter are superimposed on black-and-white dorsal images of the recipient 
animal. Color bars illustrate relative light intensities from PLuc. B) Histograms of the PLuc/RLuc ratio calculated 
from photon fluxes recorded via BLI from bioactive implant-treated infarcted animals. C) Representative 
fluorescence images from subATDPCs within the bioactive implant pre-implantation and post-sacrifice over the 
excised hearts. Upper images show fluorescence from the cell differentiation reporter (PLuc-eGFP) regulated by 
hcTnIp (green). Bottom images are representative of constitutive fluorescence from the cell-number reporter (CMVp-
RLuc-mRFP1; red). Color bars illustrate the relative fluorescence intensities from eGFP (green) and RFP (red). D) 
Immunofluorescence staining of mouse heart cross-sections shows the bioactive implant filled with human 
subATDPCs. Transplanted cells were detected via RFP immunostaining (red), and cTnI expression was detected with 
anti-eGFP (green) and anti-cTnI (white) antibodies. (BI, bioactive implant; My, myocardium). Scale bars, 20 μm 
Image obtained from Soler-Botija et.al.75. 
As it can be observed in Figure 4.5-28A and B, BLI photon counts revealed an increase in the 
ratio between hcTnIp-regulated PLuc and CMV-regulated RLuc activities in infarcted and 
sham-infarcted animals (data not shown). hcTnI was expressed de novo as early as one week 
post-implantation, with expression increasing up to 9-fold at 3 weeks. Interestingly, an 
important RFP signal was detected in excised hearts, indicating the retention and local presence 
of the implanted cells after sacrifice (Figure 4.5-28C). In concordance with BLI, GFP was also 
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detected, indicating hcTnI expression at the time of sacrifice. Comparisons of the GFP/RFP 
ratio pre-implantation and at sacrifice demonstrated a 16-fold increase in hcTnI expression. 
Immunodetection of RFP in histological analyses of excised heart cross-sections revealed the 
presence of subATDPCs in the bioactive implant up to 4 weeks after implantation in all 
analyzed groups (Figure 4.5-28D). Additionally, to relate hcTnI gene and protein expression, 
immunostaining against hcTnI protein was performed in all cell-treated animals. RFP, GFP, and 
hcTnI proteins co-localized in implanted subATDPCs (Figure 4.5-28D), validating the BLI 
analysis and providing evidence of differentiation into the cardiac lineage. However, no 
implanted subATDPCs were observed in the myocardium of infarcted or sham-treated animals, 
indicating the absence of migration from the bioactive implant to the underlying heart75. This 
results correlate with the in vitro results obtained for the bioactive implant of PCLMA (Figure 
4.5-25). 
In terms of adaptability and vascularization of the bioimplant, macroscopic and histological 
observations of excised hearts and cross-sections demonstrated that the bioactive implants were 
perfectly adapted to the mouse myocardium covering the infarcted scar (Figure 4.5-29A and B).  
 
Figure 4.5-29: Adaptability and vascularization of PCLMA bioactive implant in the mouse model of MI. A) 
Representative image of a heart excised from a bioactive implant-treated animal. Dotted lines indicate localization of 
the implant. Scale bars, 1 mm. B) Masson’s trichrome staining in a heart cross-section reveals the presence of a 
myocardial scar (blue) and the good adaptability of the bioactive implant. Scale bars, 1 mm. C) Cells inside the 
bioactive implant three days post-implantation were detected via the constitutively active reporter CMVp-RLuc-
mRFP1 (red). C’) Detail of the spindle-shape morphology of subATDPCs. Scale bars, 25 μm. D and E) Functional 
vessel detection with FITC-dextran (green) in mice treated with subATDPCs. Arrowheads indicate a vessel 
connection between the mouse myocardium and the bioactive implant in a cell-treated animal. Nuclei were 
counterstained with Hoechst 33342. Scale bars, 20 μm and 250 μm. Image obtained from Soler-Botija et.al75. 
Moreover, RFP-expressing subATDPCs were seen inside the bioactive implant and displayed 
the same spindle-shaped morphology observed in culture (Figure 4.5-29C and 2C’). All these 
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results suggested that the PCLMA elastomeric membrane confers a suitable environment for 
subATDPCs survival. 
In parallel, it was determined whether functional vessel connections were established between 
the bioactive implant and the myocardium. Animals received Fluorescein isothiocyanate–
dextran (FITC-dextran) through the tail vein prior to sacrifice, and it was observed that the 
bioactive implant was fully vascularized in all cases. Even animal controls that did not receive 
cell transplants showed vessel connection to the circulatory system (Figure 4.5-29D, arrowhead) 
and were functional (Figure 4.5-29D and 2E). 
Large animal models (sheep)92 
In parallel, experiments using large animal models were carried out by Cardio-Monde group. 
Specifically, sheep models, which are physiologically and biomechanically more similar to 
humans, were used to obtain more predictive analysis for future human use. In this model, both 
PEA and PCLMA elastomeric membranes were tested. 
In this part of the work autologous cells were used to prepare the bioactive implants. Samples 
were collected from mediastinal adipose tissue undergoing myocardial infarct surgery. The 
samples collected were sent to IGTP group, who was responsible of cells isolation and 
expansion under standard conditions. The cells were labeled with fluorescent reporters as 
explained in the section 4.4.13, and expanded. UPV and IQS group were responsible of 
bioactive implants preparation before surgery. The elastomeric membranes used in this case 
measured 45x45 mm. After loading with the self-assembling peptide and cells, the bioactive 
implant was maintained under standard conditions (37 °C in 5 % CO2 humidified atmosphere) 
for 24 hours. The obtained bioactive implant was placed onto the left ventricular surfaces, and 
the infarct regions were mostly covered. Afterwards, the pericardial sac was closed using 
interrupted biodegradable sutures. The animals were divided into three groups: (1) 5 animals 
non-treated, (2) 5 animals with a bioactive implant consisted in PEA composite, and (3) 5 
animals with a bioactive implant consisted in PCLMA composite. 
LV function and dimensions were measured the day that myocardial infarction was induced and 
2 and 6 months post-infarction, respectively. At baseline and after infarction, the mean LV 
Diastolic Volume (DV) and Ejection Fraction (EF) were similar in all three groups. Over the 
course of 6 months, each group increased their LV end diastolic dimension compared with their 
baseline value. A statistically significant attenuation of LV dilation was demonstrated with the 
implantation of the bioactive implant (both PEA and PCLMA) compared with the non-treated 
control group. Functional results at 6 months showed greater benefits in the hearts treated with 
PCLMA bioactive implant compared with those receiving PEA bioactive implant or without 
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treatment. Diastolic function was improved in the PCLMA group but not in the other groups. 
Additionally, histopathology shows that the necrotic areas were much less prominent, mainly in 
the group treated with PCLMA bioimplants. Fluorescent marked cells were founded into the 
bioactive implant and infarct scars as well as focuses of angiogenesis (capillary network). These 
preliminary findings seemed to indicate that ADPSCs growing in bioactive implants and 
migrating to the nearby cardiac tissue could be involved in the regenerative process, promoting 
angiogenesis and possibly cardiomyogenesis. Furthermore, at the level of the epicardium we 
found minimal fibrosis interface without inflammation between both bioactive implants and the 
heart surface. The PCLMA bioactive implant was completely anchored and integrated to the 
nearest infarct area and the myocardium. In contrast, the PEA bioactive implants showed poor 
adhesions to the heart and the infarct scar.  
In conclusion, these results demonstrated that these bioactive implants improved systolic and 
diastolic functions, reducing adverse cardiac dilatation in large animal models that better mimic 
human systems. Better results were obtained using semidegradable materials and, interestingly, 
no inflammatory reaction was observed after long-term implantation for any of the bioactive 
implants. 
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4.6 CONCLUDING REMARKS 
The first steps or MI treatments are directed to recover blood flow. Once this goal is achieved, it 
is possible to focus all the efforts on mitigating the collateral problems arising from lack of 
blood supply. Necrotic tissue formed after MI is not static as it continues progressing through 
the healthy tissue and contributing to progressive ventricular dilatation. Therefore, due to 
continuous CM death, ECM degradation, and myocardial fibrosis it is increasingly difficult to 
repair the myocardial scar to obtain again a functional tissue. A spectrum of surgical procedures, 
cardiac resynchronization therapy (biventricular pacing), or pharmacologic therapy (e.g. 
angiotensin-converting enzyme inhibitors and beta-blockers) have been applied in the clinical 
setting in an effort to limit adverse LV remodeling. Surgical approaches include ventricular 
restoration with left ventricular reconstitutive surgery (Dor procedure) or ventricular wrapping 
with an epicardial patch6. However, a definitive solution that faces LV remodeling and CM 
death has not yet been found. The association of stem cells (1) with tissue-engineered scaffolds 
(2) constitutes an attractive approach. The first component is hoped to help to improve tissue 
functionality, while the second one could avoid ventricular chamber dilatation, which changes 
from a natural elliptical to spherical shape in heart failure patients.  
The challenge to find an efficient regenerative therapy for heart function recovery after MI 
resides in the vast complexity of the heart muscle, where different factors at macroscopic and 
microscopic level such as heart contraction and cell connectivity must be taken into account to 
repair the damaged tissue. Although cell therapy appeared as an interesting approach, the 
environmental conditions that remain after MI are not suitable for cell survival and proliferation. 
For this reason, the design and fabrication of biomaterials to be used as vehicles or even to give 
specific signaling to the cells are of great interest. These materials must be (1) easy handling 
and cell-friendly, (2) reproduce heart ECM, (3) have sufficient mechanical stability and high 
porosity to lodge a high cell density, and (4) do not produce an inflammatory response in vivo. 
Numerous polymers (natural and synthetic) have been widely investigated for CTE, shaped in a 
variety of architectures57,93,94. These structures act as physical support for the seeded cells, 
allowing the exchange of oxygen and nutrients and removal of cellular secretions, to facilitate 
cell adhesion, survival, proliferation and differentiation9. On the other end, nanofibers in the 
form of self-assembling peptides emerged as a good system to better recreate a 3D 
environment95. 3D structures are essential for an appropriate spatial organization of cell surface 
receptors involved in cell–cell and cell-ECM interactions96. Here, a combination of elastomeric 
membranes with RAD16-I self-assembling peptide is proposed and analyzed. Elastomeric 
membranes fulfill many of the essential characteristics prescribed for necrotic myocardium 
repair, but fail to emulate the cardiac tissue at the nano-scale. The peptide gel network provided 
by RAD16-I resembles ECM environment and has been shown to increase growth and cellular 
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proliferation of different cell types. However, the RAD16-I poor mechanical properties are an 
important drawback for its implantation in the continuous beating heart97. Therefore, the 
combination of RAD16-I soft material with synthetic polymeric materials with improved 
elasticity and tensile strength (both PEA and PCLMA elastomeric membranes) arise as an 
interesting approach. Both materials would contribute to the implant success at different levels: 
the elastomeric membrane would be responsible for providing an adequate physical support, 
whereas the synthetic gel would confer an in vivo-like environment to the cells. 
First of all, as the cells are the active component of the bioimplant it is critical to culture as 
many cells as possible in the composite. It has been reported that at least one billion cells are 
needed to be replaced in patients with heart failure3. Therefore, the seeding efficiency of the 
bioimplant was intended to be improved for further in vivo implantation.  
After setting the two-step protocol, subATDPCs viability, growth, mobilization and progenitor 
phenotype maintenance in elastomeric membranes filled with peptide gel (composites) was 
assessed in vitro. The bioactive bioactive implants (both PEA and PCLMA) developed presents 
a good advantage as a cell vehicle for cell therapies. PEA bioactive implant has been 
demonstrated to allow cell proliferation to a five-fold increase after 10 days of in vitro culture (p 
< 0.001). However, PCLMA bioactive implant did not presented a significant increase in cell 
number. Additionally, it was observed a migration of subATDPCs outwards PEA elastomeric 
membrane (both bare and composite) but not outwards PCLMA elastomeric membrane (both 
bare and composite). We attribute this result to the self-assembling peptide distribution inside 
the microporous structure. Inside PEA scaffold the gel works as cell diffusion medium, 
facilitating the invasibility of the scaffold’s pores upon seeding and after 10 days both the 
polymeric surface and the inner trabeculae were covered with cells98. However, inside PCLMA 
scaffold the nanofibers cover the trabecular structure attaching the cells on the surface. The 
main advantaged of the composite resides in the capacity of promoting cell mobilization 
outwards, which could facilitate cell grafting at the affected site. Specific to cell proliferation 
and migration, PEA-composite may present better properties to be used as a cell vehicle as 
compared to PCLMA-composite. 
In other terms within the composites (for both PEA and PCLMA elastomeric membranes), 
subATDPCs completely covered the surface of the scaffolds and adopted an elongated shape, 
contacting one to each other. However, in bare scaffolds, cells remained adhered on the 
trabeculae and arranged forming circumferences, rather than occupying the ‘empty’ pores.   
SubATDPCs (MSC-like) were used in this work due to their cardiogenic potential lineage. It 
was the primary aim to ensure that these cells in the proposed biomaterials (bare elastomeric 
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membrane or the composite) did not alter their gene expression. As it has been described in 
Materials and Methods section, the cells used for these experiments were prepared as pools of 
cells from 5 different patients. Therefore, it was expected slight difference in the genes analyzed 
depending on the pool used. For this reason, each experiment was compared with the same pool 
of cells growing in flat surfaces. It has been shown that subATDPCs preserved their cardiogenic 
potential lineage by the expression of early cardiac markers such as TBX5 and MEF2C or 
definitive markers such as ACTN1 and cTnT in PEA elastomeric membranes or ACTN1 and 
GJA1 in PCLMA elastomeric membranes. No significant differences in gene or protein 
expression between the cells cultured in composites, bare scaffolds and controls were observed. 
TBX5 early cardiac marker is critical in heart development, and it has been reported to regulate 
the activity of other genes by attaching to specific regions of DNA88. It has also been shown to 
interact with NKX2.5, GATA4 and MEF2C to synergistically activate target genes expression 
in CMs88. MEF2C expression, which plays a key role in myogenesis, has been related with the 
expression of genes such as ACTN1 and MHC. In terms of definitive cardiac markers, ACTN1 
is a marker of mature CM that helps to anchor the myofibrillar actin filaments. It is the major 
component of the contractile apparatus99. Interestingly, cTnT, a constituent of the troponin 
complex, which connects the troponin complex to tropomyosin regulating muscle contraction in 
response to alteration in intercellular calcium concentration, was detected in PEA elastomeric 
membranes. This complex controls the calcium mediated interaction between actin and myosin. 
In contrast with other multigene families, the skeletal and cardiac proteins of this complex are 
not derived from alternative splicing of exons from a single gene100. Therefore, they have, 
theoretically, the potential of being unique to the myocardium. This gene was not expressed in 
the pool of cells cultured in PCLMA elastomeric membranes, but GJA1 was detected at gene 
and protein level. This protein is the major gap junction in the heart and has a crucial role in 
synchronic contraction. Although these results are not conclusive to resolve a differentiation 
toward a cardiac phenotype, we observed that subATDPCs maintain their phenotype after 10 
days of culture in both PEA and PCLMA with and without RAD16-I. Therefore, we think that 
neither of these biomaterials are cardio-conductive, but are able to preserve cell potentiality, 
which could facilitate their lineage commitment once implanted. Further analysis at longer time 
points and using different kind of induction (chemical or physical) would be interesting to 
elucidate possible cardiac differentiation at more definitive stages.  
In conclusion, the proposed elastomeric scaffolds, with or without RAD16-I gel in the pores, are 
a non-inductive milieu where subATDPCs can survive, grow and mobilize after implantation at 
the ischemic tissue. 
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4.7 FURTHER STEPS 
This chapter analyzes the behavior of subATDPCs cultured in elastomeric membranes pre-filled 
with RAD16-I self-assembling peptide, which aims to provide a more realistic 3D environment 
within the microporous of PEA or PCLMA elastomeric membranes. We consider that it is only 
the beginning of the in vitro studies for this kind of bioactive implants. A part of the more basic 
studies for the in vivo implantation, the subsequent in vitro assays could be interesting to better 
characterize the proposed concept: 
 
- Propose a set up to electrically stimulate the bioactive implant. 
- Propose a set up to mechanically stimulate the bioactive implant. 
- Analyze cell behavior with chemical, electrical and mechanical stimulation alone or in 
combination. 
- Test the effect in in vivo models of the developed platform using RAD16-I with the 
modifications proposed in Chapter 2. 
 
All these studies could help to understand the response that the implanted cells would have in 
vivo after their implantation in an ischemic tissue. The obtained results could help to improve 
the bioactive implants performance. 
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Chapter 5: CONCLUSIONES (Castellano) 
 
CONCLUSIONS (English) 
- Three-dimensional in vitro models based in RAD16-I self-assembling peptide with and 
without RGD motifs and heparin polysaccharide modifications, where subcutaneous 
adipose tissue derived progenitor cells (subATDPCs) were able to form an interconnected 
cellular network, were developed.  
 
- RAD16-I/RADRGD scaffold presented higher interconnections as compared to RAD16-I 
peptide, suggesting that RGD motif is indeed enhancing cell connections and migration. 
The presence of heparin presented cluster formation and looser networks but its capacity to 
localize growth factors is of high interest. 
 
- 3D environment provided by RAD16-I self-assembling peptide is able to maintain the 
cardiac commitment of subATDPCs and in combination with chemical induction can 
induce overexpression of cardiac markers at gene and protein level. Neither the presence of 
RGD motifs or heparin polysaccharide change cardiac marker expression. 
 
- The increase of storage modulus lead to an up-regulation of some cardiac genes, but the 
signaling provided by the cardiac induction media is also of high importance. 
 
- An electro-stimulation protocol using the setup custom made by Universitat Politècnica de 
Catalunya (UPC) has been developed for 3D cultures based in RAD16-I self-assembling 
peptide. 
 
- No differences in terms of viability, cellular network formation and condensation were 
observed after the application of electro-stimulation protocol in 3D cultures of 
subATDPCs. Therefore, it can be stated that the stipulated protocol do not cause a harmful 
effect to the cells. 
 
- It was observed that at long periods of culture inside RAD16-I self-assembling peptide, 
subATDPCs started to migrate outwards the 3D construct. This fact is of high interest for 
further in vivo implantation of the proposed model.  
 
- A two-steps methodology to assemble the bioactive implant was achieved. 
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- Both PEA and PCLMA microporous elastomeric membranes are elastomeric, 
hydrophobic, highly porous, and present similar electrical resistivity below the resistivity 
of transmural and non-transmural infarcted myocardium. Therefore, they can provide 
mechanical strength and geometrical definiteness to the heart and a low-resistance pathway 
that should contribute to facilitate the electrical signal propagation from the native heart 
tissue into the scaffold. 
 
- Both proposed bioactive patches (PEA and PCLMA) intimately attach to the myocardium 
and remain in the position at the infarction area where they were placed suggesting 
resilience to the heart mechanical forces.  
 
- SubATDPCs growing in composites were uniformly distributed whereas, on bare scaffolds, 
a heterogeneous layout was observed. Moreover, subATDPCs cultured on composites’ 
surfaces were organized in a well-ordered pattern, which would facilitate cell-cell contact. 
Therefore, RAD16-I self-assembling peptide inside the porous provides a proper milieu for 
the cells. 
 
- PEA-composites were able to proliferate and migrate outwards, but subATDPCs cultured 
in PCLMA-composites did not proliferate and remained inside the composite. We 
hypothesize that this can be caused by the lack of a 3D nanofiber network filling the 
microporous of the PCLMA elastomeric membrane. 
 
- The combination of RAD16-I with this elastomeric membranes leads to the obtaining of a 
non-cardio-conductive biomaterial which is able to maintain the gene expression of the 
seeded cells. 
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CONCLUSIONES (Castellano) 
- Se ha desarrollado un modelo tridimensional in vitro basado en el péptido auto-
ensamblable RAD16-I con y sin motivos RGD y heparina, dónde las células progenitoras 
derivadas de tejido adiposo subcutáneo (subATDPCs) pueden comunicarse unas con las 
otras formando una red interconectada. 
 
- Las células cultivadas en la matriz modificada con motivos RGD presentaron una mayor 
interconexión al ser comparadas con cultivos control de RAD16-I. Esto sugiere que el 
motivo RGD puede incrementar las conexiones intercelulares y la migración de las 
mismas. La presencia de heparina presentó la formación de agrupaciones celulares y la 
formación de redes más laxas, pero su capacidad de localizar factores de crecimiento es de 
gran interés. 
 
- El ambiente tridimensional proporcionado por el péptido autoensamblable RAD16-I 
mantiene el compromiso cardíaco de las subATDPCs y en combinación con la inducción 
química lleva a la sobreexpresión de marcadores cardíacos a nivel de gen y proteína. La 
presencia de motivos RGD o el polisacárido de heparina no varía la expresión de 
marcadores cardiacos en comparación con RAD16-I. 
 
- El aumento del módulo de almacenamiento provoca una sobreexpresión de algunos genes 
cardíacos, pero la señalización del medio sigue siendo de gran importancia. 
 
- Se ha desarrollado un protocolo de estimulación eléctrica utilizando el sistema propuesto 
por la Universitat Politècnica de Catalunya (UPC) para cultivos 3D basados en el péptido 
auto-ensamblable RAD16-I. 
 
- No se observaron diferencias en términos de viabilidad, formación de red celular y 
condensación macroscópica después de la aplicación de la estimulación eléctrica en 
cultivos 3D de subATDPCs. Así pues se puede concluir que el sistema no causa ningún 
efecto dañino a las células. 
 
- Se ha observado que a largos periodos de cultivo en la matriz 3D de RAD16-I, las 
subATDPCs inician una migración hacia fuera del cultivo 3D. Esta observación resulta ser 
de gran interés para la posible implantación in vivo del modelo propuesto. 
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- Se ha diseñado una metodología de dos pasos para ensamblar el implante bioactivo.  
 
- Ambas membranas elastoméricas (PEA y PCLMA) son matrices elásticas porosas muy 
hidrofóbicas con una resistividad eléctrica parecida y por debajo de la resistividad del 
miocardio infartado (transmural y no transmural). Así pues, aportan tanto fuerza mecánica 
y definición geométrica al corazón como un camino de baja resistencia que puede 
contribuir a facilitar la propagación eléctrica desde el tejido nativo al bioimplante. 
 
- Ambos implantes bioactivos propuestos (PEA y PCLMA) se adhieren íntimamente al 
miocardio y se mantienen en la posición de implantación. Esto surgiere que el implante 
propuesto puede adaptarse a las fuerzas mecánicas del corazón.  
 
- Las subATDPCs creciendo en los materiales compuestos se distribuyeron uniformemente, 
pero en las membranas sin RAD16-I se observó una distribución heterogénea. Además, las 
células cultivadas en los materiales compuestos se organizaron ordenadamente facilitando 
los contactos intercelulares. Así pues, el péptido autoensamblable RAD16-I dentro de los 
poros proporciona un ambiente adecuado para las células. 
 
- Las células cultivadas en los materiales compuestos de PEA fueron capaces de proliferar y 
migrar hacia fuera de la plataforma, pero las cultivadas en los materiales compuestos de 
PCLMA no proliferaron y permanecieron dentro de la plataforma. Este resultado se puede 
explicar por la falta del ambiente 3D dentro de los microporos de la membrana 
elastomérica de PCLMA.  
 
- La combinación de RAD16-I con membranas elastoméricas permite la obtención de una 
plataforma no cardio-conductiva que permite el mantenimiento de la expresión génica de 
las células cultivadas. 
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 CONCLUSIONS (Català) 
- S’ha desenvolupat un model tridimensional (3D) in vitro basat en el pèptid 
autoensamblable RAD16-I amb i sense modificacions de motius RGD i/o heparina, on les 
cèl·lules progenitores derivades de teixit adipós subcutani (subATDPCs) poden comunicar-
se unes amb les altres formant una xarxa interconnectada.  
 
- Les cèl·lules cultivades en la matriu modificada amb motius RGD van presentar una major 
interconnexió al ser comparades amb cultius control de RAD16-I. Això suggereix que el 
motiu RGD pot incrementar les connexions intercel·lulars i la migració de les mateixes. La 
combinació d’aquest motiu amb heparina va presentar la formació d’agrupacions cel·lulars 
i la formació de xarxes més laxes però la seva capacitat de localitzar factors de creixement 
segueix sent de gran interès. 
 
- L’ambient tridimensional proporcionat per el pèptid autoensamblable RAD16-I manté el 
compromís cardíac de les subATDPCs i en combinació amb la inducció química porta a la 
sobre-expressió de marcadors cardíacs a nivell de gen i proteïna. La presència de motius 
RGD o el polisacàrid heparina no varia l’expressió d’aquests marcadors en comparació 
amb RAD16-I.  
 
- L’augment del mòdul d’emmagatzematge provoca una sobre-expressió d’alguns gens 
cardíacs, però la senyalització del medi també és de gran importància.  
 
- S’ha desenvolupat un protocol d’estimulació elèctrica emprant el sistema proposat per la 
Universitat Politècnica de Catalunya (UPC) per a cultius 3D basats en el pèptid 
autoensamblable RAD16-I.  
 
- No es van observar diferencies en termes de viabilitat, formació de xarxa cel·lular i 
condensació macroscòpica després de l’aplicació de l’estimulació elèctrica en cultius 3D 
de subATDPCs. Així doncs es pot concloure que el sistema no causa cap efecte nociu per a 
les cèl·lules.  
 
- S’ha observat que a llargs períodes de cultiu en RAD16-I, les subATDPCs inicien una 
migració cap a fora del cultiu 3D. Aquesta observació resulta ser de gran interès per a la 
possible implantació in vivo del model proposat. 
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 - S’ha dissenyat una metodologia de dos passos per a preparar l’implant bioactiu. 
 
- Ambdues membranes elastomèriques (PEA y PCLMA) són matrius elàstiques poroses 
molt hidrofòbiques amb una resistivitat elèctrica semblant i per sota de la resistivitat del 
miocardi infartat (transmural y no transmural). Així doncs, aporten tant força mecànica i 
definició geomètrica com un camí de baixa resistència que pot contribuir a facilitar la 
propagació elèctrica des dels teixit natiu al bioimplant. 
 
- Ambdós implants bioactius proposats (PEA y PCLMA) s’adhereixen íntimament al 
miocardi i es mantenen en la posició d’implantació. Això suggereix que l’implant pot 
adaptar-se a les forces mecàniques del cor. 
 
- Les subATDPCs creixent els materials compostos es van distribuir uniformement, però en 
les membranes sense RAD16-1 es va observar una distribució heterogènia. Les cèl·lules 
cultivades en els materials compostos es van organitzar ordenadament facilitant els 
contactes intercel·lulars. Així doncs, el pèptid autoensamblable RAD16-I dins dels porus 
proporciona un ambient adequat per a les cèl·lules. 
 
- Les cèl·lules cultivades en els materials compostos de PEA van poder proliferar i migrar 
cap a fora de la plataforma, però en els materials compostos de PCLMA no van poder-ho 
fer i es van mantenir dins de la plataforma. Aquest resultat es pot explicar per la falta 
d’ambient 3D dins dels microporus de la membrana elastomérica de PCLMA. 
 
- La combinació de RAD16-I amb membranes elastomèriques, permet l’obtenció d’una 
plataforma no cardio-conductiva que permet el manteniment del fenotip de les cèl·lules 
cultivades. 
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